Pulmonary Medicine: Recent Episodes
ReachMD
Guest: Gilberto de Lima Lopes, Jr, MD, MBA, FASCO
Guest: Jyoti Patel, MD
The MET pathway can be activated by MET exon 14 skipping mutations, gene amplification, or overexpression. Mutations within this pathway carry a poor prognosis for patients with non-small cell lung cancer (NSCLC). Early studies of MET tyrosine kinase inhibitors (TKIs) demonstrated limited clinical benefit; however, newer selective MET TKIs, such as capmatinib and tepotinib, have improved efficacy and acceptable safety profiles. In this activity, our experts assess the role of the role of MET gene aberrations in NSCLC and optimal testing modalities, as well as the clinical evidence supporting the use of MET TKIs and the potential role of these therapies in other subsets of disease.
Guest: Paul Hunter, MD
The Advisory Committee on Immunization Practices (ACIP) recently updated their recommendations for the 2024-2025 flu season. Here to give us a breakdown of the key updates so we can protect our patients from the flu is family medicine physician Dr. Paul Hunter.
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Jill Foster, MD
Guest: John Russell, MD
According to recent studies, co-administering the flu, RSV, and COVID-19 vaccines is generally safe, which is why both the CDC and Advisory Committee on Immunization Practices support this approach. However, there are some important considerations to keep in mind when co-administering these three respiratory vaccines, which is why Dr. Mary Katherine Cheeley speaks with Drs. Jill Foster and John Russell about best practices for co-administration and improving vaccination rates. Dr. Foster is the Director of the Division of Pediatric Infectious Diseases at the University of Minnesota Medical School, and Dr. Russell is a family medicine physician at Jefferson Health System in Abington, Pennsylvania.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: John Russell, MD
According to the CDC, flu vaccine coverage for all adults is about 47 percent, and there’s been a continued decline among pregnant patients and children since 2020. These reduced vaccination rates can have serious consequences for our patients and the healthcare system as a whole, which is why it’s so important for primary care providers to embrace their role in reversing this trend. To help in this mission, Dr. Charles Turck speaks with family medicine physician Dr. John Russell about strategies for boosting flu vaccination rates in the primary care setting.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Darvin Scott Smith, MD
Vaccines play a crucial role in preventing the flu itself, but there are a lot of lesser-known benefits of flu vaccination as well, including its impact on reducing illness severity, hospitalization rates, and co-infections as well as its importance in managing chronic diseases and enhancing public health outcomes. Joining Dr. Charles Turck to examine the comprehensive advantages of flu vaccination is Dr. Darvin Scott Smith, who’s an infectious disease consultant at San Mateo Medical Center in California.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Laila Woc-Colburn, MD, DTM&H, FACP, FIDSA
Since annual flu shots help alleviate the severe disease burden on patients and the healthcare system as a whole, it’s important to make flu vaccination a part of every patient visit. Fortunately, tools like appointment reminders, in-office discussions, and infographics can help us integrate this preventative measure into routine patient care and protect them from the flu. To learn more about these strategies, Dr. Charles Turck speaks with Dr. Laila Woc-Colburn, Associate Professor at the Emory University School of Medicine in Atlanta.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Joshua E. Reuss, MD
The phase 2 ICARUS-Lung01 study evaluated not only the efficacy and safety of datopotomab deruxtecan (Dato-DXd) in patients with previously treated advanced non-small cell lung cancer (NSCLC), but also potential biomarkers associated with response and/or resistance. Here to discuss the findings with Dr. Charles Turck is Dr. Joshua Reuss, Assistant Professor in the Department of Medicine at Georgetown University Medical Center.
Host: Jacob Sands, MD
Guest: Aaron Lisberg, MD
Brain metastases are a frequent complication of lung cancer, which is why the TROPION-Lung05 trial evaluated the intracranial efficacy of datopotamab deruxtecan (Dato-DXd) in patients with previously treated advanced metastatic non-small cell lung cancer (NSCLC). According to the data, Dato-DXd demonstrated intracranial efficacy and equivalent safety between patients who had brain metastases and those who did not. Joining Dr. Jacob Sands to discuss these findings is lead investigator and thoracic medical oncologist Dr. Aaron Lisberg.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Christina Madison, BS, PharmD, BCACP, AAHIVP
The World Health Organization and the Vaccines and Related Biologics Products Advisory Committee recently recommended transitioning from quadrivalent to trivalent flu vaccines that exclude the B/Yamagata lineage. Explore the epidemiological data that led to this decision and counseling strategies that can help patients understand this new recommendation with Dr. Charles Turck and Dr. Christina Madison, founder and CEO of the Public Health Pharmacist.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Jill Foster, MD
For optimal protection, the best time for patients to receive a flu shot is between September and October, but some patients may be hesitant. In fact, flu vaccination rates have been declining since the onset of the COVID-19 pandemic according to the CDC. That’s why Dr. Charles Turck speaks with Dr. Jill Foster about how we can help ensure patients receive timely and annual flu vaccinations. Dr. Foster is the Director of the Division of Pediatric Infectious Diseases at the University of Minnesota Medical School in Minneapolis.
Guest: Darvin Scott Smith, MD
For optimal protection, the most prevalent flu strains are assessed every year and included in the vaccine. Here to talk about this process and the recent decision to exclude the B/Yamagata lineage from flu vaccines is Dr. Darvin Scott Smith, Infectious Disease and Geographic Medicine Consultant at San Mateo Medical Center in California.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Arnaud Bourdin, MD, PhD
Since many severe asthma patients have been shown to have mucus plugs, it’s important to understand the role they plan in severe asthma. Join us as we discuss an exploratory study and the role of mucus plugging in severe asthma with Dr. Charles Turck and Professor Arnaud Bourdin. Professor Bourdin is the Head of Pulmonology at the Arnaud de Villeneuve Hospital in Montpellier, France.
TEZSPIRE is a registered trademark of Amgen Inc. and AstraZeneca.
©2024 Amgen and AstraZeneca. All rights reserved. US-83499 Last Updated 1/24
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Arnaud Bourdin, MD, PhD
It’s only been a recent discovery that mucus plugging may be present and persistent in chronic severe asthma.1 In fact, studies have shown that mucus plugs may drive some lung function deficits in severe asthma.1 Given this recent finding, Dr Charles Turck speaks with Professor Arnaud Bourdin about the clinical significance and pathogenesis of mucus plugging in severe asthma. Professor Bourdin is Head of Pulmonology at Arnaud de Villeneuve Hospital in Montpellier, France.
Reference:
- Dunican EM, Watchorn DC, Fahy JV. Ann Am Thorac Soc. 2018;15(Suppl 3):S184-S191. doi:10.1513/AnnalsATS.201807-485AW
©2024 Amgen and AstraZeneca. All rights reserved. US-86740 Last Updated 3/24
Host: Jacob Sands, MD
Guest: Aakesh Desai, MD, MPH
According to research featured at the 2023 ASCO Annual Meeting, novel immune checkpoint targets have the potential to inform drug development and combination strategies to optimize the care of patients with non-small cell lung cancer. Tune in to hear Dr. Jacob Sands explore the key findings with Dr. Aakash Desai, an Assistant Professor of Medicine at the O’Neal Cancer Center at the University of Alabama at Birmingham.
Host: Matthew Davis, MD
The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia (IH), acknowledging the cardiovascular implications of IH, and developing a comprehensive treatment strategy. This curriculum incorporates compelling patient video vignettes that convey the perspective of individuals living with IH and the profound impact that it has on their lives. This program aims to not only educate healthcare professionals on the rapidly evolving field but also to bring about positive changes in clinical practice, ultimately leading to an enhanced quality of life for individuals affected by IH.
Host: Matthew Davis, MD
Host: Alcibiades J. Rodriguez, MD, FAASM
The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia (IH), acknowledging the cardiovascular implications of IH, and developing a comprehensive treatment strategy. This curriculum incorporates compelling patient video vignettes that convey the perspective of individuals living with IH and the profound impact that it has on their lives. This program aims to not only educate healthcare professionals on the rapidly evolving field but also to bring about positive changes in clinical practice, ultimately leading to an enhanced quality of life for individuals affected by IH.
Host: Matthew Davis, MD
Host: Logan Schneider, MD
The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia (IH), acknowledging the cardiovascular implications of IH, and developing a comprehensive treatment strategy. This curriculum incorporates compelling patient video vignettes that convey the perspective of individuals living with IH and the profound impact that it has on their lives. This program aims to not only educate healthcare professionals on the rapidly evolving field but also to bring about positive changes in clinical practice, ultimately leading to an enhanced quality of life for individuals affected by IH.
Host: Logan Schneider, MD
The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia (IH), acknowledging the cardiovascular implications of IH, and developing a comprehensive treatment strategy. This curriculum incorporates compelling patient video vignettes that convey the perspective of individuals living with IH and the profound impact that it has on their lives. This program aims to not only educate healthcare professionals on the rapidly evolving field but also to bring about positive changes in clinical practice, ultimately leading to an enhanced quality of life for individuals affected by IH.
Host: Kevin Trice, MD
Host: Lee Surkin, MD, FACC, FCCP, FASNC, FAASM
This program aims to provide healthcare professionals (HCPs) with a comprehensive, evidence-based curriculum in caring for individuals with Narcolepsy. This curriculum addresses unmet clinical needs, including improving the accuracy and timing of diagnosing Narcolepsy, understanding how Narcolepsy increases the risk of cardiovascular disease, and addressing how treating Narcolepsy can improve sleep, which is an important aspect of overall health. The main goal is to educate clinicians about the latest developments in this field in order to positively impact clinical practice and significantly improve the quality of life for individuals affected by Narcolepsy.
This program covers best practices in:
- Recognizing the symptoms of Narcolepsy, including the common ones and those that are less well-known
- Exploring the relationship between cardiovascular disease and Narcolepsy
- Addressing diagnosis and treatment of Narcolepsy in relation to the AHA Life Essential 8, which focuses on key aspects of a healthy lifestyle
Host: Ana C. Krieger, MD
This program aims to provide healthcare professionals (HCPs) with a comprehensive, evidence-based curriculum in caring for individuals with Narcolepsy. This curriculum addresses unmet clinical needs, including improving the accuracy and timing of diagnosing Narcolepsy, understanding how Narcolepsy increases the risk of cardiovascular disease, and addressing how treating Narcolepsy can improve sleep, which is an important aspect of overall health. The main goal is to educate clinicians about the latest developments in this field in order to positively impact clinical practice and significantly improve the quality of life for individuals affected by Narcolepsy.
This program covers best practices in:
- Recognizing the symptoms of Narcolepsy, including the common ones and those that are less well-known
- Exploring the relationship between cardiovascular disease and Narcolepsy
- Addressing diagnosis and treatment of Narcolepsy in relation to the AHA Life Essential 8, which focuses on key aspects of a healthy lifestyle
Host: Lee Surkin, MD, FACC, FCCP, FASNC, FAASM
This program aims to provide healthcare professionals (HCPs) with a comprehensive, evidence-based curriculum in caring for individuals with Narcolepsy. This curriculum addresses unmet clinical needs, including improving the accuracy and timing of diagnosing Narcolepsy, understanding how Narcolepsy increases the risk of cardiovascular disease, and addressing how treating Narcolepsy can improve sleep, which is an important aspect of overall health. The main goal is to educate clinicians about the latest developments in this field in order to positively impact clinical practice and significantly improve the quality of life for individuals affected by Narcolepsy.
This program covers best practices in:
- Recognizing the symptoms of Narcolepsy, including the common ones and those that are less well-known
- Exploring the relationship between cardiovascular disease and Narcolepsy
- Addressing diagnosis and treatment of Narcolepsy in relation to the AHA Life Essential 8, which focuses on key aspects of a healthy lifestyle
Host: Lee Surkin, MD, FACC, FCCP, FASNC, FAASM
This program aims to provide healthcare professionals (HCPs) with a comprehensive, evidence-based curriculum in caring for individuals with Narcolepsy. This curriculum addresses unmet clinical needs, including improving the accuracy and timing of diagnosing Narcolepsy, understanding how Narcolepsy increases the risk of cardiovascular disease, and addressing how treating Narcolepsy can improve sleep, which is an important aspect of overall health. The main goal is to educate clinicians about the latest developments in this field in order to positively impact clinical practice and significantly improve the quality of life for individuals affected by Narcolepsy.
This program covers best practices in:
- Recognizing the symptoms of Narcolepsy, including the common ones and those that are less well-known
- Exploring the relationship between cardiovascular disease and Narcolepsy
- Addressing diagnosis and treatment of Narcolepsy in relation to the AHA Life Essential 8, which focuses on key aspects of a healthy lifestyle
Host: Lee Surkin, MD, FACC, FCCP, FASNC, FAASM
This program aims to provide healthcare professionals (HCPs) with a comprehensive, evidence-based curriculum in caring for individuals with Narcolepsy. This curriculum addresses unmet clinical needs, including improving the accuracy and timing of diagnosing Narcolepsy, understanding how Narcolepsy increases the risk of cardiovascular disease, and addressing how treating Narcolepsy can improve sleep, which is an important aspect of overall health. The main goal is to educate clinicians about the latest developments in this field in order to positively impact clinical practice and significantly improve the quality of life for individuals affected by Narcolepsy.
This program covers best practices in:
- Recognizing the symptoms of Narcolepsy, including the common ones and those that are less well-known
- Exploring the relationship between cardiovascular disease and Narcolepsy
- Addressing diagnosis and treatment of Narcolepsy in relation to the AHA Life Essential 8, which focuses on key aspects of a healthy lifestyle
Host: Matthew Davis, MD
Host: Alcibiades J. Rodriguez, MD, FAASM
The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia (IH), acknowledging the cardiovascular implications of IH, and developing a comprehensive treatment strategy. This curriculum incorporates compelling patient video vignettes that convey the perspective of individuals living with IH and the profound impact that it has on their lives. This program aims to not only educate healthcare professionals on the rapidly evolving field but also to bring about positive changes in clinical practice, ultimately leading to an enhanced quality of life for individuals affected by IH.
Host: Kevin Trice, MD
This program aims to provide healthcare professionals (HCPs) with a comprehensive, evidence-based curriculum in caring for individuals with Narcolepsy. This curriculum addresses unmet clinical needs, including improving the accuracy and timing of diagnosing Narcolepsy, understanding how Narcolepsy increases the risk of cardiovascular disease, and addressing how treating Narcolepsy can improve sleep, which is an important aspect of overall health. The main goal is to educate clinicians about the latest developments in this field in order to positively impact clinical practice and significantly improve the quality of life for individuals affected by Narcolepsy.
This program covers best practices in:
- Recognizing the symptoms of Narcolepsy, including the common ones and those that are less well-known
- Exploring the relationship between cardiovascular disease and Narcolepsy
- Addressing diagnosis and treatment of Narcolepsy in relation to the AHA Life Essential 8, which focuses on key aspects of a healthy lifestyle
Host: Kevin Trice, MD
Host: Ana C. Krieger, MD
This program aims to provide healthcare professionals (HCPs) with a comprehensive, evidence-based curriculum in caring for individuals with Narcolepsy. This curriculum addresses unmet clinical needs, including improving the accuracy and timing of diagnosing Narcolepsy, understanding how Narcolepsy increases the risk of cardiovascular disease, and addressing how treating Narcolepsy can improve sleep, which is an important aspect of overall health. The main goal is to educate clinicians about the latest developments in this field in order to positively impact clinical practice and significantly improve the quality of life for individuals affected by Narcolepsy.
This program covers best practices in:
- Recognizing the symptoms of Narcolepsy, including the common ones and those that are less well-known
- Exploring the relationship between cardiovascular disease and Narcolepsy
- Addressing diagnosis and treatment of Narcolepsy in relation to the AHA Life Essential 8, which focuses on key aspects of a healthy lifestyle
Host: Alcibiades J. Rodriguez, MD, FAASM
The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia (IH), acknowledging the cardiovascular implications of IH, and developing a comprehensive treatment strategy. This curriculum incorporates compelling patient video vignettes that convey the perspective of individuals living with IH and the profound impact that it has on their lives. This program aims to not only educate healthcare professionals on the rapidly evolving field but also to bring about positive changes in clinical practice, ultimately leading to an enhanced quality of life for individuals affected by IH.
Host: Alcibiades J. Rodriguez, MD, FAASM
The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia (IH), acknowledging the cardiovascular implications of IH, and developing a comprehensive treatment strategy. This curriculum incorporates compelling patient video vignettes that convey the perspective of individuals living with IH and the profound impact that it has on their lives. This program aims to not only educate healthcare professionals on the rapidly evolving field but also to bring about positive changes in clinical practice, ultimately leading to an enhanced quality of life for individuals affected by IH.
Host: Kevin Trice, MD
Host: Ana C. Krieger, MD
This program aims to provide healthcare professionals (HCPs) with a comprehensive, evidence-based curriculum in caring for individuals with Narcolepsy. This curriculum addresses unmet clinical needs, including improving the accuracy and timing of diagnosing Narcolepsy, understanding how Narcolepsy increases the risk of cardiovascular disease, and addressing how treating Narcolepsy can improve sleep, which is an important aspect of overall health. The main goal is to educate clinicians about the latest developments in this field in order to positively impact clinical practice and significantly improve the quality of life for individuals affected by Narcolepsy.
This program covers best practices in:
- Recognizing the symptoms of Narcolepsy, including the common ones and those that are less well-known
- Exploring the relationship between cardiovascular disease and Narcolepsy
- Addressing diagnosis and treatment of Narcolepsy in relation to the AHA Life Essential 8, which focuses on key aspects of a healthy lifestyle
Host: Logan Schneider, MD
The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia (IH), acknowledging the cardiovascular implications of IH, and developing a comprehensive treatment strategy. This curriculum incorporates compelling patient video vignettes that convey the perspective of individuals living with IH and the profound impact that it has on their lives. This program aims to not only educate healthcare professionals on the rapidly evolving field but also to bring about positive changes in clinical practice, ultimately leading to an enhanced quality of life for individuals affected by IH.
Host: Logan Schneider, MD
Host: Diana Kimmel
The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia (IH), acknowledging the cardiovascular implications of IH, and developing a comprehensive treatment strategy. This curriculum incorporates compelling patient video vignettes that convey the perspective of individuals living with IH and the profound impact that it has on their lives. This program aims to not only educate healthcare professionals on the rapidly evolving field but also to bring about positive changes in clinical practice, ultimately leading to an enhanced quality of life for individuals affected by IH.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Ravi Rajaram, MD, MSC
NEOSTAR is a phase 2 trial with multiple arms looking at different combination therapies in the setting of resectable lung cancer. So what results were found from this study? Join in as Dr. Charles Turck discusses this further with Dr. Ravi Rajaram, Assistant Professor and the Clinical Medical Director in the Thoracic Center in the Department of Thoracic and Cardiovascular Surgery, Division of Surgery, at the University of Texas MD Anderson Cancer Center in Houston.
Host: Jacob Sands, MD
Guest: Liza Villaruz, MD
According to a recent study, the immune checkpoint inhibitor durvalumab is not only considered safe, but it may also offer overall survival benefits for individuals with advanced or metastatic non-small cell lung cancer (NSCLC) and restricted performance status. Here to talk about this research are Dr. Jacob Sands and Dr. Liza Villaruz, Associate Professor of Medicine at the University of Pittsburgh School of Medicine.
Host: Tom Corbridge, MD, FCCP
Guest: De De Gardner, DrPH, RRT, RRT-NPS, FAARC, FCCP
Guest: Diego Maselli, MD
Guest: Praveen Akuthota, MD
As we continue to learn more about the underlying inflammatory pathways in asthma, we now have more novel tools and treatments to help us achieve control, remission, and better outcomes for our patients. But in order to achieve those goals, we must first detect severe asthma early enough to take full advantage of the latest advancements. Learn more about the importance of early detection and intervention in severe asthma care through the lens of a real-world patient case with Drs. Tom Corbridge, De De Gardner, Diego Maselli, and Praveen Akuthota. This is a non-promotional, non-CME disease state disease education podcast series brought to you by American College of CHEST Physicians in collaboration with and paid for by GSK.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Justin Reinert, PharmD
Acute respiratory distress syndrome (ARDS) is a severe lung condition characterized by the rapid onset of widespread inflammation in the lungs, but inhaled epoprostenol can be used as a last-line treatment strategy for these patients. Learn more about this treatment option’s efficacy and safety with Dr. Charles Turck and Dr. Justin Reinert, Assistant Professor of Clinical Pharmacy at the University of Toledo.
Host: Demondes Haynes, MD
Guest: Njira Lugogo, MD
Guest: Neil Skolnik, MD
According to data from the CDC, over half of patients in the United States are not considered well controlled, and there hasn’t been much improvement in exacerbations as measured by ER visits or by deaths per year in the last 30 years or so. But fortunately, the use of single maintenance and reliever therapy (SMART) has been shown to help address inflammation and decrease exacerbations. Drs. Demondes Haynes, Njira Lugogo, and Neil Skolnik discuss this approach and other combination treatment for asthma. This non-CME education is brought to you by CHEST and is sponsored by AstraZeneca.
Host: Demondes Haynes, MD
Guest: Njira Lugogo, MD
Guest: Neil Skolnik, MD
When it comes to managing acute asthma symptoms and reducing risk for patients, our focus is now on relieving bronchoconstriction and inflammation. Given this fundamental change, it’s important to ensure that our patients understand this shift. Find out how taking a shared decision-making approach can help patients embrace this change in addition to improving their adherence and outcomes with Drs. Demondes Haynes, Njira Lugogo, and Neil Skolnik.
This non-CME education is brought to you by CHEST and is sponsored by AstraZeneca.
Host: Demondes Haynes, MD
Guest: Njira Lugogo, MD
Guest: Neil Skolnik, MD
Expert opinions from NAEPP and GINA recommend treating both symptoms and inflammation in asthma patients concomitantly. Joining Dr. Demondes Haynes to talk about these updates and therapies for asthma like short-acting beta agonists and inhaled corticosteroids are Drs. Njira Lugogo and Neil Skolnik.
This non-CME education is brought to you by CHEST and is sponsored by AstraZeneca.
Host: Victor Moles, MD
Host: Jonathan Haft, MD
Host: Daniel Schimmel, MD
Host: Michael J. Cuttica, MD, MS
Host: Thomas Cascino, MD
Host: Ruben Mylvaganam, MD
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
Host: Ruben Mylvaganam, MD
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
Host: Daniel Schimmel, MD
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
Host: George Hanna, MD
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
Host: Jonathan Haft, MD
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
Host: Sydney Schacht, DO
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
Host: Michael J. Cuttica, MD, MS
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
Host: Victor Moles, MD
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
Host: Michael J. Cuttica, MD, MS
Host: Victor Moles, MD
Host: Vallerie V. McLaughlin, MD
Host: Ruben Mylvaganam, MD
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
Host: Yasmin Raza, MD
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
Host: Ravi B. Patel, MD, MSc
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
Host: Thomas Cascino, MD
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
Host: Vallerie V. McLaughlin, MD
Host: Ravi B. Patel, MD, MSc
Host: Thomas Cascino, MD
Host: Yasmin Raza, MD
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
Host: Vallerie V. McLaughlin, MD
Host: Ruben Mylvaganam, MD
Host: Michael J. Cuttica, MD, MS
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
Host: Vallerie V. McLaughlin, MD
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
Host: Vallerie V. McLaughlin, MD
Host: Victor Moles, MD
Host: Michael J. Cuttica, MD, MS
Host: Ravi B. Patel, MD, MSc
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
Host: Victor Moles, MD
Host: Michael J. Cuttica, MD, MS
Host: Vallerie V. McLaughlin, MD
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
Host: Michael J. Cuttica, MD, MS
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
Host: Ravi B. Patel, MD, MSc
Host: Vallerie V. McLaughlin, MD
Host: Michael J. Cuttica, MD, MS
Host: Yasmin Raza, MD
Host: Victor Moles, MD
The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.
Host: Andrew Wilner, MD, FACP, FAAN
Guest: Neil Skolnik, MD
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) recently updated some of the recommendations for treating patients with chronic obstructive pulmonary disease (COPD). Two large conceptual changes occurred in this update: one is an increased emphasis on treating exacerbations, and the other is looking at decreasing mortality as an important treatment goal. Learn more about this and other key updates from the GOLD recommendations with Dr. Andrew Wilner and Dr. Neil Skolnik, Professor of Family and Community Medicine at the Sidney Kimmel Medical College of Thomas Jefferson University in Philadelphia.
Host: Jennifer Shu, MD, FAAP
Guest: Steven H. Abman, MD
Bronchopulmonary dysplasia is a chronic lung disease that can have significant impacts on a newborn’s overall respiratory health, making it imperative to know how to recognize and treat it. Tune in to hear Dr. Jennifer Shu talk about the symptoms, impacts, and treatment of bronchopulmonary dysplasia with Dr. Steven Abman, a Professor in the Department of Pediatrics at the University of Colorado School of Medicine and the Director of the Pediatric Heart Lung Center at Children’s Hospital Colorado.
Guest: Julie A. Barta, MD, ATSF
Host: Peter J. Mazzone, MD, MPH, FCCP
Early detection of lung cancer is difficult, with many cases going undetected until it is too late. New methods using minimally invasive liquids biopsy and molecular biomarkers are in development to improve early detection of lung cancer. Join Dr. Peter Mazzone and Dr. Julie Barta as they discuss the latest data around two new blood-based assays with promising results for detecting lung cancer in high-risk individuals and the potential for improving patient survival.
Host: Suzanne Kafaja, MD
This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event:
- Important advancements and updates across the PH disease spectrum
- The latest ERS/ESC guidelines for diagnosing and treating PH
- Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH
- Real-world examples and data related to all discussion topics
Host: Suzanne Kafaja, MD
This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event:
- Important advancements and updates across the PH disease spectrum
- The latest ERS/ESC guidelines for diagnosing and treating PH
- Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH
- Real-world examples and data related to all discussion topics
Host: Suzanne Kafaja, MD
Host: Siyuan Cao, MD
Host: Michael Lewis, MD
Host: Rajan Saggar, MD
Host: Shelley Shapiro, MD, PhD
Host: Antoine Hage, MD
Host: Richard N. Channick, MD
This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event:
- Important advancements and updates across the PH disease spectrum
- The latest ERS/ESC guidelines for diagnosing and treating PH
- Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH
- Real-world examples and data related to all discussion topics
Host: Christopher B. Cooper, MD, PhD
Host: Alexander Sherman, MD
This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event:
- Important advancements and updates across the PH disease spectrum
- The latest ERS/ESC guidelines for diagnosing and treating PH
- Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH
- Real-world examples and data related to all discussion topics
Host: Christopher B. Cooper, MD, PhD
Host: Alexander Sherman, MD
This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event:
- Important advancements and updates across the PH disease spectrum
- The latest ERS/ESC guidelines for diagnosing and treating PH
- Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH
- Real-world examples and data related to all discussion topics
Host: Houda Boucekkine, MD
This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event:
- Important advancements and updates across the PH disease spectrum
- The latest ERS/ESC guidelines for diagnosing and treating PH
- Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH
- Real-world examples and data related to all discussion topics
Host: Richard N. Channick, MD
Host: Khushboo Goel, MD
Host: Michael Troy, MD
Host: Sonia Jasuja, MD
Host: Christopher B. Cooper, MD, PhD
Host: Michael Lewis, MD
This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event:
- Important advancements and updates across the PH disease spectrum
- The latest ERS/ESC guidelines for diagnosing and treating PH
- Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH
- Real-world examples and data related to all discussion topics
Host: Sonia Jasuja, MD
This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event:
- Important advancements and updates across the PH disease spectrum
- The latest ERS/ESC guidelines for diagnosing and treating PH
- Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH
- Real-world examples and data related to all discussion topics
Host: Michael Troy, MD
This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event:
- Important advancements and updates across the PH disease spectrum
- The latest ERS/ESC guidelines for diagnosing and treating PH
- Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH
- Real-world examples and data related to all discussion topics
Host: Rajan Saggar, MD
This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event:
- Important advancements and updates across the PH disease spectrum
- The latest ERS/ESC guidelines for diagnosing and treating PH
- Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH
- Real-world examples and data related to all discussion topics
Host: Rajan Saggar, MD
Host: Houda Boucekkine, MD
Host: Yuri Matusov, MD
Host: Sivagini Ganesh, MD, MPH
Host: Shelley Shapiro, MD, PhD
This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event:
- Important advancements and updates across the PH disease spectrum
- The latest ERS/ESC guidelines for diagnosing and treating PH
- Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH
- Real-world examples and data related to all discussion topics
Host: Siyuan Cao, MD
This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event:
- Important advancements and updates across the PH disease spectrum
- The latest ERS/ESC guidelines for diagnosing and treating PH
- Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH
- Real-world examples and data related to all discussion topics
Host: Rajan Saggar, MD
This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event:
- Important advancements and updates across the PH disease spectrum
- The latest ERS/ESC guidelines for diagnosing and treating PH
- Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH
- Real-world examples and data related to all discussion topics
Host: Richard N. Channick, MD
This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event:
- Important advancements and updates across the PH disease spectrum
- The latest ERS/ESC guidelines for diagnosing and treating PH
- Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH
- Real-world examples and data related to all discussion topics
Host: Adam J. Brownstein, MD
This year's West Regional PH Summit occurred on September 9, 2023, in Los Angeles, CA. Over a dozen regional faculty presented key topics impacting clinical practice and PH patient outcomes. The following topics were discussed at the event:
- Important advancements and updates across the PH disease spectrum
- The latest ERS/ESC guidelines for diagnosing and treating PH
- Critical advancements in screening, diagnosis, and treatment of CTEPH/CTED, lung disease-associated PAH, and CTD-associated PAH
- Real-world examples and data related to all discussion topics
Host: Paul Paik, MD
Guest: D. Ross Camidge, MD, PhD
Guest: Keith Kerr, BSc, MB ChB
Drs. Paul Paik, Keith Kerr, and Ross Camidge take us through testing considerations for MET exon 14 skipping mutations and optimal treatment approaches once a mutation is detected. They also discuss the emerging data and how to apply what we’re learning to everyday clinical practice.
Host: Michael E. Yurcheshen, MD, FAASM
Insomnia is characterized by difficulty falling asleep, staying asleep, and experiencing non-restorative or poor-quality sleep; it often leaves individuals feeling unrefreshed upon awakening. Symptoms during the day may include fatigue, irritability, impaired focus, and excessive sleepiness. The condition can significantly deteriorate a person’s quality of life, leading to reduced productivity, impaired cognitive function, mood disturbances, and an increased risk of accidents or injuries due to daytime sleepiness.
This educational program delves into the pathophysiology and diagnosis of insomnia as well as the role of the orexin system in the sleep/wake cycle. The program also evaluates the latest treatments, including the dual orexin receptor antagonists (DORAs), daridorexant, and lemborexant, and how these DORAs compare to other insomnia treatments with the aim of improving treatment choices, reducing adverse events, and improving patient outcomes.
Host: Michael E. Yurcheshen, MD, FAASM
Host: Kevin Trice, MD
Insomnia is characterized by difficulty falling asleep, staying asleep, and experiencing non-restorative or poor-quality sleep; it often leaves individuals feeling unrefreshed upon awakening. Symptoms during the day may include fatigue, irritability, impaired focus, and excessive sleepiness. The condition can significantly deteriorate a person’s quality of life, leading to reduced productivity, impaired cognitive function, mood disturbances, and an increased risk of accidents or injuries due to daytime sleepiness.
This educational program delves into the pathophysiology and diagnosis of insomnia as well as the role of the orexin system in the sleep/wake cycle. The program also evaluates the latest treatments, including the dual orexin receptor antagonists (DORAs), daridorexant, and lemborexant, and how these DORAs compare to other insomnia treatments with the aim of improving treatment choices, reducing adverse events, and improving patient outcomes.
Host: Kevin Trice, MD
Insomnia is characterized by difficulty falling asleep, staying asleep, and experiencing non-restorative or poor-quality sleep; it often leaves individuals feeling unrefreshed upon awakening. Symptoms during the day may include fatigue, irritability, impaired focus, and excessive sleepiness. The condition can significantly deteriorate a person’s quality of life, leading to reduced productivity, impaired cognitive function, mood disturbances, and an increased risk of accidents or injuries due to daytime sleepiness.
This educational program delves into the pathophysiology and diagnosis of insomnia as well as the role of the orexin system in the sleep/wake cycle. The program also evaluates the latest treatments, including the dual orexin receptor antagonists (DORAs), daridorexant, and lemborexant, and how these DORAs compare to other insomnia treatments with the aim of improving treatment choices, reducing adverse events, and improving patient outcomes.
Host: Michael E. Yurcheshen, MD, FAASM
Insomnia is characterized by difficulty falling asleep, staying asleep, and experiencing non-restorative or poor-quality sleep; it often leaves individuals feeling unrefreshed upon awakening. Symptoms during the day may include fatigue, irritability, impaired focus, and excessive sleepiness. The condition can significantly deteriorate a person’s quality of life, leading to reduced productivity, impaired cognitive function, mood disturbances, and an increased risk of accidents or injuries due to daytime sleepiness.
This educational program delves into the pathophysiology and diagnosis of insomnia as well as the role of the orexin system in the sleep/wake cycle. The program also evaluates the latest treatments, including the dual orexin receptor antagonists (DORAs), daridorexant, and lemborexant, and how these DORAs compare to other insomnia treatments with the aim of improving treatment choices, reducing adverse events, and improving patient outcomes.
Host: Kevin Trice, MD
Host: Michael E. Yurcheshen, MD, FAASM
Insomnia is characterized by difficulty falling asleep, staying asleep, and experiencing non-restorative or poor-quality sleep; it often leaves individuals feeling unrefreshed upon awakening. Symptoms during the day may include fatigue, irritability, impaired focus, and excessive sleepiness. The condition can significantly deteriorate a person’s quality of life, leading to reduced productivity, impaired cognitive function, mood disturbances, and an increased risk of accidents or injuries due to daytime sleepiness.
This educational program delves into the pathophysiology and diagnosis of insomnia as well as the role of the orexin system in the sleep/wake cycle. The program also evaluates the latest treatments, including the dual orexin receptor antagonists (DORAs), daridorexant, and lemborexant, and how these DORAs compare to other insomnia treatments with the aim of improving treatment choices, reducing adverse events, and improving patient outcomes.
Host: Kevin Trice, MD
Insomnia is characterized by difficulty falling asleep, staying asleep, and experiencing non-restorative or poor-quality sleep; it often leaves individuals feeling unrefreshed upon awakening. Symptoms during the day may include fatigue, irritability, impaired focus, and excessive sleepiness. The condition can significantly deteriorate a person’s quality of life, leading to reduced productivity, impaired cognitive function, mood disturbances, and an increased risk of accidents or injuries due to daytime sleepiness.
This educational program delves into the pathophysiology and diagnosis of insomnia as well as the role of the orexin system in the sleep/wake cycle. The program also evaluates the latest treatments, including the dual orexin receptor antagonists (DORAs), daridorexant, and lemborexant, and how these DORAs compare to other insomnia treatments with the aim of improving treatment choices, reducing adverse events, and improving patient outcomes.
Guest: Natalia Castillo Almeida, MD
感染流感会增加住院和罹患严重疾病的风险，尤其对高风险患者而言。幸运的是，接种流感疫苗可以帮助个人有效应对此类情况。在本节目中，内布拉斯加州大学医学院传染病系助理教授 Natalia Castillo Almeida 医生分享了关于住院率的关键数据和流感疫苗的接种建议。
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Keith C. Ferdinand, MD, FACC, FAHA, FASPC, FNLA
Vaccines are essential in reducing death and disability related to influenza, but unfortunately, not all patients have equal access to these life-saving resources. In fact, many barriers exist, like misinformation and lack of public awareness and education. That’s why Dr. Charles Turck speaks with Dr. Keith Ferdinand about ways we can break down barriers and improve vaccination rates among members of racial and ethnic minority communities.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: John J. Russell, MD
Guest: Darvin Scott Smith, MD
Hospitals and health systems face several economic and logistical challenges due to low rates of flu vaccination. Fortunately, there are policies, programs, and initiatives that can be implemented in health system environments and at the community level to increase flu vaccination rates. Learn more with Drs. Darvin Scott Smith and John Russell. Dr. Smith is an Infectious Disease Consultant of Public Health Works, LLC in Northern California, and Dr. Russell is a family medicine physician at Jefferson Health System in Abington, Pennsylvania.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Darvin Scott Smith, MD
There are several benefits associated with using real-world evidence to assess vaccine effectiveness, especially in the context of flu vaccines. Find out why and what the real-world evidence says about the effectiveness of flu vaccines with Dr. Charles Turck and Dr. Darvin Scott Smith. Dr. Smith is an infectious disease consultant of Public Health Works, LLC in Northern California.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Jill Foster, MD
The clinical and economic burden associated with the flu is particularly heavy for our youngest patients. Learn more about this burden and how influenza vaccines can help reduce it with Dr. Charles Turck and Dr. Jill Foster, Professor in the Department of Pediatrics and the Director of the Division of Pediatric Infectious Diseases at the University of Minnesota Medical School in Minneapolis.
Host: Ryan Maves, MD
Guest: Kelly Pennington, MD
It’s estimated that respiratory syncytial virus (RSV) is responsible for up to 30 percent of viral respiratory infections in the stem cell transplant population. So how can we help RSV patients achieve their best outcomes? Learn more with Dr. Ryan Maves as he speaks with Dr. Kelly Pennington, Assistant Professor of Medicine at the Mayo Clinic in Rochester, Minnesota.
This program is produced in partnership with the American College of CHEST Physicians and is supported by an educational grant from GSK.
Host: Ryan Maves, MD
Guest: Megan Conroy, MD, MA(Ed)
Respiratory syncytial virus (RSV) is most commonly recognized for the significant disease it causes in infants and young children. However, over time its prevalence in adults has increased. Tune in to learn more with Dr. Ryan Maves as he speaks with Dr. Megan Conroy, Assistant Professor of Medicine at the Ohio State University in Columbus.
This program is produced in partnership with the American College of CHEST Physicians and is supported by an educational grant from GSK.
Host: Ryan Maves, MD
Guest: Kelly Pennington
It’s estimated that respiratory syncytial virus (RSV) is responsible for up to 30 percent of viral respiratory infections in the stem cell transplant population. So how can we help RSV patients achieve their best outcomes? Learn more with Dr. Ryan Maves as he speaks with Dr. Kelly Pennington, Assistant Professor of Medicine at the Mayo Clinic in Rochester, Minnesota.
Guest: Natalia Castillo Almeida, MD
Influenza can increase the risk of hospitalization and disease severity, specifically for high-risk patients. Fortunately, the influenza vaccine can help combat this. Join Dr. Natalia Castillo Almeida, an Assistant Professor in the Division of Infectious Diseases at the University of Nebraska School of Medicine, as she shares key data on hospitalization rates and recommendations for vaccination.
Host: Ioana Preston, MD
Host: Oksana A. Shlobin, MD
Host: Richard N. Channick, MD
While there are now many effective drug treatments for PAH and PH, new molecular pathways of disease offer horizons for novel therapeutic developments that may, alone or in combination with existing, approved medications, alter the process of PH as a disease. This program examines some of the bright lights on the horizon of PH treatment and emerging drug delivery approaches to getting PH medications to their intended site of action. The emergence of these new agents could radically alter the way we think about combination therapy for PAH and other forms of PH.
Host: Pamela J. McShane, MD
Host: Gregory Tino, MD
Host: Ashwin Basavaraj, MD
An estimated 350,000-500,000 adults are affected by bronchiectasis in the United States, and up to 90% of patients with bronchiectasis present with chronic cough. This educational activity provides a framework of treatment options for NCFBE, empowering medical practitioners to work collaboratively with pulmonary specialists and confidently proceed with a sustainable treatment plan that is evidence-based and makes sense for both practitioner and patient.
Host: Ashwin Basavaraj, MD
Host: Jungae Kole, RN, BSN
An estimated 350,000-500,000 adults are affected by bronchiectasis in the United States, and up to 90% of patients with bronchiectasis present with chronic cough. This educational activity provides a framework of treatment options for NCFBE, empowering medical practitioners to work collaboratively with pulmonary specialists and confidently proceed with a sustainable treatment plan that is evidence-based and makes sense for both practitioner and patient.
Host: Ashwin Basavaraj, MD
Host: Jungae Kole, RN, BSN
An estimated 350,000-500,000 adults are affected by bronchiectasis in the United States, and up to 90% of patients with bronchiectasis present with chronic cough. This educational activity provides a framework of treatment options for NCFBE, empowering medical practitioners to work collaboratively with pulmonary specialists and confidently proceed with a sustainable treatment plan that is evidence-based and makes sense for both practitioner and patient.
Host: Gregory Tino, MD
Host: Pamela J. McShane, MD
An estimated 350,000-500,000 adults are affected by bronchiectasis in the United States, and up to 90% of patients with bronchiectasis present with chronic cough. This educational activity provides a framework of treatment options for NCFBE, empowering medical practitioners to work collaboratively with pulmonary specialists and confidently proceed with a sustainable treatment plan that is evidence-based and makes sense for both practitioner and patient.
Host: Ashwin Basavaraj, MD
An estimated 350,000-500,000 adults are affected by bronchiectasis in the United States, and up to 90% of patients with bronchiectasis present with chronic cough. This educational activity provides a framework of treatment options for NCFBE, empowering medical practitioners to work collaboratively with pulmonary specialists and confidently proceed with a sustainable treatment plan that is evidence-based and makes sense for both practitioner and patient.
Host: Colin Swenson, MD
An estimated 350,000-500,000 adults are affected by bronchiectasis in the United States, and up to 90% of patients with bronchiectasis present with chronic cough. This educational activity provides a framework of treatment options for NCFBE, empowering medical practitioners to work collaboratively with pulmonary specialists and confidently proceed with a sustainable treatment plan that is evidence-based and makes sense for both practitioner and patient.
Host: Gregory Tino, MD
Host: Colin Swenson, MD
An estimated 350,000-500,000 adults are affected by bronchiectasis in the United States, and up to 90% of patients with bronchiectasis present with chronic cough. This educational activity provides a framework of treatment options for NCFBE, empowering medical practitioners to work collaboratively with pulmonary specialists and confidently proceed with a sustainable treatment plan that is evidence-based and makes sense for both practitioner and patient.
Host: Colin Swenson, MD
An estimated 350,000-500,000 adults are affected by bronchiectasis in the United States, and up to 90% of patients with bronchiectasis present with chronic cough. This educational activity provides a framework of treatment options for NCFBE, empowering medical practitioners to work collaboratively with pulmonary specialists and confidently proceed with a sustainable treatment plan that is evidence-based and makes sense for both practitioner and patient.
Host: Vallerie V. McLaughlin, MD
In late 2022, the ERS/ESC issued new guidances for screening, diagnosis, and treatment of all forms of pulmonary hypertension. The new guidelines insist on regular and consistent risk assessment for all patients, not just for initial diagnostic purposes but for monitoring and management once a diagnosis is made. This program covers numerous aspects of the new ERS/ESC guidelines, with some practical examples and a focus on Group 1 PAH and other forms. New diagnostic approaches are considered, and accurate and complete cardiac imaging is a focus.
Host: Richard N. Channick, MD
Guest: Dinesh Khanna, MD, MS
Guest: Rajan Saggar, MD
In late 2022, the ERS/ESC issued new guidances for screening, diagnosis, and treatment of all forms of pulmonary hypertension. The new guidelines insist on regular and consistent risk assessment for all patients, not just for initial diagnostic purposes but for monitoring and management once a diagnosis is made. This program covers numerous aspects of the new ERS/ESC guidelines, with some practical examples and a focus on Group 1 PAH and other forms. New diagnostic approaches are considered, and accurate and complete cardiac imaging is a focus.
Host: Dinesh Khanna, MD, MS
In late 2022, the ERS/ESC issued new guidances for screening, diagnosis, and treatment of all forms of pulmonary hypertension. The new guidelines insist on regular and consistent risk assessment for all patients, not just for initial diagnostic purposes but for monitoring and management once a diagnosis is made. This program covers numerous aspects of the new ERS/ESC guidelines, with some practical examples and a focus on Group 1 PAH and other forms. New diagnostic approaches are considered, and accurate and complete cardiac imaging is a focus.
Host: Vallerie V. McLaughlin, MD
Guest: Richard Krasuski, MD
Guest: Dinesh Khanna, MD, MS
In late 2022, the ERS/ESC issued new guidances for screening, diagnosis, and treatment of all forms of pulmonary hypertension. The new guidelines insist on regular and consistent risk assessment for all patients, not just for initial diagnostic purposes but for monitoring and management once a diagnosis is made. This program covers numerous aspects of the new ERS/ESC guidelines, with some practical examples and a focus on Group 1 PAH and other forms. New diagnostic approaches are considered, and accurate and complete cardiac imaging is a focus.
Host: Richard Krasuski, MD
In late 2022, the ERS/ESC issued new guidances for screening, diagnosis, and treatment of all forms of pulmonary hypertension. The new guidelines insist on regular and consistent risk assessment for all patients, not just for initial diagnostic purposes but for monitoring and management once a diagnosis is made. This program covers numerous aspects of the new ERS/ESC guidelines, with some practical examples and a focus on Group 1 PAH and other forms. New diagnostic approaches are considered, and accurate and complete cardiac imaging is a focus.
Host: Richard Krasuski, MD
In late 2022, the ERS/ESC issued new guidances for screening, diagnosis, and treatment of all forms of pulmonary hypertension. The new guidelines insist on regular and consistent risk assessment for all patients, not just for initial diagnostic purposes but for monitoring and management once a diagnosis is made. This program covers numerous aspects of the new ERS/ESC guidelines, with some practical examples and a focus on Group 1 PAH and other forms. New diagnostic approaches are considered, and accurate and complete cardiac imaging is a focus.
Host: Richard Krasuski, MD
In late 2022, the ERS/ESC issued new guidances for screening, diagnosis, and treatment of all forms of pulmonary hypertension. The new guidelines insist on regular and consistent risk assessment for all patients, not just for initial diagnostic purposes but for monitoring and management once a diagnosis is made. This program covers numerous aspects of the new ERS/ESC guidelines, with some practical examples and a focus on Group 1 PAH and other forms. New diagnostic approaches are considered, and accurate and complete cardiac imaging is a focus.
Host: Vallerie V. McLaughlin, MD
Guest: Jean M. Elwing, MD
Guest: Martha Kingman, FNP-C, DNP
In late 2022, the ERS/ESC issued new guidances for screening, diagnosis, and treatment of all forms of pulmonary hypertension. The new guidelines insist on regular and consistent risk assessment for all patients, not just for initial diagnostic purposes but for monitoring and management once a diagnosis is made. This program covers numerous aspects of the new ERS/ESC guidelines, with some practical examples and a focus on Group 1 PAH and other forms. New diagnostic approaches are considered, and accurate and complete cardiac imaging is a focus.
Host: Vallerie V. McLaughlin, MD
In late 2022, the ERS/ESC issued new guidances for screening, diagnosis, and treatment of all forms of pulmonary hypertension. The new guidelines insist on regular and consistent risk assessment for all patients, not just for initial diagnostic purposes but for monitoring and management once a diagnosis is made. This program covers numerous aspects of the new ERS/ESC guidelines, with some practical examples and a focus on Group 1 PAH and other forms. New diagnostic approaches are considered, and accurate and complete cardiac imaging is a focus.
Host: Vallerie V. McLaughlin, MD
In late 2022, the ERS/ESC issued new guidances for screening, diagnosis, and treatment of all forms of pulmonary hypertension. The new guidelines insist on regular and consistent risk assessment for all patients, not just for initial diagnostic purposes but for monitoring and management once a diagnosis is made. This program covers numerous aspects of the new ERS/ESC guidelines, with some practical examples and a focus on Group 1 PAH and other forms. New diagnostic approaches are considered, and accurate and complete cardiac imaging is a focus.
Host: Vallerie V. McLaughlin, MD
In late 2022, the ERS/ESC issued new guidances for screening, diagnosis, and treatment of all forms of pulmonary hypertension. The new guidelines insist on regular and consistent risk assessment for all patients, not just for initial diagnostic purposes but for monitoring and management once a diagnosis is made. This program covers numerous aspects of the new ERS/ESC guidelines, with some practical examples and a focus on Group 1 PAH and other forms. New diagnostic approaches are considered, and accurate and complete cardiac imaging is a focus.
Host: Dinesh Khanna, MD, MS
In late 2022, the ERS/ESC issued new guidances for screening, diagnosis, and treatment of all forms of pulmonary hypertension. The new guidelines insist on regular and consistent risk assessment for all patients, not just for initial diagnostic purposes but for monitoring and management once a diagnosis is made. This program covers numerous aspects of the new ERS/ESC guidelines, with some practical examples and a focus on Group 1 PAH and other forms. New diagnostic approaches are considered, and accurate and complete cardiac imaging is a focus.
Host: Oksana A. Shlobin, MD
Guest: Rajan Saggar, MD
Guest: Sudarshan Rajagopal, MD, PhD
In late 2022, the ERS/ESC issued new guidances for screening, diagnosis, and treatment of all forms of pulmonary hypertension. The new guidelines insist on regular and consistent risk assessment for all patients, not just for initial diagnostic purposes but for monitoring and management once a diagnosis is made. This program covers numerous aspects of the new ERS/ESC guidelines, with some practical examples and a focus on Group 1 PAH and other forms. New diagnostic approaches are considered, and accurate and complete cardiac imaging is a focus.
Host: Sudarshan Rajagopal, MD, PhD
In late 2022, the ERS/ESC issued new guidances for screening, diagnosis, and treatment of all forms of pulmonary hypertension. The new guidelines insist on regular and consistent risk assessment for all patients, not just for initial diagnostic purposes but for monitoring and management once a diagnosis is made. This program covers numerous aspects of the new ERS/ESC guidelines, with some practical examples and a focus on Group 1 PAH and other forms. New diagnostic approaches are considered, and accurate and complete cardiac imaging is a focus.
Host: Dinesh Khanna, MD, MS
In late 2022, the ERS/ESC issued new guidances for screening, diagnosis, and treatment of all forms of pulmonary hypertension. The new guidelines insist on regular and consistent risk assessment for all patients, not just for initial diagnostic purposes but for monitoring and management once a diagnosis is made. This program covers numerous aspects of the new ERS/ESC guidelines, with some practical examples and a focus on Group 1 PAH and other forms. New diagnostic approaches are considered, and accurate and complete cardiac imaging is a focus.
Host: Jacob Sands, MD
Guest: Aliyah Pabani, MD
Lung cancer patients undergoing immunotherapy may be at risk for developing life-threatening toxicities. Find out how you can manage them with Dr. Jacob Sands and Dr. Aliyah Pabani, Clinical Assistant Professor in the Department of Medicine at the University of Calgary and Director of the Alberta Immunotherapy Database.
Guest: Ashwin Basavaraj, MD
Host: Christopher Lippincott, MD, MPH
From airway clearance techniques and mucoactive therapy—what can clinicians do to manage bronchiectasis exacerbations? To answer this question, Dr. Christopher Lippincott and Dr. Ashwin Basavaraj explore the mechanisms that lead to bronchiectasis and share strategies to manage exacerbations.
This program is produced in partnership with the American College of CHEST Physicians, and is sponsored by Insmed Incorporated.
Host: Ashwin Basavaraj, MD
Guest: Christopher Lippincott, MD, MPH
Bronchiectasis is a complex syndrome that can lead to an interconnected cascade of airway dysfunction and inflammation. How has our understanding of this syndrome evolved with Cole’s vicious cycle hypothesis? Dr. Ashwin Basavaraj and Dr. Christopher Lippincott take a closer look at this hypothesis and the clinical mechanisms behind bronchiectasis.
This program is produced in partnership with the American College of CHEST Physicians, and is sponsored by Insmed Incorporated.
Host: Mark Socinski, MD
Guest: Patrick Forde, M.B.B.Ch.
The optimal management of non-small cell lung cancer (NSCLC) has fundamentally changed. Targeted agents, mono and combination immunotherapy, and immunochemotherapy options continue to emerge. You also need to factor in new and investigational neoadjuvant and adjuvant regimens. So how do you determine which patients will benefit most within this new landscape of options? Join Drs. Mark Socinski and Patrick Forde as they address these questions and provide a measure of order in the chaos.
Host: Mark Socinski, MD
Guest: Kristin Higgins, MD
The clinical value of adding immunotherapy together with chemoradiation in locally advanced non-small cell lung cancer (NSCLC) has been evident since 2017. This concept has been extended through the emergence of key clinical trials, such as KEYNOTE-799, which includes both squamous and non-squamous subsets. In fact, the coalescence of chemoradiation and immunotherapy has begun to not only push up overall survival, but to also improve cure rates with manageable toxicity. But as the landscape rapidly changes, it becomes increasingly difficult to link evolving data to clinical practice. Join Drs. Mark Socinski and Kristin Higgins as they parse the key trials and offer insights that will help you provide better care, and possibly more hope, for your patients with locally advanced NSCLC.
Host: Mark Socinski, MD
Guest: Patrick Forde, M.B.B.Ch.
The optimal management of non-small cell lung cancer (NSCLC) has fundamentally changed. Targeted agents, mono and combination immunotherapy, and immunochemotherapy options continue to emerge. You also need to factor in new and investigational neoadjuvant and adjuvant regimens. So how do you determine which patients will benefit most within this new landscape of options? Join Drs. Mark Socinski and Patrick Forde as they address these questions and provide a measure of order in the chaos.
Guest: Jason Goldman, MD
How are standard versus adjuvanted influenza vaccines made? Here to break down the manufacturing process for these types of influenza vaccines is primary care physician Dr. Jason Goldman.
Host: Marius M. Hoeper
A recent study explored the safety and efficacy of sotatercept on top of background pulmonary arterial hypertension (PAH) therapy. To learn more about this clinical data, Dr. Marius M. Hoeper, a Professor of Medicine and the Deputy Director of the Department of Respiratory Medicine at Hannover Medical School in Hannover, Germany, dives into the results of this trial and explores how they may impact patients with PAH.
Host: Matt Birnholz, MD
Guest: Jonathan Corren, MD
As recent research demonstrates the important role that TSLP plays in asthma inflammation, Dr Matt Birnholz is joined by Dr Jonathan Corren, an Associate Clinical Professor of Medicine and Pediatrics at David Geffen School of Medicine in Los Angeles. Together, they review how TSLP acts across the spectrum of asthma inflammation, the correlation of TSLP with clinical features of asthma, and more.
©2021 Amgen. All rights reserved. US-53813 Last Updated 6/21
Host: Navitha Ramesh, MD, FCCP
Guest: Allen Blaivas, DO
When selecting the right delivery device for your patient with COPD, there are a lot of factors to consider. To help us better understand these key components, Dr. Navitha Ramesh and Dr. Allen Blaivas from the Rutgers New Jersey Medical School discuss nebulizer therapy, delivery devices, and patient education.
This is a non-promotional, non-CME disease state educational program brought to you by CHEST. Sponsored by Theravance BioPharma and Viatris.
Guest: Narjust Duma, MD
Guest: David J. Feller-Kopman, MD
Guest: Bruce E. Johnson, MD
Guest: Razelle Kurzrock, MD, FACP
Guest: Ignacio Wistuba, MD
Lung cancer incidence is decreasing due in part to reduced smoking rates, and new trends are emerging as things change. But despite these advancements, some challenges remain to be solved. Explore those challenges and key strategies for overcoming them in this four-part series.
PP-US-8201a-1520 12/22
Guest: Andrew Menzies-Gow, PhD
Host: Charles Turck, PharmD, BCPS, BCCCP
Is now the time to shift the asthma management paradigm to prioritize remission as our goal? Dr. Charles Turck is joined by Professor Andrew Menzies-Gow, Director of the Lung Division and Deputy Medical Director at the Royal Brompton and Harefield Hospitals, London, UK, to discuss remission as a goal for patients with asthma. Together, they review a recently published expert consensus framework for asthma remission and discuss whether targeting remission could lead to better outcomes for patients.
At the time of recording, Professor Menzies-Gow provided services to AstraZeneca as an External Expert; Professor Menzies-Gow is now a permanent employee at AstraZeneca.
©2022 Amgen and AstraZeneca. All rights reserved. US-69837 Last Updated 12/22
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Paul Hunter, MD
It’s important to recognize that older adults are more susceptible to influenza infection—as well as increased severity of infection—than younger, healthier populations.1 Fortunately, there are vaccines available that can help prevent influenza in this aging population. But do the relative benefits and harms of higher-dose and adjuvanted vaccines, compared with one another and with other influenza vaccines, favor the use of any one or more of these vaccines over other age-appropriate options for people 65 and older?2 That's the exact question the CDC’s Advisory Committee on Immunization Practices (ACIP) sought to answer and what Dr. Charles Turck discusses with Dr. Paul Hunter, Associate Professor in the Department of Family Medicine and Community Health at the University of Wisconsin School of Medicine and Public Health.
References:
1. Centers for Disease Control and Prevention. Fly & People 65 Years and Older. Accessed August 16, 2022. https://www.cdc.gov/flu/highrisk/65over.htm.
2. National Center for Immunization & Respiratory Diseases. Advisory Committee on Influenza Practices. Influenza Vaccines for Older Adults: GRADE Summary. Accessed August 16, 2022.
USA-FLUD-22-0056 December 2022
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Natalia Castillo Almeida, MD
Patients in urban communities often face challenges when accessing influenza vaccines. But there are ways we can help address those geographic and socioeconomic barriers. Joining Dr. Charles Turck to share key strategies for improving influenza vaccination rates in urban communities is Dr. Natalia Castillo, Assistant Professor in the Division of Infectious Diseases at University of Nebraska Medical Center.
Host: David Schulman, MD, MPH, FCCP
Guest: William Lago, MD
Guest: Tejaswini Kulkarni, MD, MPH, FCCP
What are some of the barriers to early diagnosis for idiopathic pulmonary fibrosis (IPF)? Joining Dr. David Schulman to share their perspectives on the latest diagnostic challenges and provide strategies to combat them are Drs. Tejaswini Kulkarni and William Lago.
This is a non-promotional, non-CME disease state educational podcast produced in partnership with the American College of Chest Physicians and is supported by Three Lakes Foundation.
Guest: Professor Christopher Brightling, PhD, FMedSci
Guest: Professor Bruce Levy, MD
Host: Charles Turck, PharmD, BCPS, BCCCP
For an asthma patient with active airway hyperresponsiveness, what kind of role do airway structural changes and mast cells play? And why is airway hyperresponsiveness so important? Professor Chris Brightling and Professor Bruce Levy share their clinical perspectives on airway hyperresponsiveness.
©2022 Amgen and AstraZeneca. All rights reserved. US-69836 Last Updated 10/22
Host: Christina Madison, BS, PharmD, BCACP, AAHIVP
In the midst of a potential tridemic between COVID-19, RSV, and influenza, it’s now more critical than ever to raise awareness among patients about the importance of flu vaccines. Here to provide counseling strategies for educating patients about flu vaccines is Dr. Christina Madison, Associate Professor of Pharmacy Practice at Roseman University of Health Sciences.
Host: Jennifer Caudle, DO
Guest: Carolyn Bridges, MD
We all know that influenza vaccinations can help prevent serious infections and save lives. But how often do you consider the underrecognized benefits of these vaccines—like how influenza vaccinations can be a cost-effective solution for both patients and the entire healthcare system? Joining Dr. Jennifer Caudle to discuss these underrecognized benefits and how we can educate patients about the benefits of influenza vaccination is Dr. Carolyn Bridges, Director of Adult Immunizations at Immunize.org.
Host: Kevin Cleveland, PharmD, ANP
Older adults face a variety of unique challenges that increase their risk of serious influenza infections. But fortunately, vaccinations can help address these challenges. Learn more with Dr. Kevin Cleveland, Associate Professor at the Idaho State University College of Pharmacy.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Kimberly McKeirnan, Pharm.D., BCACP
Vaccination rates are much lower in rural communities compared to other regions, which has a big impact on patients and the larger healthcare system as a whole. So what are some of the factors contributing to this disparity, and what strategies can we use to address them? Joining Dr. Charles Turck to discuss how we can increase vaccination rates in rural communities is Dr. Kimberly McKeirnan, Director of the Center for Pharmacy Practice Research at Washington State University.
Host: Benjamin Levy, MD
Guest: Rebecca Heist, MD, MPH
Guest: Peter Bela Illei, MD
Antibody-drug conjugates (ADCs) have promising clinical data in the treatment of advanced non-small cell lung cancer. Listen in as Drs. Benjamin Levy, Rebecca Heist, and Peter Illei discuss current data on TROP2 ADCs and what this means for our patients.
Host: Jyoti D. Patel, MD, FASCO
Join us as Dr. Jyoti Patel illustrates her approach to treating a 75-year-old patient who was recently diagnosed with stage IV NSCLC harboring a MET exon 14 skipping mutation—then put these tips to use in your own practice!
Host: Paul Paik, MD
Guest: Catherine Shu, MD
Take a deep dive into current and ongoing clinical trials related to MET inhibitors and discover the key distinctions between these agents, such as dosing differences. Our experts also have recommendations on appropriate therapy selection for your patients with advanced NSCLC harboring MET exon 14 skipping mutations.
Host: Janani Reisenauer, MD
Host: Septimiu Murgu, MD, FCCP
Host: Eric Edell, MD, FCCP
Lung cancer screenings have shown to be effective in detecting lung cancer earlier. So what are the current guidelines? To discuss this question and give their own experiences with lung cancer screenings and the management of early-stage lung cancer are expert pulmonologists, Drs. Septimiu Murgu and Janani Reisenauer. Dr. Murgu is from the University of Chicago, and Dr. Reisenauer is from the Mayo Clinic.
Host: Matthew Sorrentino, MD
Guest: Michael A. Solomon, MD, MBA
Guest: Sean Agbor-Enoh, MD, PhD
Pulmonary arterial hypertension (PAH) is a rare, and even fatal, condition that can impair the chest and lungs. But could a new blood test help us better assess disease severity and survivability in patients with PAH? To dive deeper into this topic, Dr. Matthew Sorrentino is joined by Dr. Michael Solomon and Dr. Sean Agbor-Enoh from the National Institutes of Health.
Host: Matt Birnholz, MD
Guest: David Canaday, MD
As we age, our immune system becomes weaker and is therefore unable to ward off infection as easily as in our younger years.1 This is particularly troublesome during flu season. In fact, the CDC’s Advisory Committee on Immunization Practices (ACIP) recently looked at flu vaccine data for adults aged 65 years and older, and they now recommend that this age group preferentially receive higher dose or adjuvanted vaccines over standard dose unadjuvanted vaccines when available.2 So what was the data that led to these updated recommendations? Joining Dr. Matt Birnholz to share those key findings and the role of adjuvanted vaccines like FLUAD® QUADRIVALENT (Influenza Vaccine, Adjuvanted) in preventing influenza in older adults is Dr. David Canaday, Professor in the Division of Infectious Diseases & HIV Medicine at Case Western Reserve University in Cleveland.
Avoid use in patients who have experienced any severe allergic reactions to any component of the vaccine. For more risk information please see below or consult the Full US Prescribing Information for FLUAD® QUADRIVALENT here.
References:
1. Gavazzi G, Krause KH. Ageing and infection. Lancet Infect Dis. 2002;2(11):659-666.
2. Centers for Disease Control and Prevention. Past seasons estimated influenza disease …
Host: John J. Russell, MD
Guest: Vallerie V. Mclaughlin, MD
Join Dr. John Russell as he speaks about diagnosing and treating pulmonary arterial hypertension using the latest pharmacologic and medical management strategies with Dr. Valerie McLaughlin, Director of the Pulmonary Hypertension Program at the University of Michigan.
Host: Dixon W. Wilde, PhD, FAHA
Guest: Jean M. Elwing, MD
Many pulmonary arterial hypertension (PAH) patients remain undiscovered, undiagnosed, and underserved. The reasons for this are many-fold, but central to the treatment of these patients is a need to make PAH care more accessible, affordable, and attractive. The COVID-19 pandemic has further exacerbated the need to connect with not only undiscovered PAH patients, but even those currently under physician care. That’s why this program explores myriad aspects of finding means to discover, connect with, and manage the disease of these underserved PAH patients in our general population. Key explorations brought to light in the program include the burdens many patients and physicians face with the financial costs to care, the prejudices many experience or perceive, and the lack of education and awareness of patients and healthcare providers alike. Part of the solution to these modern-day issues centers on the education of physicians, reducing medical and ancillary costs to patients, and making the most of the developing practices of telemedicine.
Host: Septimiu Murgu, MD, FCCP
Host: Eric Edell, MD, FCCP
Guest: Narjust Duma, MD
Guest: Janani Reisenauer, MD
Guest: Colleen Channick, MD, FCCP, DAABIP
A multidisciplinary panel including a medical oncologist, a thoracic surgeon, and an interventional pulmonologist will discuss the role of lung cancer teams in their thoracic oncology practices. The panelists will review their management of patients with lung cancer during the COVID-19 pandemic, including the impact of delayed procedures and telemedicine on patient outcomes.
Host: Mark Socinski, MD
Guest: Jennifer Marie Suga, MD, MPH
There are new targeted therapies that are now approved for the treatment of advanced non-small cell lung cancer. Dr. Mark Socinski & Dr. Marie Suga discuss evolving diagnostic approaches and best practices for selecting the right therapy for patients with NSCLC.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Nick Kusnezov, MD
Can you balance locum tenens with a full-time career? To answer that question, Dr. Charles Turck is joined by board-certified orthopedic surgeon, Dr. Nicholas Kusnezov, to walk us through his journey from joining the military to locum tenens.
Host: Septimiu Murgu, MD, FCCP
Host: Eric Edell, MD, FCCP
Guest: Narjust Duma, MD
Guest: Andreas Rimner, MD
Two internationally known medical and radiation oncologists will discuss ongoing and recent clinical trials and offer their perspectives on how they will impact thoracic oncology practice. The panelists will also discuss current guidelines for managing patients with advanced lung cancer and emphasize the role of tissue and blood biomarkers.
The treatment landscape for eosinophilic asthma is a rapidly changing field, with new therapies arriving on a regular basis. One of the newer therapeutic approaches available is biologics. But how do they work to treat eosinophilic asthma? And which of our patients should be prescribed biologics and when? Tune in to hear Dr. Ian Pavord answer those and other key questions about the role of biologics in the eosinophilic asthma treatment landscape with Dr. Charles Turck.
Eosinophils are part of a complex set of allergic mechanisms in eosinophilic asthma. But eosinophils are far from the only component or driver of disease. Here to share key insights on the role of eosinophils along with genetic and environmental factors in the pathophysiology of eosinophilic asthma is pulmonary and critical care physician Dr. Praveen Akuthota.
Host: Jennifer Caudle, DO
Guest: Wendy Wright, DNP, FNP-BC, ANP-BC, FAANP, FAAN, FNAP
Guest: Gary Marshall, MD
It's well understood that annual vaccination is the best way to help reduce the high burden associated with influenza. And while most influenza vaccines available in the United States are produced in eggs, this presents some inherent challenges, which can lead to reduced vaccine effectiveness. Fortunately, alternative production processes can help us overcome those challenges, and to learn more, Dr. Jennifer Caudle speaks with Dr. Wendy Wright and Dr. Gary Marshall.
USA-CRP-22-0018 May 2022
HER2 (ERBB2) mutations may increase receptor internalization and lead to hyperactive downstream signaling, uncontrolled cell growth, and tumorigenesis. Learn more about how HER2 mutations affect several types of cancer, including non-small cell lung cancer (NSCLC).
Intended for US Healthcare Professions only
©2022 Daiichi Sankyo, Inc. and AstraZeneca. PP-US-8201a-1332 06/22
Host: Dixon W. Wilde, PhD, FAHA
Guest: Vallerie V. Mclaughlin, MD
In the management of the pulmonary arterial hypertension (PAH) patient, the use of risk assessment algorithms has become de rigueur for the regular determination of disease progression and the effectiveness of treatment. However, based on the registries, from which the modern risk assessment models have been developed, it’s clear that the majority of patients fall into the intermediate-risk category. And yet, within this broad category, there’s a spectrum of disease severity, medical treatment need, and survivorship. Using risk assessment effectively in the modern era will rely on a rethinking of how to use risk assessment and adjusting disease management strategies appropriately. This program explores new ideas in the use and application of risk assessment protocols and the impact these have on the use of multimodal, combination therapy and lung transplantation.
Host: Eric Edell, MD, FCCP
Host: Septimiu Murgu, MD, FCCP
Guest: Narjust Duma, MD
Guest: Christopher Hartley, MD
Guest: Jeffrey Mueller, DO
Expert pathologists and a medical oncologist will discuss current guidelines and their own practices regarding the role of liquid biopsy and comprehensive genetic and PD-L1 testing in the management of advanced lung cancer. The panelists will also explore various strategies for optimizing the quantity and quality of cytology and small volume biopsy specimens.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Brian Smith, MD, MPH
Guest: Charlie Strange, MD
Screening for alpha-1 antitrypsin deficiency in patients with chronic obstructive pulmonary disease (COPD) plays an integral role in modern care algorithms. But screening is only the first step, however, as primary care physicians and pulmonologists must then work together to coordinate a patient’s care. Joining Dr. Charles Turck to share their perspectives on how we can better collaborate to detect and treat alpha-1 in patients with COPD are primary care physician Dr. Brian Smith and pulmonologist Dr. Charlie Strange.
Host: Septimiu Murgu, MD, FCCP
Host: Eric Edell, MD, FCCP
Guest: Nichole Tanner, MD, MS, FCCP
Guest: Fabien Maldonado, MD, FCCP
Two internationally known interventional pulmonologists will discuss current guidelines and their own experiences regarding sampling of lung lesions and mediastinal adenopathy. Specifically, the panelists will discuss the pros and cons of various diagnostic strategies and sampling techniques, including transcutaneous and bronchoscopic biopsies. This interactive webinar will offer the opportunity for learners to ask questions prior to and during the event. Learning is augmented by a few follow-up quizzes weeks after the webinar, a strategy proven to improve knowledge gain and retention.
Guest: David C. Mares, MD
Since alpha-1 antitrypsin deficiency is prevalent among patients with chronic obstructive pulmonary disease (COPD), screening for alpha-1 is absolutely critical. However, diagnosing alpha-1 in patients with COPD can be challenging. That’s why pulmonologist and critical care specialist Dr. David Mares is here to share how we can overcome those challenges and the impact screening for alpha-1 may have on our patients with COPD.
Host: David Schulman, MD, MPH, FCCP
Guest: Andrew H. Limper, MD
Guest: Timothy A. Hernandez, MD
There are many barriers to reaching a definitive diagnosis for idiopathic pulmonary fibrosis (IPF). To learn more about these obstacles—and how we can overcome them—Dr. David Schulman from the American College of Chest Physicians joins Dr. Tim Hernandez from the University of Texas Health Sciences Center and Dr. Andrew Limper from the Mayo Clinic to discuss the diagnosis of IPF.
This is a non-promotional, non-CME disease state educational podcast produced in partnership with the American College of Chest Physicians and is supported by Three Lakes Foundation.
https://info.chestnet.org/bridging-specialties-timely-diagnosis-for-ild-patients
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Trevor Cabrera, MD
What’s it like becoming a locum tenens physician right out of residency? Dr. Charles Turck joins Dr. Trevor Cabrera, a Board-Certified pediatrician who trained in Houston, Texas, to share his firsthand experience and offer advice for residents.
Host: Paul P. Doghramji, MD, FAAFP
Guest: Samantha Conroy, MD
Locum tenens can improve quality of care around the globe—especially in remote and underserved communities. To share how, Dr. Paul Doghramji joins Dr. Samantha Conroy, a family practice obstetrician to share her experiences working as a locum tenens obstetrician in underserved communities.
Host: Jennifer Caudle, DO
Guest: Maurice G. Sholas, MD, PhD
After years of serving the New Orleans community, one physician decided to pursue locum tenens work. Dr. Jennifer Caudle joins Dr. Maurice Sholas, a pediatric physical rehabilitation physician, to share his experiences with locum tenens and in New Orleans.
Host: Jennifer Caudle, DO
Guest: Brian Smith, MD, MPH
Primary care physicians play a critical role in screening for alpha-1 antitrypsin deficiency in patients with chronic obstructive pulmonary disease (COPD). But who should they be screening, and how? And what are some of the diagnostic challenges they should be aware of? Here to help answer those and other key questions for primary care physicians is Dr. Brian Smith, who’s in private practice at Versailles Family Medicine in Kentucky.
Guest: Joel Neal, MD, PhD
Guest: Alexander Spira, MD, PhD, FACP
With the recent approvals of mobocertinib and amivantamab, we now have targeted therapies for EGFR exon 20 insertion–positive locally advanced or metastatic NSCLC, following progression on or after platinum-based chemotherapy. To learn more about mobocertinib, Dr. Joel Neal (Stanford) speaks with Dr. Alexander Spira (Virginia Cancer Specialists Research Institute) about the historical unmet need for this patient population, how mobocertinib is different from classical EGFR TKIs, and the clinical data that led to its FDA approval.
All trademarks are property of their respective owners.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Trevor Cabrera, MD
What’s it like becoming a locum tenens physician right out of residency? Dr. Charles Turck joins Dr. Trevor Cabrera, a Board-Certified pediatrician who trained in Houston, Texas, to share his firsthand experience and offer advice for residents.
Host: Lyudmila Bazhenova, MD
Guest: Benjamin Levy, MD
HER2-targeted therapies have demonstrated substantial survival benefits for patients with HER2-positive breast cancer. So can we use those agents for HER2-positive NSCLC? Join Dr. Lyudmila Bazhenova and Dr. Benjamin Levy as they discuss the latest data around emerging agents for HER2-positive NSCLC and the best way to identify these mutations in clinical practice.
Guest: Peter Howarth BSc, (Hons), MBBS, DM, FRCP
Guest: Ian Pavord, MA, DM, FRCP, FERS, FMedSci
Guest: Geoffrey Chupp, MD
Type 2 inflammation can be challenging to identify. What should we be looking for in our patients with severe asthma and COPD? Joining Dr. Peter Howarth to discuss identifying this type of inflammation are Dr. Geoffrey Chupp from the Yale School of Medicine and Dr. Ian Pavord from the University of Oxford.
This is a nonpromotional, non-CME disease state educational podcast brought to you by the American College of CHEST Physicians in collaboration with and paid for by GSK.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Carlos Jesus Acuña-Villaorduña, MD
What are some of the immunologic mechanisms that alter our ability to fight off a mycobacterium tuberculosis infection—and how does this affect our immunocompromised patients? To answer this question, Dr. Charles Turck meets with Dr. Carlos Acuña-Villaorduña from the Boston University School of Medicine to discuss new insights on TB infection and immunosuppression.
Host: John J. Russell, MD
Guest: Joseph E. Bavaria, MD
Featuring a wide range of disciplines and a new approach to comprehensive care, what do we need to know about the Aorta Center at Penn Medicine? Dr. John Russell is joined by Dr. Joseph E. Bavaria to dive into this aortic program and discuss a new approach to comprehensive care.
Guest: Pranay Sinha, MD
Where are we on the path to eliminating tuberculosis? To understand this, Dr. Pranay Sinha, a postdoctoral researcher at Boston Medical Center, discusses what we need to know and shares what’s on the horizon for TB elimination.
Host: Muhammad Adrish MD, MBA, FCCP, FCCM
Guest: Navitha Ramesh, MD, FCCP
Inhalers are one of the most common methods of delivery for the treatment of COPD, but is it the best option for all of our patients? Associate Professor of Pulmonary Critical Care at Baylor College of Medicine, Dr. Muhammad Adrish, reviews LAMA use for COPD patients with Dr. Navitha Ramesh, Assistant Professor at Drexel University College of Medicine.
This episode is produced in partnership with the American College of CHEST Physicians and is sponsored by Viatris Inc.
Guest: Alexander Spira, MD, PhD, FACP
When it comes to HER2 mutations in non-small cell lung cancer (NSCLC), there’s a lot to consider, like CNS metastases, current therapies, patient characteristics, and more. That’s why Dr. Alexander Spira from Johns Hopkins is here to give us an essential overview of HER2 mutations in NSCLC.
Host: Megan Conroy, MD, MA(Ed)
Guest: Farrukh Abbas, MD
On average, more than two-thirds of patients with chronic obstructive pulmonary disease (COPD) make at least one error in using an inhaler device. Fortunately, nebulized long-acting muscarinic antagonists (LAMAs) can help our patients overcome this common challenge in COPD care. That’s why Drs. Megan Conroy and Farrukh Abbas come together to talk about the GOLD treatment guidelines, strategies for reducing patient hesitancy regarding nebulized LAMAs, and more.
This episode is produced in partnership with the American College of CHEST Physicians and is sponsored by Viatris Inc.
Guest: S. Michelle Shiller, DO, AP/CP, MGP
Guest: John V. Heymach, MD, PhD
Exon 20 insertion mutations account for up to 10 percent of EGFR mutations and approximately 2 percent of all non-small cell lung cancer mutations. Although less common, EGFR mutations at exon 20 have an important impact on therapy selection. That’s why Dr. John Heymach speaks with Dr. Michelle Shiller about what those impacts are as well as the available therapies for patients with these mutations.
All trademarks are the property of their respective owners.
Host: Mark Socinski, MD
Guest: Edward B. Garon, MD, MS
The therapeutic landscape for the first-line treatment of non-driver metastatic NSCLC has become complex and, in some cases, controversial. Based on PD-L1 status, do you know which patients should receive immune checkpoint inhibitor (ICI) monotherapy and when ICI should be combined with chemotherapy? Join Drs. Mark Socinski and Edward Garon as they focus on the intricacies associated with making these therapeutic choices, while also looking at future immunotherapeutic opportunities in the neoadjuvant and adjuvant settings.
Host: Lisa K Moores, MD, FCCP, MACP
Guest: David Jiménez MD, PhD, FERS
Guest: Geert-Jan Geersing MD, PhD
Physicians are challenged in adopting the latest clinical guidelines and integrating new and existing treatment advances into practice when managing patients with VTE.
Host: Mark Socinski, MD
Guest: Benjamin Levy, MD
With the availability of more immunotherapies for the management of first-line metastatic NSCLC, PD-L1 status takes on greater importance in determining which approach is best for each patient. Follow along as Dr. Mark Socinski and Dr. Benjamin Levy discuss the factors they use when considering either an immuno-monotherapy or immunotherapy plus chemotherapy approach, and how they monitor for and manage immunotherapy-related adverse events.
Host: Mark Socinski, MD
Guest: Vivek Subbiah, MD
RET rearrangements occur in about 1 to 2% of non-small cell lung cancers. Comprehensive genomic testing is critical for identifying these patients and selecting the appropriate treatment option. Find out the exciting progress that has been made with precision oncology in RET+ NSCLC.
Host: Tom Corbridge, MD, FCCP
Guest: Michael E. Wechsler, MD, MMSc
Severe asthma is an uncontrolled disease that can be difficult to diagnose. To help us overcome this obstacle, Dr. Tom Corbridge joins Dr. Michael Wechsler from National Jewish Health in Denver to discuss the challenges we face while trying to diagnose severe asthma.
This is a non-promotional, non-CME disease state disease education podcast series brought to you by American College of CHEST Physicians in collaboration with and paid for by GSK.
Host: Jacob Sands, MD
Guest: Millie Das, MD
Getting a better understanding of your patient’s challenges might help you improve their care and streamline the path from diagnosis to treatment. To better understand this, Dr. Jacob Sands sits down with Dr. Millie Das from the Stanford School of Medicine to share strategies to choose the best course of care.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Jeffrey D. Cirillo, PhD
How prevalent is tuberculosis in long-term care facilities? To better understand this, Dr. Charles Turck meets with Dr. Jeffrey Cirillo to examine screening and testing strategies to better monitor TB risk, specifically for high-risk patient populations.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Kathryn Gallagher, MS, RN, BSN
Guest: Kate Newcomb-DeSanto, MSN, RN, MSW
What does Penn Medicine’s newly-opened patient room facility have to offer? Dr. Charles Turck is joined by Penn Medicine Clinical Advisors Kathy Gallagher and Kate Newcomb-DeSanto to discuss the new pavilion and how it's revolutionizing patient care.
Host: Mark Socinski, MD
Guest: Sandip Patel, MD
Medical innovation in the treatment of lung cancer is at an all-time high. However, the gap between recent developments and their adoption into clinical practice continues to expand for community oncologists as the plethora of scientific and clinical data for the treatment of NSCLC rapidly emerges. Dr. Mark Socinski and Dr. Sandip Patel go through the selection and management of immune checkpoint inhibitors for patients with advanced NSCLC who do not have an actionable mutation.
Guest: Jared Nathan Silver, MD, PhD
Guest: Praveen Akuthota, MD
Eosinophilic granulomatosis with polyangiitis and hypereosinophilic syndromes are often mistaken for each other. How can we better distinguish these diseases? Dr. Jared Silver discusses how to diagnose these diseases with Dr. Praveen Akuthota, a pulmonologist from U.C. San Diego Medical Center in California.
This is a non-promotional, non-CME disease state disease education podcast series brought to you by American College of CHEST Physicians in collaboration with and paid for by GSK.
Guest: Richard Channick, MD
Guest: Vallerie V. Mclaughlin, MD
It can be very challenging to differentiate between WHO Class 1 Pulmonary Arterial Hypertension and WHO Class 3 Pulmonary Hypertension due to Lung Disease or Chronic Hypoxia. Despite similar clinical manifestations, these two conditions are characterized by different hemodynamic definitions and etiologies. Through the use of 2 case studies, clinicians can learn about the diagnosis and management of PAH versus PH due to lung disease or chronic hypoxia.
Host: Lisa Baumann Kreuziger, MD, MS
Guest: Marc Carrier MD, FRCPC
Guest: Rachel P. Rosovsky, MD, MPH
Although evidence corroborates the safety and efficacy of managing low-risk patients with VTE in outpatient settings through prophylactic extension, the majority of this subtype is still being treated in hospital settings.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Laila Woc-Colburn, MD, DTM&H, FACP, FIDSA
What are some ways we can better care for our patients prior to starting biologic therapy? Dr. Charles Turck joins Dr. Laila Woc-Colburn from the Emory University School of Medicine to discuss ways to improve safety for patients with tuberculosis.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Sandy Marks
Guest: Kim Horvath, JD
Guest: Kyle Thomson, JD
With telehealth services expanding during the COVID-19 pandemic, has our access to them changed? To better understand this, Dr. Charles Turck meets with Sandy Marks, Kim Horvath, and Kyle Thomson from the AMA to explore what’s been done to provide Medicare coverage during a public health emergency and what’s on the horizon for telehealth access.
Host: Stavros Konstantinides, MD, FRCP (Glasg)
Guest: Riyaz Bashir MD, FACC
Guest: Akhilesh Sista, MD, FSIR, FAHA
High risk patients and those with identifiable symptoms are not routinely receiving prophylaxis treatment that could prevent the development of VTE.
Host: Clete A. Kushida, MD, PhD
Guest: Lois E. Krahn, MD
Tune in to hear about new treatments for patients with narcolepsy. Data were recently presented at the American College of Chest Physicians Annual Meeting, and Drs. Clete Kushida and Lois Krahn are breaking it down for you: they examine the evolving treatment landscape and dive into the latest research on currently available and emerging pharmacologic options including the expanding range of oxybate therapies. Join us and find out why it’s such an exciting time to be caring for patients with narcolepsy.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Emily Carroll, JD, MSW
The No Surprises Act aims to protect consumers from surprise medical bills. But how exactly does it go about doing that, and what’s the current status of its implementation? Joining Dr. Charles Turck to share progress and challenges associated with the No Surprises Act is Ms. Emily Carroll, a senior legislative attorney for the American Medical Association's Advocacy Resource Center.
Guest: Adam M. Brufsky, MD, PhD
Guest: Nina Thomas, MD
Interstitial lung disease (ILD) is a heterogeneous group of diseases that produce inflammation and fibrosis of the parenchyma, affecting the alveolar, interstitial, and vascular spaces. Drug-induced (DI) ILD is associated with a range of novel targeted therapies for the treatment of multiple cancer types, including immune checkpoint inhibitors, CDK 4/6 inhibitors, EGFR tyrosine kinase inhibitors, HER2 targeted therapies, and mechanistic target of rapamycin inhibitors.
Although management of low-grade or asymptomatic ILD with corticosteroid treatment and/or treatment interruption may slow or reverse ILD progression, higher-grade/symptomatic ILD requires permanent discontinuation of therapy. Therefore, it is critical that the interprofessional care team is prepared to monitor for and detect anti-cancer therapy–induced ILD. This educational activity will review the latest evidence and strategies for the early detection of medication-induced ILD and pneumonitis and appropriate management strategies to overcome these treatment challenges in patients who receive select anti-cancer therapies. Expert thought leaders will present relevant information about cancer therapy–induced ILD and pneumonitis and how to integrate the latest advances into real-world clinical practice regarding differential diagnosis, hallmark signs/symptoms, recommended management strategies, implications of patient/caregiver education, and the essentials of team-based management to optimize patient outcomes.
Host: Jennifer Caudle, DO
Guest: Sarah Ali, MD
From working in a big city to taking on an assignment in a small mountain village, Dr. Sarah Ali from the Ventura County Medical Center joins Dr. Jennifer Caudle to talk about her adventures abroad with locum tenens and share key lessons she learned along the way.
Host: Jacob Sands, MD
Guest: Tejas Patil, MD
What kind of role does next-generation sequencing play in HER2-mutated non-small cell lung cancer? Dr. Jacob Sands is joined by Dr. Tejas Patil from the University of Colorado Medicine to explore the clinical utility of NGS and highlight opportunities to expand molecular testing into clinical practice.
Host: Hector O. Chapa, MD, FACOG
Guest: Sandra Misale, MD
As the treatment landscape continues to evolve, what do we need to know about current treatment challenges and novel therapeutic options? Dr. Hector Chapa is joined by Dr. Sandra Misale to explore emerging therapies in HER2-mutated non-small cell lung cancer.
Guest: Nicolas Girard, MD
Guest: Alex Spira, MD, PhD, FACP
While the management and treatment of HER2-mutated non-small cell lung cancer continues to evolve, patients still face many unmet needs. Dr. Nicolas Girard, a pneumologist and Professor of Respiratory Medicine at Versailles Saint Quentin University, explores these unmet needs and how we can solve them.
Host: Misako Nagasaka, MD, PhD
One area of recent progress in the treatment of non–small cell lung cancer (NSCLC) is the development of HER2 targeted therapies for the rare, emerging genetic variant, ERBB2 (HER2) mutations. In fact, the NCCN lists ERBB2 (HER2) mutations as an emerging biomarker to identify novel therapies for patients with metastatic NSCLC. The HER2-directed antibody-drug conjugates (ADC) ado-trastuzumab emtansine (T-DM1) and fam-trastuzumab deruxtecan-nxki are now listed as available targeted agents with activity against HER2 mutations. ADCs with other targets such as Trop-2 and HER3 are now also under investigation and showing promise in NSCLC. ADCs have the potential to increase treatment choices for patients with mNSCLC.
For practicing clinicians, this evolution of HER2-directed therapy and ADCs will add to the complexity of NSCLC treatment. This activity will review the emerging role and potential application of ADCs in mNSCLC, including HER2 as a target in NSCLC, biomarker testing, HER2-, HER3-, and TROP2-targeted ADCs, available clinical data on safety and efficacy, evidence-based guideline recommendations, and how newer targeted agents may fit into the treatment paradigm for patients with mNSCLC.
Host: Hector O. Chapa, MD, FACOG
Guest: Sandra Misale, MD
Did you know that HER2 mutations can be found in about 4 percent of patients with non-small cell lung cancer (NSCLC)? Although it’s not a very common genetic event, it’s still important to know how these mutations drive disease progression and how you can treat these NSCLC patients. That’s why Dr. Sandra Misale joins Dr. Hector Chapa to explore the clinical features and characteristics of HER2 mutations along with the available therapeutic options.
Guest: Howard (Jack) West, M.D.
For patients with advanced non-small cell lung cancer, broad molecular testing can be both a solution and a challenge. Here to share key challenges for next-generation sequencing is Dr. Jack West, Associate Clinical Professor at the City of Hope Comprehensive Cancer Center in California.
Host: Jacob Sands, MD
Guest: Howard (Jack) West, MD
Guest: Nicolas Girard, MD
How can we better diagnose and treat patients with HER2-mutated non-small cell lung cancer? Dr. Jacob Sands is joined by Dr. Nicolas Girard and Dr. Jack West to explore diagnostic and therapeutic challenges and share collaborative patient management strategies for these patients.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Hassan Bencheqroun, MD
Evaluating the need for therapy escalation can be challenging. So joining Dr. Charles Turck to help us understand how to escalate treatment for patients with chronic obstructive pulmonary disease is Dr. Hassan Bencheqroun, Assistant Professor of Medicine at the University of California Riverside School of Medicine.
This is a non-promotional, non-CME disease state disease education podcast series brought to you by American College of CHEST Physicians in collaboration with and paid for by GSK.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Deborah Levine, MD, FCCP
To better understand whether or not corticosteroids should be incorporated in treatment for our patients with COPD, Dr. Charles Turck is joined by Dr. Deborah Jo Levine, a Professor of Medicine and Director of the Pulmonary Hypertension Center at the University of Texas Health.
This is a non-promotional, non-CME disease state disease education podcast series brought to you by American College of CHEST Physicians in collaboration with and paid for by GSK.
Host: Michael E. Wechsler, MD, MMSc
Guest: Eileen Wang, MD, MPH
In this session, National Jewish Health faculty experts will discuss a new paradigm of severe asthma pathophysiology and potential treatment targets that may impact patients with non-allergic and non-eosinophilic as well as eosinophilic severe asthma. This session will explore new understanding of the immunology of severe asthma, new potential targets for treatment, and emerging data on novel therapies that may improve outcomes for your patients with severe asthma.
Guest: Garth W. Garrison, MD
The diagnosis and management of chronic cough can be challenging. Only an estimated 50% of patients with chronic cough are accurately diagnosed. Recent advances in the understanding and management of refractory chronic cough, have led to the development of novel therapies and ongoing clinical studies. In this two-part educational curriculum, pulmonary experts will discuss the prevalence, unmet clinical needs, and impact of chronic cough in patients who do not find relief from recommended management strategies. They will also review the clinical trial data and mechanisms of action of emerging therapies for patients with refractory chronic cough; and finally, summarize the current guidelines and emerging treatment strategies for the management of patients with chronic cough.
Guest: Alexander Spira, MD, PhD, FACP
The 2021 ESMO Congress featured a lot of new advancements in non-small cell lung cancer (NSCLC) treatment. Here to provide a recap of one of those treatments for NSCLC patients with HER2 mutations is Dr. Alexander Spira, Co-Director of the VCS Research Institute, Director of the Thoracic and Phase I Program, and Clinical Assistant Professor at Johns Hopkins.
Host: Paul P. Doghramji, MD, FAAFP
Guest: Mojgan Saber, MD
Can Locum Tenens be an option for healthcare professionals just completing their residency? Dr. Paul Doghramji is joined by Dr. Mojgan Saber to share her own experience as well as tips and tricks for residents looking at Locum Tenens right after residency.
Host: Mario R. Nacinovich, Jr., MSc
Guest: Randy Young, MD
Amid the surge of the Delta variant, critical care physician Dr. Randy Young is traveling to ICUs across the country to help treat patients. Tune in to hear Dr. Young share how this surge is impacting both patients infected with the variant and the healthcare professionals caring for them.
Host: Charles P. Vega, MD
Guest: Sateria Venable
Regional healthcare disparities are biases that are based on where people live. Are your patients’ treatment options being impacted and limited by their geographical location? Join us as our two experts discuss how to support broader policy issues and highlight the importance of diagnostic algorithms that have been developed with diverse input. These steps may be of value in your clinical practice to ensure all patients have equal access to care regardless of their epidemiologic, socioeconomic, or insurance circumstances.
Host: Charles P. Vega, MD
Guest: Robert O. Roswell, MD, FACC, FACP
Diversifying our physician workforce so that it is more racially, ethnically, and geographically balanced can ultimately have a positive impact on community health. Join us as two experts discuss how pipeline programs reaching children as early as elementary school can help ensure workplace diversity. Also find out how clinicians can be advocates for their patients by helping to disentangle them from structural inequities and working towards policy changes. There’s a lot than can be done to provide more balanced care, but we need to look beyond simple fixes to the root causes of the issues. So find your bandwidth – that’s what you can do today – and discover why it’s so important to move upstream to solve the problems manifesting downstream.
Host: John J. Russell, MD
Guest: Greg Berry, MD
We are at a time when COVID-19, respiratory syncytial virus, and the flu all pose serious risks. Quick and accurate diagnoses are vital to determining the correct patient pathway and minimizing viral spread. But what diagnostic challenges do we face, and how can we overcome them? Joining Dr. John Russell to discuss these respiratory testing challenges and Cepheid’s 4-in-1 respiratory test is Dr. Greg Berry, Associate Director of the Center for Advanced Laboratory Medicine at the Columbia University Irving Medical Center in New York.
Host: Charles P. Vega, MD
Guest: Candice Taylor Lucas, MD, MPH, FAAP
What is cultural humility, and how can it be incorporated into clinical practice? How does your patient's culture impact their health behaviors, and why does your culture matter?
Listen in as two leading experts navigate concerns surrounding cultural humility and emphasize the importance of empathy, awareness, and advocacy. Discover ways to integrate small but important changes into your clinical practice to help bridge communication gaps and enable your patients to thrive.
Host: Charles P. Vega, MD
Guest: Lionel Phillips, MBA
Learn why diversity in clinical trials is so important to community health. Two experts discuss the key role that trusted messengers play in enrollment, why it is critical to break the cycle of medical mistrust, and the downstream effect of a lack of diversity in clinical trials.
Guest: Maria E. Arcila, MD
Guest: Alexander Drilon, MD
Capitalizing on the advances in identification of oncogenic driver mutations, genetic testing, and therapeutic approaches that target actionable mutations, targeted therapy is the current standard of care in NSCLC. The use of molecular testing and targeted therapies has yielded remarkable and practice-changing improvements for patients harboring these actionable mutations.
The current availability of multiple targeted agents, such as second- and third-generation ALK and ROS1 tyrosine kinase inhibitors, some of which are approved for use both in first-line and subsequent lines of therapy, coupled with the presence of concomitant actionable mutations, can make selection of the appropriate targeted treatment for eligible patients complicated.
This web-based, on-demand activity will feature an expert panel that will provide their interprofessional perspectives on the latest trends and emerging research regarding biomarker testing and evidence-based biomarker-guided targeted therapy for patients with NSCLC with ROS1 and ALK rearrangements.
Guest: Cheryl Pirozzi, MD, MS
Guest: Charlie Strange, MD
Alpha-1 antitrypsin deficiency (AATD) is a common yet underdiagnosed genetic disorder. Led by 2 AATD experts, this activity will address the most current information on the screening, diagnosis, and treatment of this potentially fatal disorder. AATD primarily affects the lungs and liver and requires a multidisciplinary care approach. Faculty will review patients who are at risk for AATD, its clinical manifestations (including similarities with COPD), and possible consequences to the lung and liver. Current treatment involves augmentation therapy with IV administration of AAT; there are ongoing investigations into other potential treatments. Patient cases will help clinicians apply the foundational information to clinical practice.
Guest: Garth W. Garrison, MD
Guest: Prema Menon, MD, PhD
The diagnosis and management of chronic cough can be challenging. In fact, only an estimated 50 percent of patients with chronic cough are accurately diagnosed. Recent advances in the understanding and management of refractory chronic cough have led to the development of novel therapies and ongoing clinical studies. In this two-part educational curriculum, pulmonary experts will discuss the prevalence, unmet clinical needs, and impact of chronic cough in patients who do not find relief from recommended management strategies. They will also review the clinical trial data and mechanisms of action of emerging therapies for patients with refractory chronic cough and summarize the current guidelines and emerging treatment strategies for the management of patients with chronic cough.
Host: Jacob Sands, MD
Guest: Derek Raghavan, MD, PhD, FACP, FRACP
CT scans have the potential to dramatically improve lung cancer outcomes, but are underserved communities receiving access to these types of screenings? Dr. Jacob Sands joins Dr. Derek Raghavan, President of Atrium Health Levine Cancer Institute in Charlotte, North Carolina, to discuss his research presented at the 2021 American Society of Clinical Oncology Annual Meeting.
Host: Tracey Evans, MD
Guest: Raja Mudad, MD
For thirty years, there were limited therapeutic advancements leading to FDA approvals in extensive-stage small cell lung cancer (ES-SCLC). However, this all changed with the IMpower133 trial, which led to the emergence of immunotherapy as a first line treatment option in ES-SCLC. Joining Dr. Tracey Evans is medical oncologist Dr. Raja Mudad to discuss the IMpower133 trial and the reasons to consider TECENTRIQ® (atezolizumab), the first immunotherapy combination for patients with ES-SCLC.
This program is intended for US Physicians.
M-US-00010808(v1.0)
Host: Matt Birnholz, MD
Guest: Jonathan Corren, MD
As recent research demonstrates the important role that TSLP plays in asthma inflammation, Dr Matt Birnholz is joined by Dr Jonathan Corren, an Associate Clinical Professor of Medicine and Pediatrics at David Geffen School of Medicine in Los Angeles. Together, they review how TSLP acts across the spectrum of asthma inflammation, the correlation of TSLP with clinical features of asthma, and more.
©2021 Amgen. All rights reserved. US-53813 Last Updated 6/21
Host: Jennifer Caudle, DO
Guest: Michael Wechsler, MD
In addition to understanding the definitions of severe asthma and uncontrolled asthma, it’s important for clinicians to be aware of the overall burden that severe asthma and uncontrolled asthma can impose on a patient’s life. So to help us better understand the severe asthma spectrum, Dr Jennifer Caudle is joined by Dr Michael Wechsler, Director of the Cohen Family Asthma Institute at National Jewish Health in Denver, Colorado.
©2021 Amgen. All rights reserved. US-53805 Last Updated 6/21
Host: Tracey Evans, MD
Guest: Raja Mudad, MD
TECENTRIQ® (atezolizumab), in combination with carboplatin and etoposide, is a first-line treatment option for adult patients with extensive-stage small cell lung cancer. What does this treatment path look like in clinical practice? Dr. Tracey Evans is joined by medical oncologist Dr. Raja Mudad to walk us through an example patient case that gives us a better sense of key diagnostic factors, treatment approach, and patient management.
This program is intended for US Physicians.
M-US-00010814(v1.0)
Host: Cassandra B. Donnelly, DO
Guest: Charles P. Vega, MD
Post-exposure influenza prophylaxis should be a top-of-mind discussion with patients receiving an influenza diagnosis. Unfortunately, it remains an underused means to reduce secondary infections in at-risk households. Join Drs. Cassandra Donnelly and Charles Vega as they examine an extended patient case and offer practical strategies to overcome common clinical barriers surrounding post-exposure influenza prophylaxis, including how to match the right patient with the right antiviral treatment.
Host: Matt Birnholz, MD
Guest: Jacob Sands, MD
ReachMD hosts Drs. Matt Birnholz and Jacob Sands come together to discuss the rationales, limitations, and pathways forward in the treatment of relapsing small cell lung cancer as well as platinum rechallenge therapy.
Guest: John J. Ryan MD, MB, BCh, BAO, MRCPI, FACC, FAHA
John Ryan, MD discusses screening protocols, diagnostic and treatment algorithms, clinical trial evidence, and the vital role of multidisciplinary teams for the management of patients with CTD-PAH in this four-chapter series.
Guest: David R. Gandara, MD
Dr. David R. Gandara walks us through some of the most recent clinical trial data on non-small cell lung cancer from the 2021 American Society of Clinical Oncology Annual Meeting.
Guest: Rami Manochakian, MD
Dr. Rami Manochakian, a thoracic medical oncologist at the Mayo Clinic, dives into three clinical trials on developments in lung cancer treatment that were presented at the 2021 American Society of Clinical Oncology Annual Meeting.
Host: Cassandra B. Donnelly, DO
Guest: Charles P. Vega, MD
Antiviral agents are underutilized against influenza in clinical practice, a failure that places many patients, especially those with comorbidities, at high risk for influenza-associated complications. Join Drs. Cassandra Donnelly and Charles Vega as they explore management strategies for patients with symptomatic influenza, compare and contrast clinical applications for the available antiviral agents, and reflect upon the increasing use of these agents as post-exposure influenza prophylaxis.
Host: Jacob Sands, MD
ReachMD host Dr. Jacob Sands joins us to share key updates that were presented on lung cancer at the American Society of Clinical
Host: Jennifer Caudle, DO
Guest: Tracey Evans, MD
Small cell lung cancer (SCLC) is a highly aggressive, lethal, and widely metastatic lung cancer. While therapeutic progress in SCLC has been limited over the years, immunotherapy has made some meaningful advancements in the treatment landscape. Joining Dr. Jennifer Caudle to discuss key diagnostic and therapeutic considerations such as TECENTRIQ® (atezolizumab) for 1L ES-SCLC, is Dr. Tracey Evans, Director of Thoracic Oncology Research at Lankenau Institute for Medical Research and Co-Director of the Thoracic Oncology Program at Main Line Health.
This program is intended for US Physicians.
M-US-00010802(v1.0)
Guest: Jeffrey R. Starke, MD
Host: Paul P. Doghramji, MD, FAAFP
Dr. Paul Doghramji joins Dr. Jeffrey Starke, an Infection Control Officer at Texas Children’s Hospital and a Professor of Pediatric Infectious Disease Medicine at Baylor College of Medicine, to discuss the impact that the COVID-19 pandemic has had on testing for tuberculosis.
Host: Matt Birnholz, MD
Guest: Kelly Cawcutt, MD
Adapting to the drastic changes COVID-19 has forced clinicians to make is one of the many obstacles faced during this pandemic. Joining Dr. Matt Birnholz to talk about how vascular access teams are changing their protocols and roles in response to COVID-19 is Dr. Kelly Cawcutt, an infectious disease and critical care physician at the University of Nebraska Medical Center.
Published May 5, 2020
Host: Fernando J Martinez, MD, FCCP
Guest: Navitha Ramesh, MD, FCCP
At least 50 percent of our patients with asthma continue to experience uncontrolled asthma, and they remain at risk of asthma exacerbations, which can be serious. To learn more about the impacts of uncontrolled asthma, Dr. Fernando J. Martinez sits down with Dr. Navitha Ramesh, who discusses how we can better diagnose, assess, and treat this condition.
A non-promotional, non-CME educational program brought to you by CHEST in collaboration with GlaxoSmithKline
Host: Paul Paik, MD
Guest: Joshua K. Sabari, MD
For the 3% to 4% of patients with non-small cell lung cancer (NSCLC) who harbor a MET exon 14 skipping mutation, the prognosis is grave. MET gene dysregulation may also play a role in the emergence of resistance to EGFR TKI therapy in patients with EGFR-mutated NSCLC, further complicating treatment. Join our case discussion as Dr. Paul Paik and Dr. Josh Sabari highlight the importance of identifying MET gene aberrations in patients with NSCLC.
Guest: D. Ross Camidge, MD, PhD
The discovery of predictive biomarkers, such as sensitizing epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) rearrangements, ROS1 rearrangements, and BRAF V600E mutations has led to an improvement in overall survival and progression-free survival in non–small cell lung cancer (NSCLC) by identifying subgroups of patients who benefit from targeted treatment. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) note, “For patients with recurrent and metastatic disease, the NCCN Guidelines recommend that histologic subtype should be determined before therapy so that the best treatment can be selected. In addition, biomarker testing for genetic alterations (ie, oncogenic driver events) is recommended in patients with NSCLC, because targeted therapy has been shown to decrease tumor burden, decrease symptoms, and dramatically improve the quality of life for patients with specific genetic alterations. The number of available targeted agents is increasing.” (Ettinger et al, 2020.)
Approximately 5% of patients with NSCLC have ALK gene rearrangements. One of the most noteworthy areas of progress is the development of effective ALK-targeting therapies to treat NSCLC, including crizotinib, ceritinib, alectinib, brigatinib, and lorlatinib. Because of the fast pace of developments in this area, it may be difficult for clinicians to remain up-to-date on …
Host: Matthew S. Keller MD
Guest: Maria L. Wei MD, PhD
Wildfires are most often associated with respiratory and cardiovascular health threats, but could they also affect the skin? That’s the exact question dermatologist and melanoma specialist Dr. Maria Wei sought to answer with her recent study and the one that she addresses with Dr. Matthew Keller.
Host: Jacob Sands, MD
Guest: Millie Das, MD
What are some of the latest advancements in small cell lung cancer? Dr. Jacob Sands discusses small-cell lung cancer treatment developments with Dr. Millie Das, a Clinical Associate Professor of Medical Oncology at Stanford University and Chief of Oncology at the Veteran’s Affairs Palo Alto Healthcare System.
Guest: Andy Arwari, MD
With more patients opting for home-based care over long-term, acute, and office-based care, it’s important that we align with our patients on what’s most important to them and how they want to be cared for, especially those who are nearing the end of life.
That’s why VITAS Medical Director, Dr. Andy Arwari, is here to share the purpose of goals-of-care conversations and how an app can aid in determining if an advanced illness patient is eligible for hospice.
Host: Matthew P. Bars, MS, CTTS, NCTTP
Guest: Michael C. Fiore, MD, MPH, MBA
Guest: Laura E. Crotty Alexander, MD
Dr. Matt Bars is joined by his two colleagues: Dr. Laura Crotty Alexander, Associate Professor of Pulmonary Critical Care Medicine at the University of California San Diego, and Dr. Michael Fiore, Professor of Medicine at the University of Wisconsin and Director of the University of Wisconsin Center for Tobacco Research Intervention. Together, they review tobacco dependence, the CHEST Tobacco Dependence Treatment Toolkit, and resources to help patients.
Supported in part by an independent medical educational grant from Pfizer.
Guest: Osita Onugha, MD, MBA
Dr. Osita Onugha, thoracic surgeon at the Providence Specialty Medical Group in Santa Monica, California discusses how prognostic markers can be used to help guide non-small cell lung cancer treatment decisions.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Ana C Zamora Martinez, MD
The COVID-19 pandemic led many clinicians to make life-altering decisions. Dr. Ana Zamora, a pulmonary disease and critical care specialist, discusses her work with Locum Tenens and why she decided it was time for a change.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Christine Bestvina, MD
Dr. Charles Turck sits down with Dr. Christine Bestvina, Assistant Professor of Medicine in the Section of Hematology and Oncology at University of Chicago Medicine, to discuss best practices and adverse events when it comes to treating non-small cell lung cancer.
Host: Gerard A. Silvestri MD, MS, FCCP
Guest: Lynn Tanoue, MD, MBA
About 10 percent of all cancer patients develop treatment-related pulmonary complications, and for lung cancer patients, that risk is even greater. Dr. Gerard Silvestri sits down with Dr. Lynn Tanoue, Professor of Medicine and Vice Chair of Clinical Affairs in the section of pulmonary critical care and sleep medicine at the Yale Cancer Center in New Haven, Connecticut, to discuss pulmonary toxicities related to lung cancer treatment.
Host: Gerard A. Silvestri MD, MS, FCCP
Guest: Michael S. Machuzak, MD
Clinicians can uncover a wealth of information from a non-small cell lung cancer patient’s collected tissue that can help inform treatment decisions. To dive into this idea further, Dr. Gerard Silvestri is joined by his colleague Dr. Michael Machuzak, Full Staff Member in the Department of Pulmonary, Allergy, and Critical Care Medicine at Cleveland Clinic. Together they review the importance of tissue acquisition, proper handling of specimens, rapid onsite evaluation during EBUS-TBNA procedures, and much more.
Host: Jacob Sands, MD
Guest: Mark Awad, MD, PhD
Immunotherapy has led to impressive results, but when is it needed? Dr. Jacob Sands discusses the role of immunotherapy in managing lung cancer with Dr. Mark Awad, a thoracic medical oncologist, Clinical Director of the Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute, and Assistant Professor of Medicine at Harvard Medical School.
Host: Jacob Sands, MD
Guest: Mark Awad, MD, PhD
What do we need to know about the role of biomarkers in non-small cell lung cancer? Dr. Mark Awad from the Dana-Farber Cancer Institute explains.
Host: Paul Paik, MD
Guest: Viola Zhu, MD
Dysregulation of MET signaling has been widely described in oncogenic processes. While all 3 types of MET dysregulation (amplification, overexpression, and gene mutations) have been documented in non-small cell lung cancer (NSCLC), MET exon 14 skipping alterations are a primary oncogenic driver in approximately 3% to 4% of these patients, often with a poor outcome. Join us as Dr. Paul Paik and Dr. Viola Zhu discuss the importance of testing patients for MET gene aberrations and their relevance in the management of NSCLC, especially as related to recently approved and emerging therapies for patients harboring a MET gene aberration.
Guest: D. Ross Camidge, MD, PhD
After starting on a RET inhibitor, what do you do? Dr. Ross Camidge, the Director of the Thoracic Oncology Clinical and Clinical Research Programs at the University of Colorado, breaks down the progression of RET inhibitors in patients with non-small cell lung cancer and what tests should be utilized throughout the process.
Guest: D. Ross Camidge, MD, PhD
With only two targeted therapy options available for RET rearranged advanced non-small cell lung cancer, how do we select the best approach? Dr. Ross Camidge, the Director of the Thoracic Oncology Clinical and Clinical Research Programs at the University of Colorado, discusses treatment options for NSCLC.
Guest: Michael R. Shafique, MD
Once we identify RET fusion abnormalities in patients with non-small cell lung cancer, what targeted therapies are available to us? Tune in to hear Dr. Michael Shafique, Assistant Professor of Thoracic Oncology at the Moffitt Cancer Center, share a brief overview of targeted therapies for patients with RET-rearranged non-small cell lung cancer.
Guest: Michael R. Shafique, MD
Here to give us a look at the unique genetic characteristics and prognostic implications for male and female patients with non-small cell lung cancer who harbor the RET fusion gene is Dr. Michael Shafique, Assistant Professor of Thoracic Oncology at the Moffitt Cancer Center in Tampa, Florida.
Host: Paul Paik, MD
Guest: Jyoti D. Patel, MD, FASCO
Lung cancer remains the most common cancer in the United States and Europe and second most common in Japan. Of patients with non-small cell lung cancer (NSCLC), approximately 3% to 4% have tumors that harbor MET gene aberrations including MET exon 14 skipping mutations. These patients have an even worse prognosis than others with NSCLC, and early diagnosis and targeted therapies are essential. Join us as Dr. Paul Paik and Dr. Jyoti Patel discuss the value that liquid biopsy brings to patients with NSCLC, specifically those with MET exon 14 skipping mutations.
Guest: D. Ross Camidge, MD, PhD
What are some of the clinical considerations for RET-rearranged non-small cell lung cancer? Dr. Ross Camidge, Director of the Thoracic Oncology Clinical and Clinical Research Programs at the University of Colorado, briefly discusses the guidelines and benefits of therapy recommended for non-small cell lung cancer by the National Comprehensive Cancer Network.
Host: Jacob Sands, MD
Guest: Andrea B. McKee, MD
Lung cancer screening is one of the most critical components of reducing cancer mortality rates. Dr. Andrea McKee, Chair Emeritus in Radiation Oncology and Director of the Lung Screening Program at Lahey Hospital and Medical Center, joins Dr. Jacob Sands to discuss updates in lung screening.
Host: Jacob Sands, MD
Guest: Andrea B. McKee, MD
How can a lung screening program enhance the quality of care for patients with lung cancer? Dr. Andrea McKee, Chair Emeritus in Radiation Oncology and Director of the Lung Screening Program at Lahey Hospital and Medical Center, shares how she and her colleagues designed this program at Lahey Hospital and Medical Center.
Host: Jacob Sands, MD
Guest: Aaron S. Mansfield, MD
There are different treatment options available for early-stage mesothelioma, and there seem to be differences in standard practice from one center to the next. Joining Dr. Jacob Sands to share how he approaches the treatment of early-stage mesothelioma using the latest options is Dr. Aaron Mansfield, an Associate Professor of Oncology and Co-Director of Precision Cancer Therapeutics at Mayo Clinic in Rochester.
Guest: Balazs Halmos, MD, MS
How is multiplex testing with next-generation sequencing different from other diagnostic tools? Dr. Balazs Halmos, the Director of Thoracic Oncology and Clinical Cancer Genomics at Montefiore Medical Park at Eastchester in the Bronx, New York, discusses how this type of testing can contribute to improved health outcomes and tailored treatment regimens for patients with non-small cell lung cancer, or NSCLC.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Balazs Halmos, MD, MS
What are some of the most recent advancements in RET diagnostics? Dr. Balazs Halmos discusses molecular testing for patients with non-small cell lung cancer, or NSCLC, and best practices to use when treating patients with RET alterations.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Andrea B. McKee, MD
Often diagnosed in its later stages, lung cancer often leaves little time for treatment. But an preventive screening technique may help detect this disease early on. Andrea Mckee discusses the lung cancer screening guidelines from the U.S. Preventative Services Task Force and what to know about prevention screening using a low dose computed tomography (LDCT) to help close the time gap.
Guest: Pavani Chalasani MD, MPH
Dr. Pavani Chalasani, Associate Professor of Medicine and Program Director of the Hematology/Oncology Fellowship at the University of Arizona Cancer Center, discusses the utility of prognostic markers to improve outcomes for patients with breast cancer.
Host: Federico Cappuzzo
Guest: Professor Solange Peters
Guest: Professor Yi-Long Wu
Are dMMR and MSI-H both markers that will soon replace or work in conjunction with PD-L1 when determining immunotherapy for patients with metastatic NSCLC? Accurate testing and treatment selection is critical in identifying patients who will benefit from these therapies. Dr. Federico Cappuzzo, Dr. Solange Peters, and Professor Yi-Long Wu discuss emerging data from the recent WCLC, ESMO, and ASCO virtual conferences and offer their international and regional perspectives on the evolving use of immunotherapies in advanced NSCLC.
Host: Andrew Wilner, MD, FACP, FAAN
Guest: Jennifer A. Frontera, MD
Although the impact of COVID-19 can be long-lasting, many have had similar effects, even if they aren’t diagnosed with the disease. Dr. Jennifer Frontera, a neurocritical care specialist and professor of neurology at the NYU Grossman School of Medicine, shares some insight on the neurological symptoms that patients with COVID-19 are facing.
Host: Andrew Wilner, MD, FACP, FAAN
Guest: Jennifer A. Frontera, MD
Most commonly associated with respiratory symptoms, COVID-19 infections have led to a myriad of neurological symptoms such as encephalopathy and stroke. Dr. Andrew Wilner joins Dr. Jennifer Frontera, a neurocritical care specialist and professor of neurology at the NYU Grossman School of Medicine, to discuss obstacles that neurologists have faced during the COVID-19 pandemic.
Host: Gerard A. Silvestri MD, MS, FCCP
Guest: Lonny Brett Yarmus, DO, FCCP
Dr. Gerard Sylvestri, the Hillenbrand Professor of Thoracic Oncology at the Medical University of South Carolina in Charleston and Dr. Lonny Yarmus, Clinical Director of the Division of Pulmonary and Critical Care Medicine at Johns Hopkins University, come together to discuss staging in early-stage lung cancer.
An educational campaign brought to you by CHEST, in collaboration with AstraZeneca.
Host: Gerard A. Silvestri MD, MS, FCCP
Guest: Catherine R. Sears, MD
When it comes to managing lung cancer, should we be considering a multidisciplinary approach? Dr. Gerard Sylvestri is joined by Dr. Katie Sears, an assistant professor at the Indiana University School of Medicine, to discuss multidisciplinary lung cancer programs and share suggestions on how to implement this kind of approach.
Host: Jacob Sands, MD
Guest: Aaron S. Mansfield, MD
Mesothelioma is a cancer with limited treatment options, so how can we manage it in the first and second-line settings and beyond? Here with Dr. Jacob Sands to walk us through the various treatment approaches to mesothelioma is Dr. Aaron Mansfield, Associate Professor of Oncology and Co-Director of Precision Cancer Therapeutics at Mayo Clinic in Rochester.
Host: Paul Doghramji, MD
Guest: Sarojini Qasba, MD
With the World Health Organization’s goal to eliminate tuberculosis by 2030 quickly approaching, what can we be doing now to help us meet that goal? Joining Dr. Paul Doghramji to discuss three key factors and how the COVID-19 pandemic has impacted this global goal is Dr. Sonia Qasba, an infectious disease specialist at the Suburban Hospital in Bethesda, Maryland.
Host: Jacob Sands, MD
Guest: Benjamin Levy, MD
What is genomic testing, and how has this advancement become such an important part of lung cancer treatment? Dr. Jacob Sands is joined Dr. Ben Levy, an associate professor of oncology at the Johns Hopkins University School of Medicine to discuss targeted therapies and testing strategies in patients with lung cancer.
Guest: Richard Channick, MD
Guest: Vallerie Mclaughlin, MD
Pulmonary Arterial Hypertension is a progressive disease and is associated with poor clinical outcomes. This first live webinar provides an in-depth discussion of the new thresholds for the diagnosis of PAH, and differential diagnostic considerations, along with the emerging data on the optimal management of patients with PAH. This activity provides a case discussion on the clinical application and effective strategies to integrate the emerging data into treatment regimens to improve outcomes for individuals with this highly complex disease.
Host: De De Gardner, DrPH, RRT, RRT-NPS, FAARC, FCCP
Guest: Stephanie Briney, DO
Despite widespread availability, only half of Americans received the flu shot last year. With that in mind, Dr. De De Gardner is joined by Dr. Stephanie Briney, Assistant Professor in Family, Community, and Preventive Medicine at the University of Arizona College of Medicine, Phoenix to discuss why Americans avoid getting the flu shot and how she approaches this in her practice.
Host: Jacob Sands, MD
Cancer care has evolved since the initial outbreak of the COVID-19 pandemic. What do we need to know about caring for our cancer patients during this winter season? Dr. Jacob Sands, Thoracic Medical Oncologist at the Dana-Farber Institute in Boston shares what cancer patients can do to take care of themselves during the winter season.
Host: Jacob Sands, MD
Guest: Taofeek K. Owonikoko, MD, PhD, MSCR
After years without new approvals, advancements in small cell lung cancer are at the forefront of oncology. But what do these therapeutic developments mean for the field? Dr. Taofeek Owonikoko, professor and vice-chair for faculty development in the Department of Hematology and Medical Oncology at Emory University School of Medicine, joins Dr. Jacob Sands to talk about long-awaited developments in small cell lung cancer.
Host: Linda Bernstein, Pharm.D.
The U.S. Food and Drug Administration issued an emergency use authorization, or EUA, for the Moderna COVID-19 vaccine. The second vaccination to achieve EUA designation, the Moderna vaccine will be distributed throughout the US for patients 18 years and older. In this episode of The Drug Report, Dr. Linda Bernstein discusses this newly-approved vaccine and how it compares to others.
Published December 29, 2020
Host: Linda Bernstein, Pharm.D.
The first vaccine to receive Emergency Use Authorization from the US Food and Drug Administration, this authorization allows the Pfizer-BioNTech COVID-19 vaccine to be distributed throughout the US. But what do we know about this vaccine? In this episode of The Drug Report, Dr. Linda Bernstein discusses the Pfizer-BioNTech COVID-19 vaccine.
Published December 18, 2020
Host: Linda Bernstein, Pharm.D.
To prevent the flu from spreading concurrently with COVID-19, The U.S. Food and Drug Administration has expanded the approved indication for baloxavir marboxil to include post-exposure prevention of influenza. On this episode of The Drug Report, Dr. Linda Bernstein dives into this oral anti-influenza drug.
Published December 2, 2020
Host: Linda Bernstein, Pharm.D.
This episode of The Drug Report takes a look at a COVID-19 cocktail comprised of the coadministration of casirivimab and imdevimab, which has proven to decrease hospitalization and emergency room visits.
Published November 30, 2020
Host: Linda Bernstein, Pharm.D.
With the spread of the COVID-19 pandemic, fewer children have received a measles vaccination, and progress towards eliminating this disease has halted. How can pharmacists encourage more pediatric measles vaccinations? In this episode of The Drug Report, Dr. Linda Bernstein takes a look at the vast number of children globally who’ve yet to receive this vaccine.
Published November 30, 2020
Host: Linda Bernstein, Pharm.D.
The U.S. Food and Drug Administration has granted Eli Lilly and Company’s trial vaccine for COVID-19 an Emergency Use Authorization, or EUA. On this episode of The Drug Report, learn more about this monoclonal antibody and how the company plans on distributing it.
Published November 30, 2020
Host: Linda Bernstein, Pharm.D.
Pfizer and BioNTech recently announced that their mRNA vaccine for the COVID-19 virus was 90 percent effective, and the companies plan to apply for Emergency Use Authorization. This episode of The Drug Report dives into this vaccine’s Phase 3 clinical trial and explores developments made by other companies in the search for a COVID-19 vaccine.
Published November 30, 2020
Host: Linda Bernstein, Pharm.D.
In light of the COVID-19 pandemic, the Centers for Disease Control and Prevention, or the CDC, plans to use pharmacies to increase access to the COVID-19 vaccine when it is ready for distribution. In this episode of The Drug Report, Linda Bernstein will explain the CDC’s recently-developed Vaccination Program Interim Playbook.
Published November 17, 2020
Host: Linda Bernstein, Pharm.D.
The Food and Drug Administration announced that Remdesivir is the first treatment for COVID-19 to receive their approval. To help us better understand this antiviral agent, Dr. Linda Bernstein discusses emerging studies uncovering the benefits and limitations of Remdesivir.
Published November 6, 2020
Host: Timothy Aksamit, MD
Guest: Amy Levinger, MSN, FNP-C
Guest: David E. Griffith, MD
The prevalence of non-tuberculous mycobacterial (NTM) lung disease in the United States has almost doubled between 2008 and 2015. But despite this increase, its diagnosis can often be delayed, which is why pulmonary nurse practitioner Amy Levinger and Dr. David Griffith join Dr. Tim Aksamit to discuss the diagnostic criteria, tools that can help us make a timely diagnosis of NTM lung disease, and more.
For more information and to access clinician & patient tools about NTM and MAC Lung Disease, click here to visit the CHEST Foundation NTM webpage.
This program is produced in partnership with the American College of CHEST Physicians, and is sponsored by Insmed Incorporated.
Host: Xavier Soler, MD, PhD
Guest: Nicola A. Hanania, MD, MS, FCCP
To help us address the current lack of awareness of uncontrolled or symptomatic asthma in all stages of the disease, Dr. Xavier Soler is joined by Dr. Nicola Hanania, Associate Professor of Pulmonary Medicine and Director of the Airway Clinical Research Center at Baylor College of Medicine in Houston, Texas. Together, they’ll discuss how we can better recognize and treat our patients with uncontrolled asthma.
A non-promotional, non-CME educational program brought to you by CHEST in collaboration with GlaxoSmithKline.
Host: Richard K. Bogan, MD
While positive airway pressure is the standard of care treatment for obstructive sleep apnea (OSA), it may not always be enough to address the excessive daytime sleepiness (EDS) that some patients experience. In fact, in one study, up to 34 percent of patients with OSA still reported EDS (Epworth Sleepiness Score ≥10) despite more than 5 hours of CPAP use a night.
Here, Dr. Richard K. Bogan, Associate Clinical Professor at the University of South Carolina School of Medicine and Chairman and Chief Medical Officer at SleepMed, Inc., sheds light on the prevalence of EDS in OSA. Specifically, Dr. Bogan discusses key data that has raised important observations about how commonly EDS may persist even when patients adhere to CPAP therapy.
This promotional, non-CME program is intended for U.S. physicians treating OSA.
Dr. Bogan is a paid consultant of Jazz Pharmaceuticals, Inc.
© 2020 Jazz Pharmaceuticals Inc., a subsidiary of Jazz Pharmaceuticals plc, all rights reserved.
Guest: Richard K. Bogan, MD
Emerging science can help us better understand the link between obstructive sleep apnea (OSA) and excessive daytime sleepiness (EDS). While many factors, such as insufficient sleep, medication, or comorbid disorders, can cause your patients with OSA to feel sleepy, chronic sleep disruption and chronic intermittent hypoxia associated with OSA may also contribute to EDS.
Here to discuss the important physiologic changes to gray and white matter that may occur in OSA and lead to EDS is Dr. Richard K. Bogan, Associate Clinical Professor at the University of South Carolina School of Medicine and Chairman and Chief Medical Officer at SleepMed, Inc.
This promotional, non-CME program is intended for U.S. physicians treating OSA.
Dr. Bogan is a paid consultant of Jazz Pharmaceuticals, Inc.
© 2020 Jazz Pharmaceuticals Inc., a subsidiary of Jazz Pharmaceuticals plc, all rights reserved.
Guest: Paul Doghramji, MD
Excessive daytime sleepiness (EDS) in obstructive sleep apnea (OSA) is frequently underrecognized, as patients may not understand the extent of their sleepiness and EDS does not always correlate with other OSA symptoms. However, it’s important for physicians to identify EDS as it may lead to adverse consequences.
Dr. Paul P. Doghramji, Senior Family Physician at Collegeville Family Practice and Medical Director of Health Services at Ursinus College, discusses identifying EDS and the vital role assessment tools like the Epworth Sleepiness Scale can have in practice.
This promotional, non-CME program is intended for U.S. physicians treating OSA.
© 2020 Jazz Pharmaceuticals Inc., a subsidiary of Jazz Pharmaceuticals plc, all rights reserved.
Host: David E. Griffith, MD
Guest: Amy Levinger, MSN, FNP-C
Guest: Timothy Aksamit, MD
The care team supporting a patient with mycobacterium avium complex, or MAC, lung disease is just as important as the treatment itself. Joining Dr. David Griffith to discuss how we can provide optimal treatment using established guideline-based strategies all while protecting patients’ quality of life are Dr. Tim Aksamit and pulmonary nurse practitioner Amy Levinger.
For more information and to access clinician & patient tools about NTM and MAC Lung Disease, click here to visit the CHEST Foundation NTM webpage.
This program is produced in partnership with the American College of CHEST Physicians, and is sponsored by Insmed Incorporated.
Host: Megan Carreon, MHA, RRT
Guest: Amy Levinger, MSN, FNP-C
Guest: Timothy Aksamit, MD
There are numerous factors that contribute to an overall wellness of patients with of NTM refractory MAC lung disease. Listen in as Megan Carreon, Assistant Professor with the Division of Respiratory Care at UT Health San Antonio, Texas, sits down with pulmonary nurse practitioner Amy Levinger from NYU Langone Health and Dr. Tim Aksamit, Associate Professor of Pulmonary and Critical Care Medicine at Mayo Clinic.
For more information and to access clinician & patient tools about NTM and MAC Lung Disease, click here to visit the CHEST Foundation NTM webpage.
This program is produced in partnership with the American College of CHEST Physicians, and is sponsored by Insmed Incorporated.
Host: Tom Corbridge, MD, FCCP
Guest: Matt Hegewald, MD FCCP
With uncontrolled asthma placing such a tremendous burden on our patients and our society, how can we use the latest treatment guidelines to help alleviate that burden? Dr. Matt Hegewald is here to talk about the new and emerging guideline-based treatments for uncontrolled asthma, like long-acting muscarinic antagonists.
A non-promotional, non-CME educational program brought to you by CHEST in collaboration with GlaxoSmithKline.
Host: Tom Corbridge, MD, FCCP
Guest: Navitha Ramesh, MD, FCCP
Now that long-acting muscarinic receptor antagonists (LAMAs) have entered the scene, Dr. Tom Corbridge is joined by Dr. Navitha Ramesh, a pulmonologist and critical care physician at UPMC, to review some patient cases demonstrating how LAMAs may be changing the way we approach step-up treatment for some patients with asthma.
A non-promotional, non-CME educational program brought to you by CHEST in collaboration with GlaxoSmithKline.
Host: Andrew Wilner, MD, FACP, FAAN
Guest: William W. Li, MD
How do the lungs of healthy patients differ from the lungs of patients with COVID-19 or the flu? That’s the exact question Dr. William Li wanted to answer, and now, he’s sharing the results of his study that was recently published in the New England Journal of Medicine.
Published August 12, 2020
Host: Jennifer Caudle, DO
Guest: Tracey Evans, MD
Join Dr. Tracey Evans as she discusses the efficacy data for TAGRISSO® (osimertinib) and the potential impact for metastatic EGFRm NSCLC patients.
In 2018, first-line TAGRISSO became a standard of care for metastatic EGFRm NSCLC with an unprecedented 18.9 months median PFS vs 10.2 months for erlotinib/gefitinib (HR=0.46 [95% CI: 0.37, 0.57]; P<0.0001).1
Now, TAGRISSO is the only EGFR TKI to deliver statistically significant Overall Survival beyond 3 years in a global, phase 3 randomized clinical trial in the first-line setting, (38.6 months vs 31.8 months for erlotinib/gefitinib (HR=0.799 [95.05% CI: 0.641, 0.997]; P=0.0462)).2
Visit TagrissoHCP.com to learn what these data could mean for your patients.
FLAURA study design: Randomized, double-blind, active-controlled trial in 556 patients with metastatic EGFRm NSCLC who had not received prior systemic treatment for advanced disease. Patients were randomized 1:1 to either TAGRISSO (n=279; 80 mg orally, once daily) or EGFR-TKI comparator (n=277; gefitinib 250 mg or erlotinib 150 mg orally, once daily). All US patients in the comparator arm received erlotinib. Crossover was allowed for patients in the EGFR-TKI comparator arm at confirmed progression if positive for the EGFR T790M resistance mutation. Patients with CNS metastases not requiring …
Host: Mario R. Nacinovich, Jr., MSc
Guest: David Fajgenbaum, MD
Since its founding, the Castleman Disease Collaborative Network (CDCN) has worked to identify an effective treatment for Castleman disease, a rare immune system disorder that leads to a cytokine storm and multi-organ failure—much like what’s being seen in COVID-19 patients. Here to review how the CDCN’s innovations are now being leveraged toward the fight against COVID-19 is the CDCN’s Co-Founder and Executive Director Dr. David Fajgenbaum.
Guest: Bret Nelson, MD
When it comes to using ultrasound at the point of care in the setting of COVID-19, what do we need to keep in mind? Here to share his five key considerations is Dr. Bret Nelson, Professor of Emergency Medicine and the Chief of the Emergency Medicine Ultrasound Division at Mount Sinai Hospital.
Published June 5, 2020
Guest: Charles Turck, PharmD, BCPS, BCCCP
Against the backdrop of a global push to get more ventilators and other critical gear into the hands of healthcare professionals, some clinicians are opting out of using ventilators to treat their COVID-19 patients as several hospitals have reported unusually high death rates. Listen in as Dr. Charles Turck explains.
Published June 5, 2020
Host: Joshua Sharfstein, MD
Host: Stephanie Desmon
Guest: James Robert Ficke, M.D.
The Joint Hopkins Maryland Federal Medical Station, a 250-bed unit inside Baltimore’s convention center, opened on April 27 for non-critical patients recovering from COVID-19. Dr. James Ficke, the Station’s Director, talks with Stephanie Desmon about how his experience standing up combat hospitals in northern Iraq prepared him, the influx of patients they’re seeing, and what it takes to set up a fully operational contingency hospital with food, bathrooms, showers, and even its own pharmacy.
Published May 19, 2020
Host: Joshua Sharfstein, MD
Host: Stephanie Desmon
Guest: Albert Wu, MD
It’s been a few months since COVID-19 first arrived in the US, so what have we learned? Dr. Albert Wu returns to the podcast with Stephanie Desmon to discuss social distancing fatigue, new symptoms and disease observations, hopes for treatment, and what we should expect in the coming months in terms of a “return to normal.”
Published May 13, 2020
Host: Tom Corbridge, MD, FCCP
Guest: Gary T. Ferguson, MD, F.C.C.P
Listen in as Dr. Tom Corbridge and Dr. Gary Ferguson discuss the challenges physicians and patients face when there is an underreporting of COPD symptoms. Together, they’ll also explore the ways physicians can overcome these obstacles and give their patients the appropriate treatment.
This episode is supported in part by an unrestricted/independent medical educational grant from GlaxoSmithKline.
Guest: Mangala Narasimhan, DO, FCCP
Managing COVID-19 continues to be a work in progress as healthcare systems struggle to prepare for high volumes of patients in such a quick time. To help address this, Dr. Mangala Narasimhan shares her experiences and the importance of planning for double during this outbreak.
Published March 16, 2020
Host: Steven Simpson, MD, FCCP
Tune in as Dr. Steven Simpson speaks with a clinician on the frontlines of COVID-19 who shares her experience managing a COVID-19 case that was caught days after the patient was admitted to the hospital.
Published May 19, 2020
Guest: Martha Billings, MD, MSc
Guest: Renea Jablonski, MD
Amid the COVID-19 pandemic, clinicians have quickly transitioned to telemedicine. To give us a better idea of what that transition has looked like in practice, Dr. Martha Billings and Dr. Renea Jablonski share their experiences in a pulmonary clinic setting.
Published March 19, 2020
Host: Victor Test, MD, FCCP
Guest: Andrew Klein, MS, RT
Tune in as Andrew Klein, a clinical nurse specialist in respiratory therapy, discusses his experiences caring for COVID-19 patients in a teamwork environment. Through these collaborations, the best care can be made available during this pandemic.
Published March 26, 2020
Host: Joshua Sharfstein, MD
Host: Sara Bennett, PhD
Guest: Timothy J. Roberton, DrPH
The global health community has worked for years to lower rates of maternal and child mortality in low- and middle-income countries. But while the world focuses on the number of deaths from COVID-19, estimates of indirect mortality due to disruptions in health systems cannot be ignored.
Tim Roberton, an assistant scientist in international health, talks with guest host Sara Bennett, a professor in international health, about a paper he co-authored that estimates there could be a 45 percent increase in child mortality and a 38 percent increase in maternal mortality in severe scenarios where care is disrupted due to COVID-19. One way to head off these numbers is to categorize care by prioritizing only emergency care that cannot be delivered in any other way.
Published May 7, 2020
Host: Joshua Sharfstein, MD
Guest: Arturo Casadevall, MD, PhD
Dr. Arturo Casadevall—head of the convalescent plasma research project at Johns Hopkins—talks through the WHO’s recent statement that there’s no evidence of COVID-19 infection leading to short- or long-term immunity. Dr. Casadevall and Dr. Josh Sharfstein also discuss how COVID-19 is not like HIV or pneumonia and what we currently know about new strains of the novel coronavirus.
Published May 6, 2020
Host: Mario R. Nacinovich, Jr., MSc
Guest: Randy Young, MD
Here to give us a firsthand look into how ICUs across the country are confronting the COVID-19 pandemic head-on is Dr. Randy Young, a critical care doctor who’s treating COVID-19 patients in the mid-Atlantic area. Dr. Young joins Mario Nacinovich to discuss what he has seen during the pandemic and how the ICU is responding to both expected and unexpected challenges.
Published May 13, 2020
Host: Matt Birnholz, MD
Guest: April Taylor, MS, MHA, CPPS, CPHQ
Every organization has disaster preparedness plans for one-day and one-week events like fires, hurricanes, and earthquakes, but how do those plans come into play during a pandemic like COVID-19 when there isn’t an end date in sight? Joining Dr. Matt Birnholz to discuss this and more is April Taylor, Senior Director of Improvement and Project Management at the Children’s Hospital of Philadelphia.
Published May 13, 2020
Host: Joshua Sharfstein, MD
Guest: Lauren M. Sauer, MS
What makes this virus different from hundreds of other similar viruses? What happens if parents don’t take their children for routine immunizations? Does prone body positioning help ICU patients? Does coronavirus spread best in wet or dry environments? What are randomized control trials and why is everyone talking about them? Is it possible to give someone a tattoo from six feet away? Lauren Sauer, Director of Operations with the Johns Hopkins Office of Critical Event Preparedness and Response (CEPAR) and Assistant Professor of Emergency Medicine at Johns Hopkins Medicine, addresses these questions.
Published May 1, 2020
Host: Joshua Sharfstein, MD
Guest: Karen C. Carroll, MD
In March, Johns Hopkins Hospital began making its own COVID-19 tests. The lab now has the capacity to run 600 tests per day but is limited by shortages in the supply of reagents: the chemicals needed to process the tests. Dr. Karen Carroll, Director of the Division of Medical Microbiology at Johns Hopkins Hospital talks with Dr. Josh Sharfstein about what it takes to develop a working COVID-19 test, why labs across the US are struggling with shortages, and what needs to happen to fix access to testing.
Published May 1, 2020
Host: Joshua Sharfstein, MD
Host: Stephanie Desmon
Guest: Maximilian Konig, MD
Guest: Chetan Bettegowda, MD, PhD
For the subset of people who become critically ill from the novel coronavirus, cytokine storms could be to blame. This severe inflammatory disease happens when the immune system goes haywire in response to a novel threat. Rheumatology fellow Dr. Max Konig and neurosurgeon Dr. Chetan Bettegowda talk with Stephanie Desmon about the vital role of cytokine in immune responses, how to identify who might be at risk, and how research is looking into stopping the storms before they start.
Published April 28, 2020
Host: Joshua Sharfstein, MD
Guest: Derek C. Angus, MD, MPH, FRCP
Until there is a vaccine, the best hope for the novel coronavirus is finding the right “cocktail” of treatments for managing severe illness. A unique clinical trial model developed several years ago may now help identify treatments that work. Dr. Derek Angus talks to Dr. Josh Sharfstein about the Bayesian inference model, a “March Madness” of testing multiple therapies at once.
Published April 27, 2020
Host: Joshua Sharfstein, MD
Host: Stephanie Desmon
Guest: Andrew Stanley Pekosz, PhD
Virologist Dr. Andrew Pekosz returns to the podcast with an update on what his team has learned about COVID-19. Dr. Pekosz and Stephanie Desmon discuss further indications that COVID-19 may not be seasonal, why COVID-19 is “the flu on steroids,” and how learning about how the virus replicates in our upper respiratory tracts could hold clues for treatment and prevention. PLUS: An update on the convalescent plasma therapy trial.
Published April 27, 2020
Host: Joshua Sharfstein, MD
Guest: Gigi Kwik Gronvall, PhD
The market is suddenly flooded with antibody tests claiming to prove whether or not people have already been exposed to COVID-19. But two critical questions are yet unanswered: Are any of these tests accurate and does past exposure mean immunity?
Immunologist Dr. Gigi Gronvall of the Johns Hopkins Center for Health Security talks to Dr. Josh Sharfstein about a new report outlining the potential and pitfalls of antibody testing. They discuss how long it might be before we understand more about antibodies and immunity to COVID-19 and how widespread testing could help capture the true footprint of the coronavirus’s spread.
Published April 24, 2020
Host: Joshua Sharfstein, MD
Guest: Jennifer Nuzzo, MD
If bats are immune to the novel coronavirus, can we learn something to help fight the virus in humans? How can I tell if my cough is spring allergies or COVID-19? Is it too soon for businesses like barber shops and salons to reopen? Can the virus crawl or be blown by the wind into your nose? Why are some people asymptomatic? Dr. Jennifer Nuzzo of the Johns Hopkins Center for Health Security addresses questions.
Published April 24, 2020
Host: Joshua Sharfstein, MD
Host: Stephanie Desmon
Guest: Annette C. Anderson, PhD
Most schools closed suddenly and have had to scramble to stand up online learning or other solutions to continue instruction in the midst of the pandemic. Further complicating the response is the fact that no one knows how long this will last.
Dr. Annette Anderson of the Johns Hopkins School of Education talks to Stephanie Desmon about the Digital Divide, how schools are trying to prevent a “COVID slide,” the fear that learning can be lost over long breaks. They also discuss the burden on parents and how some districts are stepping up to address disruptions to vital services like food and mental health support for students and their families.
Published April 23, 2020
Host: Joshua Sharfstein, MD
Guest: Caitlin Rivers, PhD, MPH
Much of our world was suddenly postponed, canceled, or shuttered in the last month or so. There’s now an opportunity to be more thoughtful about reopening. There are risks either way: wait too long and there are consequences for health, safety, and the economy. Open too soon, and viral transmission may ramp up and out of control.
Dr. Caitlin Rivers of the Center for Health Security is coauthor of a recent report geared towards governors considering how to reopen non-essential businesses. She talks to Dr. Josh Sharfstein about the basic principles behind deciding when to reopen bars, gyms, salons, and other nonessential businesses.
Published April 22, 2020
Host: Mario R. Nacinovich, Jr., MSc
Guest: Renata Schiavo, PhD, MA
COVID-19 is constantly referred to as a global pandemic, but how often do you think of it as an info-demic? Or as a health equity issue? Joining Mario Nacinovich to give us a look at COVID-19 through a different lens is Dr. Renata Schiavo, Senior Lecturer, Columbia University Mailman School of Public Health, Department of Sociomedical Sciences and Founder and President of the Board of Directors of the Health Equity Initiative. Dr. Schiavo discusses common barriers faced by the most vulnerable populations and how we can protect them during and after the COVID-19 pandemic.
Published April 28, 2020
Host: Shira Johnson, MD
Guest: James Withers, MD
The street medicine movement is faced with the challenge of administering treatments and protection methods to a population that is often excluded and in dire need of care, and that challenge has only been intensified during this unprecedented time. Street physician Dr. Jim Withers, who’s credited with starting the street medicine movement, is here to share what it’s like to care for the homeless during the COVID-19 pandemic.
Published April 27, 2020
Host: Joshua Sharfstein, MD
Host: Stephanie Desmon
Guest: Julie Messersmith
Guest: Denis Wirtz
The challenges presented by the pandemic are giving rise to a pipeline of research proposals focused on COVID-19. Julie Messersmith and Denis Wirtz are leading Johns Hopkins University's multidisciplinary research projects to develop better detection and protection tools and treatments for COVID-19 patients. They talk to Stephanie Desmon about how engineers, public health specialists, and medical doctors are teaming up to develop better testing and treatment solutions on incredibly fast-tracked timelines.
Published April 21, 2020
Host: Linda Bernstein, Pharm.D.
Join pharmacist Dr. Linda Bernstein as she highlights several articles from recent literature describing coagulopathies in severely ill COVID-19 patients in China. She explores the cause and effect theories behind these findings and whether the observed coagulopathies are due directly to the virus, the critically ill condition of the patient that predisposes them to thromboembolism, or some combination of the two.
Published April 24, 2020
Host: Linda Bernstein, Pharm.D.
The US Food and Drug Administration has authorized clinicians to prescribe chloroquine and hydroxychloroquine for hospitalized patients with COVID-19, despite warnings from scientific advisers that no randomized controlled trial has been conducted to support the drugs’ safety and efficacy in this population. Pharmacist Dr. Linda Bernstein takes us through the FDA’s decision process, the parameters of the issuance, and comments made by the experts on this emergency ruling.
Published April 24, 2020
Host: Linda Bernstein, Pharm.D.
The Drug Enforcement Administration (DEA) issued a new guidance for the issuance of oral Schedule II prescriptions in light of the COVID-19 pandemic and nationwide public health emergency. Pharmacist Dr. Linda Bernstein details the DEA’s temporary exceptions to the regulations to ease prescribing and dispensing of these controlled substances during this challenging time.
Published April 24, 2020
Host: Joshua Sharfstein, MD
Guest: Preeti N. Malani MD
Colleges and universities are already starting to think about what it would take to reopen for the fall semester. But bringing back students, faculty, and staff—and welcoming the class of 2024—will require a complete rethinking of campus life. Dr. Preeti Malani, Chief Health Officer of the University of Michigan, talks to Dr. Josh Sharfstein about how she’s considering the health and safety of 50,000 students plus faculty and staff during the COVID-19 pandemic.
Published April 20, 2020
Host: Joshua Sharfstein, MD
Guest: Tom Inglesby, MD
Does the virus cause male sterility? Are false negatives a problem with COVID tests? Is there a connection between how much virus you’re exposed to and how serious the illness is? Should people on immunosuppressive drugs stop taking them? Does the virus “reactivate?” Can people really become immune? Why are there so many more cases in the northern hemisphere? Why will a COVID-19 vaccine take so long when we come up with a new flu vaccine every year?
Tom Inglesby, Director of the Johns Hopkins Center for Health Security, answers a grab bag of listener questions.
Published April 17, 2020
Host: Joshua Sharfstein, MD
Host: Stephanie Desmon
Guest: Roni Neff
Bare shelves in grocery stores feed pandemic anxiety but Roni Neff, an expert on food systems and public health at the Johns Hopkins Center for a Livable Future, says this is not the biggest concern. Neff talks to Stephanie Desmon about how our robust food industry depends largely upon keeping its workers safe and well, how a pandemic completely shifts the model of emergency food access, and what’s being done to address these unique challenges to ensure everyone is fed.
Published April 16, 2020
Host: Joshua Sharfstein, MD
Host: Stephanie Desmon
Guest: Crystal R. Watson, DrPH
Contact tracing is a core tool of public health. Now, it could be a way to reopen the world. Crystal Watson of the Center for Health Security is the lead author of a recent report with a national plan to scale up our capability to conduct contact tracing. Watson talks to Stephanie Desmon about what contact tracing entails, how technology could help, how to approach privacy concerns, and why the plan could help employ thousands of people with some basic training.
Published April 16, 2020
Host: Joshua Sharfstein, MD
Host: Stephanie Desmon
Guest: Allison Barlow, PhD
Poor health care, lacking infrastructure, and generational poverty combine to make Native Americans especially vulnerable to COVID-19. With previous infectious respiratory illnesses like H1N1, mortality rates were sometimes four to five times higher than US averages among tribal communities. Allison Barlow, Director of the Center for American Indian Health, talks to Stephanie Desmon about COVID-19’s particular threats to Native Americans, what’s being done to help mount a “culturally informed” response, and how the virus is “revealing the cracks in our systems.”
Published April 15, 2020
Host: Joshua Sharfstein, MD
Host: Stephanie Desmon
Guest: Meghan F. Davis, PhD, DVM
Most new diseases originate from “spillover events” where humans come into contact with wild animals. Veterinarian and scientist Meghan Davis talks to Stephanie Desmon about the rise of infectious diseases and what is being done to prepare for future spillover events. She also covers how a tiger in the Bronx Zoo got a test, and the threats COVID-19 may pose to your own pets.
Published April 14, 2020
Host: Joshua Sharfstein, MD
Guest: Beth Blauer
The COVID-19 dashboard run by the Johns Hopkins Center for Systems Science and Engineering has been a critical source of near real-time tracking of the spread of the novel coronavirus since it first emerged. Beth Blauer, Executive Director of Centers for Civic Impact and an expert on the public’s use of data and analytics, is part of the team that manages the map. Blauer talks to Dr. Josh Sharfstein about how the global dashboard originated, what new features have been added, and how the data can help individuals and officials make informed decisions for COVID-19 response.
Published April 14, 2020
Host: Matt Birnholz, MD
Guest: Kathryn J. Ruddy, MD
Guest: Joerg Herrmann, MD
To give us a better sense for how some cardiology and oncology specialists have responded to the COVID-19 pandemic, Dr. Joerg Hermann and Dr. Kathryn Ruddy, who are two members of the cross-disciplinary Cardio-Oncology clinic at Mayo Clinic, discuss their perspectives on this pandemic and how they’ve been treating immunosuppressed patients.
Published April 21, 2020
Host: John J. Russell, MD
In the absence of FDA-approved therapies and vaccines to battle the COVID-19 pandemic, healthcare professionals on the frontlines are turning to malarial medicines like chloroquine and hydroquinone to treat their patients—despite the fact that there’s no evidence to support their use. But this isn’t the first time that medicines have been used for a different purpose than what they were intended for, as Dr. John Russell explains.
Published April 21, 2020
Host: Linda Bernstein, Pharm.D.
Critical medicine shortages during the COVID-19 pandemic, particularly for drugs required to support patients on mechanical ventilation, is the focus of this episode of The Drug Report. Pharmacist Dr. Linda Bernstein describes the urgent appeals made by major healthcare organizations, related reports highlighting the serious impact of these shortages on fill rates for critical medicines, and progress being made at the federal level to remedy the situation.
Published April 21, 2020
Host: Linda Bernstein, Pharm.D.
Join pharmacist Dr. Linda Bernstein as she outlines the United States Health and Human Services’ authorization of licensed pharmacists to order and administer FDA-approved COVID-19 tests as well as the priority patient testing categories as set forth by the U.S. Public Health Service.
Published April 21, 2020
Host: Linda Bernstein, Pharm.D.
Tune in as pharmacist Dr. Linda Bernstein looks at a few of the novel approaches researchers all over the world are taking to conquer the novel coronavirus in addition to evaluating what these approaches may mean for today and potential viral mutations going forward.
Published April 21, 2020
Host: John J. Russell, MD
Throughout history, diseases have acquired names from geographical landmarks, the name of the organism, the anatomy impacted, and even the media. But some naming conventions have resulted in negative consequences, which is why the World Health Organization established best practices for naming novel diseases in 2015.
Here to walk us through those guidelines and to give us a brief history of how some well-known diseases—including the COVID-19 pandemic the world is currently facing—gained their name is Dr. John Russell.
Published April 21, 2020
Host: John J. Russell, MD
The practice of quarantining ill patients goes back much further than you may realize. Tune in as Dr. John Russell walks us through the history of quarantines going all the way back to the year 1200.
Published April 21, 2020
Host: Linda Bernstein, Pharm.D.
The Centers for Disease Control provided a guidance for pharmacy staff to minimize their risk of exposure to the COVID-19 virus and reduce customer risk during the pandemic. Pharmacist Dr. Linda Bernstein presents highlights of the guidance that offers recommendations on ways to minimize viral exposure when medication dispensing along with methods to minimize patient-to-patient contact.
Published on April 17, 2020
Host: Linda Bernstein, Pharm.D.
Pharmacist Dr. Linda Bernstein highlights the key points of a New England Journal of Medicine article that given the available evidence, the authors and multiple specialty medical societies believe that—despite theoretical concerns and uncertainty pertaining to the effect of RAAS inhibitors on ACE2 and its potential relationship to COVID-19 severity—RAAS inhibitors should be continued in patients who are otherwise in stable condition who are at risk for or are being evaluated for COVID-19. Abrupt withdrawal of RAAS inhibitors in high-risk patients, including those who have heart failure or have had myocardial infarction, may result in clinical instability and adverse health outcomes.
Published April 17, 2020
Host: Linda Bernstein, Pharm.D.
The Food and Drug Administration has issued a guidance on its temporary policy for certain risk evaluation and mitigation strategies (REMS) requirements during the COVID-19 pandemic that include laboratory monitoring and imaging studies. Pharmacist Dr. Linda Bernstein discusses the guidance and its impact on patient access to certain REMS drugs when patients self-isolate or are subject to quarantine due to COVID-19.
Published April 17, 2020
Host: Linda Bernstein, Pharm.D.
The American Society of Health Systems Pharmacists (ASHP) recently published recommendations for prescribers, pharmacists and patients when considering the proper use of experimental treatments during the COVID-19 pandemic. Inappropriate prescribing of experimental treatments “just in case” or for patients not at high risk of severe illness may lead to insufficient supplies of critical medicines that are needed to treat other patients who depend on these medicines.
Linda Bernstein, Pharm.D., reports on this important guidance designed to limit drug shortages and the worsening of existing shortages that can occur when practitioners and patients stock up and hoard their medication supplies.
Published April X, 2020
Host: Linda Bernstein, Pharm.D.
The World Health Organization (WHO) and partners recently announced it was launching an international clinical trial with the goal of generating significant worldwide data from thousands of patients to find the most effective treatments for COVID-19. Pharmacist Dr. Linda Bernstein brings you an update on the WHO SOLIDARITY trial, which will offer clinicians simplified procedures to enable even overloaded hospitals to participate.
Published April 17, 2020
Host: Joshua Sharfstein, MD
Guest: Paul B. Spiegel, MD
Guest: John Barry
The historical context of 1918 shaped much of the response to the flu pandemic in the US—just as it will with COVID-19. Dr. Paul Spiegel, director of the Center for Humanitarian Health, talks with historian and author John Barry about how an absence of credible leadership and messaging hindered response efforts then and what lessons we can apply today.
Published April 13, 2020
Host: Joshua Sharfstein, MD
Guest: Amesh Adalja, MD
What did we learn this week? Is there a connection between 5G cell phone towers and the novel coronavirus? How often should you wash a homemade cloth mask? Is there any truth behind using hydroxychloroquine as a treatment? Will people on ventilators have permanent lung damage? What’s it like for doctors and nurses in the hospitals right now? Dr. Amesh Adaljaof the Johns Hopkins Center for Health Security addresses your questions.
Published April 10, 2020
Host: Joshua Sharfstein, MD
Host: Stephanie Desmon
Guest: William J. Moss, MD
Development of a COVID-19 vaccine is an essential part of halting the pandemic. But will it be months or years before we see one? Vaccine expert Dr. William Moss talks to Stephanie Desmon about the complexities of vaccine development and manufacturing, potential hold ups, how opponents of vaccination may come into play, and why COVID-19 may threaten current immunization programs.
Published April 10, 2020
Host: Joshua Sharfstein, MD
Guest: Amy Greensfelder, MSW
Guest: Shantay Jackson
Fallout from COVID-19 goes beyond case counts—we are facing “an epidemic of isolation and loneliness,” says Councilman Zeke Cohen. The Baltimore Neighbors Network is a virtual community of trained volunteers who are available to listen to city residents and provide resources for follow-up if needed.
Councilman Cohen, Shantay Jackson, executive director of the Baltimore Community Mediation Center, and Amy Greensfelder, executive director of Pro Bono Counseling, talk to Dr. Josh Sharfstein about how the network is addressing the mental health risks.
Published April 9, 2020
Host: Joshua Sharfstein, MD
Host: Stephanie Desmon
Guest: Tom Frieden
What will need to happen for businesses and schools to reopen, and what might the future look like with COVID-19? Former CDC director Tom Frieden talks to Stephanie Desmon about what governments and individuals should be doing right now to help curb the spread of the virus and move America closer to reopening.
Published April 9, 2020
Host: Joshua Sharfstein, MD
Guest: Lainie Rutkow, PhD, JD
There have been varying responses to COVID-19 carried out across local, state, and federal governments in the US. But what powers does the government have at various levels in a pandemic and how does the law work when an enemy like COVID-19 “does not respect jurisdictional boundaries?” Law expert and Hopkins professor Dr. Lainie Rutkow talks to Dr. Josh Sharfstein about a range of legal issues, including what happens if states start suing each other.
Published April 8, 2020
Host: Joshua Sharfstein, MD
Host: Stephanie Desmon
Guest: Jason E. Farley, PHD, MSN, MPH, RN
Why was the US slow to stand up testing and is this improving? Should you wear a cloth mask in your daily activities? Jason Farley, an infectious disease-trained nurse epidemiologist at the Johns Hopkins School of Nursing, talks to Stephanie Desmon and breaks down the complications of testing for COVID-19 and why recommendations on the public’s use of masks may be evolving.
Published April 8, 2020
Host: Joshua Sharfstein, MD
Guest: Vernon Lee, PhD
Early on in the COVID-19 outbreak, Singapore quickly launched a robust response which included widespread testing, diligent contact tracing and quarantining, and isolation of all sick persons, even those with mild symptoms. Alumnus Dr. Vernon Lee, Director of Communicable Diseases at the Ministry of Health of Singapore, talks to Dr. Josh Sharfstein about how lessons from the 2003 SARS outbreak informed Singapore’s risk-based approach to staying a few steps ahead of the novel coronavirus.
Published April 7, 2020
Host: Paul Doghramji, MD
Guest: Gary Lyman, MD, MPH
Just two miles away from where the first case of COVID-19 was identified, the Hutchinson Institute for Cancer Outcomes Research acted quickly to help protect patients. Here to walk us through the impacts, barriers faced, and strategies that have been implemented to help address those challenges is the oncology center’s Senior Lead of Health Care Quality and Policy Dr. Gary Lyman.
Published April 10, 2020
Host: Joshua Sharfstein, MD
Guest: Sabra L. Klein, PhD
Host: Stephanie Desmon
Guest: Rosemary Morgan, PhD
Globally, more men are dying from COVID-19 than women. But is this due to sex (biological differences), gender (social and contextual differences), or something else entirely? Stephanie Desmon talks to virologist Sabra Klein and social scientist Rosemary Morgan about risk factors associated with COVID-19.
Published April 6, 2020
Host: Joshua Sharfstein, MD
Guest: Tolbert G. Nyenswah, MPH
In 2014, Tolbert Nyenswah, then an assistant minister of health in Liberia, was tapped to lead the nation’s response to the Ebola epidemic. Under his leadership, an Incident Management System deployed thousands of epidemiologists, case managers, and contact tracers in a technical response that brought the outbreak under control. Nyenswah talks to Dr. Josh Sharfstein about what the US can learn from Liberia’s experience and what needs to happen soon to get ahead of the curve.
Published April 6, 2020
Host: Joshua Sharfstein, MD
Guest: Howard Sklamberg
What does a global pandemic mean for the world’s drug supply chain? Howard Sklamberg, lawyer and former FDA deputy commissioner, talks to Dr. Josh Sharfstein about the threats that COVID-19 poses to medications for everything from cancer to diabetes to hypertension.
Published April 3, 2020
Host: Joshua Sharfstein, MD
Guest: Dr. Eric Toner, MD
The Center for Health Security is back with another round of expert answers to your most-asked COVID-19 questions. If we reopen everything back up, what is the risk that we’ll have a new surge of infections? As China considers loosening restrictions, how are they making those decisions? Why aren’t there human temperature monitors in public places like airports, hospitals, and grocery stores? Is anyone considering breast milk for antibody therapy? Can two positive people quarantine together? How many people will actually get COVID-19? What are the most important unanswered questions right now?
Published April 3, 2020
Host: Stephanie Desmon
Guest: Chris Beyrer, MD, MPH
As public health experts stress the importance of hygiene and social distancing to slow the spread of COVID-19, what does this mean for the 2.3 million people incarcerated in the U.S.? Johns Hopkins Infectious disease epidemiologist Dr. Chris Beyrer talks to Stephanie Desmon about the difficulties of protecting people in these facilities, the low-risk/high-reward strategy of releasing those held on administrative misdemeanors, and how undocumented people may be one of our most vulnerable populations.
Published April 2, 2020
Host: Stephanie Desmon
Guest: Dr. Brian Garibaldi, MD
Caring for patients with COVID-19 requires a new playbook in many ways. Dr. Brian Garibaldi, a pulmonologist in the ICU at Johns Hopkins Hospital and the medical director of the biocontainment unit, talks to Stephanie Desmon about his observations of COVID-19 patients including new challenges, changes to protocols, and coping with fears about he and his colleagues getting sick themselves.
Published April 1, 2020
Host: Joshua Sharfstein, MD
Guest: Dr. Lisa A. Cooper, MD, MPH
Equal access to resources, care, and information is a substantial problem for at-risk groups such as older adults, ethnic minorities, or those with low incomes even in the best of times. In this pandemic, where it’s critical to “flatten the curve” among all groups, these barriers cannot be ignored. Dr. Lisa Cooper, director of the Johns Hopkins Center for Health Equity, talks to Dr. Josh Sharfstein about what needs to be done to address these significant, persistent challenges.
Published April 1, 2020
Host: Stephanie Desmon
Guest: Keri N. Althoff, PhD
Guest: Elizabeth A. Stuart, PhD
Like many, epidemiologist Keri Althoff and biostatistician Elizabeth Stuart are juggling different responsibilities and precautionary measures in the “new normal” of COVID-19. They talk to Stephanie Desmon not about their day jobs, but about play dates, community building while social distancing, ordering takeout, and how they’re managing COVID-19 as parents, neighbors, and friends.
Published March 31, 2020
Guest: Michael Greenberg, MD
Join dermatologist Dr. Michael Greenberg as he shares his unique view that blurs science and spirituality and how it’s helping him create stronger connections with patients.
Published April 10, 2020
Host: Linda Bernstein, Pharm.D.
This special episode of The Drug Report provides an update regarding the antiviral Remdesivir, which is the first investigational therapeutic to be studied under an FDA-approved NIH adaptive randomized controlled clinical trial for hospitalized COVID-19 patients. Currently, there are three options through clinical trials for obtaining remdesivir for the treatment of hospitalized patients with COVID-19 and pneumonia in the United States, as pharmacist Dr. Linda Bernstein explains.
Published April 10, 2020
Host: John J. Russell, MD
Guest: Diane E Custer, MD
As the COVID-19 pandemic continues to spread across our nation and the world, more and more patients are experiencing anxiety and depression. Joining Dr. John Russell to explain how we can console our patients—all while maintaining our own mental health along the way—is Dr. Diane Custer.
Published April 8, 2020
Host: Joshua Sharfstein, MD
Guest: Cyrus Shahpar, MD, MBA, MPH
What does it take to stand up a makeshift hospital—and enough people to staff it—in order to address critically ill patients of COVID-19? Dr. Cyrus Shahpar, Director of Prevent Epidemics team at Resolve to Save Lives talks to Dr. Josh Sharfstein about how to quickly scale up medical responses in a crisis.
Published March 30, 2020
Host: Joshua Sharfstein, MD
Guest: Bin Cao, MD
Dr. Bin Cao, Vice President and Director of Respiratory and Critical Care Medicine at the China-Japan Friendship Hospital in Beijing, has worked on the frontlines of patient care in Wuhan for the past few months. By closely monitoring the disease, he and his team are beginning to unlock some of its secrets. Dr. Cao talks to Dr. Josh Sharfstein about how the situation has changed in Wuhan, what we can learn about safeguarding providers, the primary risk factors for death, and ongoing research.
Published March 27, 2020
Host: Joshua Sharfstein, MD
Guest: Crystal R. Watson, DrPH
What do we know this week that we didn’t know last week? What’s the status of serologic testing and can it be useful in helping to end social distancing practices? How good is the current evidence on chloroquine? Should COVID-19 patients avoid taking ibuprofen? What happens next if we are successful with social distancing? If you are older but have no chronic illness, are you still at high risk?
Published March 27, 2020
Host: Joshua Sharfstein, MD
Guest: Jeremy A. Green
Guest: Graham Mooney, PhD
COVID-19 is often compared to the 1918 flu pandemic that claimed millions of lives and caused massive social disruption. But to what extent is the novel coronavirus different and what lessons can we learn from the successes and failures of previous epidemics? Medical historians Jeremy Greene and Graham Mooney talk to Stephanie Desmon about this comparison, the history of quarantines, and what we will learn from what we are living through right now.
Published March 27, 2020
Host: Joshua Sharfstein, MD
Guest: Judi Melinek, MD
Dr. Judy Melinek is a forensic pathologist in the San Francisco Bay Area. She explains the role of autopsies in the public health response to COVID-19 and how her work also plays a difficult but vital role in disposing of remains when health care systems become overloaded.
Published March 26, 2020
Host: Joshua Sharfstein, MD
Guest: Albert Wu, MD
In the midst of a pandemic, resilience is key for health care workers. Dr. Albert Wu, co-director of RISE—Resilience In Stressful Events—an emotional peer support structure at Johns Hopkins Hospital, talks to Dr. Josh Sharfstein about the importance of supporting hospital staff and what can be done to mitigate anxiety and stress in this unprecedented situation.
Published March 25, 2020
Host: Joshua Sharfstein, MD
Guest: Stephanie Desmon
Guest: Monica Malta MPH, PhD
The threat of COVID-19 presents a new challenge for citizens of many countries who are not used to government entities directing their behavior. It’s also an ideological shift for many: Change your individual behavior for the good of the greater community.
Monica Malta, an alumna of the Johns Hopkins Bloomberg School, is a social epidemiologist and a global health researcher at the University of Toronto. She examines how responses at local, national, and regional levels—along with individual and community behavioral changes—can change the pace of an outbreak. Malta talks to Stephanie Desmon of the Center for Communication Programs about effective response strategies, why the outbreak looked so different in Italy and Japan despite both countries having aging populations, and more.
Published March 25, 2020
Host: Joshua Sharfstein, MD
Guest: Susan Krenn
Guest: Stephanie Desmon
There are so many unknowns around COVID-19, so how can we find credible sources of information? What is the role of communication in the pandemic, and how can authorities get it right? Susan Krenn, Executive Director of the Johns Hopkins Center for Communication Programs, talks to Stephanie Desmon about how communication can combat fear if it’s credible, transparent, timely, and gives people the resources they need.
Published March 24, 2020
Host: Michael Greenberg, MD
To help both his patients and colleagues alike find support and comfort during the COVID-19 global pandemic, dermatologist Dr. Michael Greenberg shares his experiences, coping strategies, and outlets that are available.
Published April 3, 2020
Host: Michael Greenberg, MD
To help alleviate pressure from hospitals that are experiencing a high influx of patients due to the COVID-19 pandemic, dermatologist Dr. Michael Greenberg decided to keep his doors open and is now sharing what it’s like to see patients during this outbreak.
Published April 3, 2020
Host: Matt Birnholz, MD
A small-town emergency room in Louisiana has now seen hundreds of COVID-19 patients. Here’s what’s been learned in an anonymous ER doctor’s own words, as narrated by Dr. Matt Birnholz.
Published April 2, 2020
Host: Matt Birnholz, MD
After the American College of Surgeons and the Surgeon General's suspension of non-emergent surgeries and procedures, Dr. Matt Birnholz explains the new guidelines and their impact on patients.
Published April 2, 2020
Host: Matt Birnholz, MD
The international supply chain of medical equipment and materials has been strained by Asian and European countries already hit hard by the COVID-19 pandemic, which is why healthcare gear in dire need is now being looked at from a different perspective by university research teams. Listen in as Dr. Matt Birnholz sheds light on innovative ways PPE is being manufactured by Georgia Tech.
Published April 1, 2020
Host: Matt Birnholz, MD
In the absence of a vaccine or antivirals against COVID-19, controlling its transmission through social distancing has been an essential strategy. And to prove it, a team from the University of Western Australia conducted research using a simulation city which implemented social distancing versus a city without it. Dr. Matt Birnholz summarizes this study's staggering findings.
Published April 1, 2020
Host: John J. Russell, MD
Social distancing is surprisingly not a new concept in the United States. As our country geared up for World War I in 1918, social gatherings and parades to support the military were at an all-time high. But as feelings of patriotism spread at these events, so too did influenza. Join Dr. John Russell as he recounts The Tale of Two Cities: Philadelphia and St. Louis and how the spread of influenza was dramatically different between the two cities due to the actions each took to mitigate risk.
Published March 28, 2020
Host: Matt Birnholz, MD
Strategies of self-isolation from caregivers treating patients with COVID-19 are taking an emotional toll, cutting them off from their support networks at a time when workplace stress is at an all-time high. But the alternative, to many, is unthinkable.
Published March 27, 2020
Host: Linda Bernstein, Pharm.D.
As the number of novel coronavirus cases continue to rise on a national and global scale, how is the FDA responding? Pharmacist Dr. Linda Bernstein provides an overview of the FDA’s action plan with the overall goal of collaborating with interagency and international partners, product developers, and global regulators to speed up the development and availability of medical products needed to diagnose, treat, mitigate, and prevent such outbreaks.
Published March 27, 2020
Host: Linda Bernstein, Pharm.D.
Although there are currently no antiviral medicines or vaccines licensed by the FDA for the treatment and prevention of COVID-19, some progress has been made as the first investigational therapeutic is to be studied under an FDA-approved NIH adaptive randomized controlled clinical trial for hospitalized COVID-19 patients. Pharmacist Dr. Linda Bernstein reports on this and other investigational therapies.
Published March 27, 2020
Host: Matt Birnholz, MD
Healthcare workers face a new threat beyond the difficult prospects of overrun hospitals, PPE shortages, and incidental spread of the virus to their loved ones. As the pandemic escalates, shifting perceptions and moods from the public have put some clinicians in the crosshairs.
Published March 27, 2020
Host: Matt Birnholz, MD
Emerging reports are painting a far more complex picture of clinical presentations for COVID-19 than previously thought, stemming to exceptionally high viral loads in nasal cavities. How will this affect the risk profile for otolaryngologists performing essential ENT procedures?
Published March 27, 2020
Host: Joshua Sharfstein, MD
Guest: Monica Schoch-Spana, PhD
For many, COVID-19 has revealed an anxiety-ridden world of unknowns. Protecting our mental health is just as important as protecting our physical health in this pandemic. But how can we find comfort if we’re inundated with scary messages and physically cut off from people we love? Dr. Monica Schoch-Spana of the Center for Health Security talks to Dr. Josh Sharfstein about caring for ourselves and for vulnerable populations like frontline healthcare providers, friends, and neighbors in quarantine, and those with underlying health conditions like anxiety or depression.
Published March 23, 2020
Host: Joshua Sharfstein, MD
Guest: Jennifer Nuzzo, MD
Why is the response to COVID-19 so much more severe than the response to other outbreaks like H1N1 or SARS? Will a vaccine be more effective than the usual flu vaccine? Has the shortage of available testing been resolved? Are we seeing more cases because of increases in transmission or testing? Why does COVID-19 cause shortness of breath? Can drinking cold water increase your risk of infection?
Jennifer Nuzzo of the Johns Hopkins Center for Health Security addresses some myths and questions.
Published March 20, 2020
Host: Joshua Sharfstein, MD
Guest: Stephanie Desmon
Recent volatility in the financial markets have shaken investors and left everyone asking: Are we currently in a financial crisis? Author and expert on financial crises Kathleen Day of the Johns Hopkins Carey Business School talks to Stephanie Desmon of the Johns Hopkins Center for Communication Programs about how the novel coronavirus is affecting local and global economies and what consumers should do right now.
Published March 19, 2020
Host: Joshua Sharfstein, MD
Guest: Leonard S. Rubenstein, JD
What are the human rights considerations in the response to COVID-19? How can societies move to control the spread of the virus in ways that do not create panic or unnecessarily restrict communities? What are critical considerations as governments try to strike the right balance between restrictions and depriving people of the ability to live their lives? Dr. Josh Sharfstein talks to Len Rubenstein, Conflict and Health program director of the Center for Public Health and Human Rights.
Published March 18, 2020
Host: Joshua Sharfstein, MD
Guest: Caitlin Rivers, PhD, MPH
What is #FlattenTheCurve? Caitlin Rivers, senior scholar at the Center for Health Security talks to Dr. Josh Sharfstein about this response strategy, what it means for you, and how staying home can help ensure that everyone who needs healthcare in an outbreak will be able to get it.
Published March 17, 2020
Host: Joshua Sharfstein, MD
Guest: Arturo Casadevall, MD, PhD
Is there potential for using antibodies generated by people who have recovered from COVID-19 to prevent infection and treat those who are sick? Dr. Josh Sharfstein talks to Arturo Casadevall, chair of Department of Molecular Microbiology and Immunology at the Bloomberg School of Public Health, about a landmark 1934 case where antibodies helped stopped a measles outbreak.
Published March 17, 2020
Host: Joshua Sharfstein, MD
Guest: Jeffrey Kahn, MD
Guest: Nancy E. Kass, ScD
Is it right to publicly disclose information about people who get sick with COVID-19? What are society’s obligations to people who are quarantined? Is it time to start thinking about how to allocate critical healthcare resources in case this epidemic stretches the healthcare system beyond its capacity to care for everyone? Dr. Josh Sharfstein speaks with renowned ethicists Jeffery Kahn and Nancy Kass, the director and deputy director of the Johns Hopkins Berman Institute of Bioethics.
Published March 16, 2020
Host: Joshua Sharfstein, MD
Guest: Professor Lucy Wilson
Dr. Lucy Wilson, professor of Emergency Health Services at University of Maryland Baltimore County, talks with Dr. Josh Sharfstein about why the Seattle outbreak is an important bellwether for the rest of the country in terms of protecting vulnerable populations and what facilities and first responders can do to control and stop outbreaks like COVID-19.
Published March 13, 2020
Host: Joshua Sharfstein, MD
Guest: Thomas V. Inglesby, MD
Can people without symptoms spread COVID-19? Can children get COVID-19? Should you cancel an upcoming gathering? Are school closures helpful? If you’ve had COVID-19, are you immune? Are men more affected than women? Dr. Tom Inglesby from the Center for Health Security answers these and some of the most asked questions.
Published March 13, 2020
Host: Joshua Sharfstein, MD
Guest: Georges Benjamin, MD
Weak points in the U.S.’s health and social policies—like paid sick leave and universal health coverage—disproportionately affect underserved communities. COVID-19 may present added challenges for these populations. Dr. Josh Sharfstein talks to Dr. Georges Benjamin, executive director of the American Public Health Association, about public health’s role in preventing communities from being left behind.
Published March 12, 2020
Host: Joshua Sharfstein, MD
Guest: Gabor Kelen, MD
What role do local health departments play in outbreaks, and how are they preparing for COVID-19? As Commissioner of the Cuyahoga County Board of Health in Ohio, Terry Allan is responsible for the well-being of over 850,000 people. Allan talks to Dr. Josh Sharfstein about public trust and the importance of open information sharing and how ongoing relationship building and past experience help set the stage for protecting people in their communities.
Published March 11, 2020
Host: Joshua Sharfstein, MD
Guest: Terry Allan
Why the director of Hopkins’ Office of Critical Event Preparedness is preparing but not panicking: Dr. Gabor Kelen, Director of the Johns Hopkins Office of Critical Event Preparedness and Response (CEPAR) talks to Dr. Josh Sharfstein about what’s contributing to public fears about COVID-19, how the institution assesses what actions to take, and his one piece of advice for people experiencing mild symptoms.
Published March 10, 2020
Host: Joshua Sharfstein, MD
Guest: Lisa Maragakis, MD
COVID-19 presents new challenges for health care providers in the midst of respiratory virus season. Dr. Lisa Maragakis, Senior Director of Infection Prevention at Johns Hopkins University School of Medicine, talks to Dr. Josh Sharfstein about standard precautions, protecting hospital staff while ensuring coverage, how previous outbreaks have laid some groundwork to address this one, and what you can do to help.
Published March 9, 2020
Host: Joshua Sharfstein, MD
Guest: Jennifer Nuzzo, MD
Is hand sanitizer effective? Will this spread throughout the US? Should I cancel my upcoming travel plans? Can COVID-19 tests tell the difference between someone who has had the virus and someone who currently has it? Are face masks effective?
Jennifer Nuzzo of the Johns Hopkins Center for Health Security answers these and some of the most asked questions.
Published March 6, 2020
Host: Joshua Sharfstein, MD
Guest: Andrew Stanley Pekosz, PhD
Tune in for an interview with Professor Andrew Pekosz of the Johns Hopkins Bloomberg School of Public Health, an expert in the basic science of respiratory viruses, including influenza and SARS. Dr. Pekosz shares what’s known and what is yet to be discovered about the novel coronavirus.
Published March 5, 2020
Host: Joshua Sharfstein, MD
Guest: Justin Lessler, PhD
Dr. Josh Sharfstein interviews infectious disease epidemiologist Dr. Justin Lessler on the features of viruses that lead to worldwide contagion, how COVID-19 compares with the flu in terms of speed, and where the evidence now points for this novel coronavirus.
Dr. Justin Lessler is an Associate Professor in Epidemiology. Dr. Josh Sharfstein is the Vice Dean of the Johns Hopkins Bloomberg School of Public Health and former secretary of Maryland’s Department of Health.
Published March 4, 2020
Host: Joshua Sharfstein, MD
Guest: Jennifer Nuzzo, MD
Guest: Tara Kirk Sell, PhD, MA
Guest: Lauren M. Sauer, MS
With COVID-19 beginning to spread via community transmission in the U.S. and the WHO raising its risk assessment to “very high,” experts from the Johns Hopkins School of Public Health and Johns Hopkins University School of Medicine offer insights on the growing global public health concern.
Featuring Dr. Jennifer Nuzzo and Dr. Tara Kirk Sell of the Johns Hopkins Center for Health Security and Lauren Sauer of the Johns Hopkins Office of Critical Event Preparedness and Response; moderated by Dr. Josh Sharfstein, Vice Dean of the Johns Hopkins Bloomberg School of Public Health and former secretary of Maryland's Department of Health.
Published March 3, 2020
Host: Matt Birnholz, MD
COVID-19 has irreversibly altered the progression track for the next generation of physicians, with cancellations of Match Day events, Board exams, and clinical rotations in effect. Now an increasing number of entities are calling on medical students to join front-line efforts to combat the virus.
Published March 23, 2020
Host: Matt Birnholz, MD
Among the most touted candidates in the hunt for effective coronavirus treatments are the antimalarial drugs chloroquine and its derivative, hydroxychloroquine. Will these drugs become effective treatment and post-exposure prophylaxis agents?
Published March 23, 2020
Host: Matt Birnholz, MD
Reports from hospitals in multiple states speak to a rapidly diminishing supply of personal protective equipment, leading healthcare systems to adopt alternative solutions to the shortage. But will these approaches meet the rising demand, and will clinicians be adequately protected along the way?
Published March 23, 2020
Host: Mario R. Nacinovich, Jr., MSc
Guest: Charles P. Gerba, MD
The novel coronavirus outbreak that began in late 2019 may be the first global epidemic pronounced in the social media age, with myths and misinformation populating just as quickly and frequently as new cases. But is there any truth behind these claims? Here to shed light on this global health crisis is microbiologist Dr. Charles Gerba.
Host: Paul Doghramji, MD
Guest: Gregory S. Sawicki, MD, MPH
Even though there currently isn’t a cure for cystic fibrosis, there may finally be hope on the horizon for the more than 70,000 people around the world who are living with this debilitating disease. Joining Dr. Paul Dogramji to talk about the emerging treatment options for cystic fibrosis is Dr. Gregory Sawicki, Director at the Cystic Fibrosis Center and Assistant Professor of Pediatrics at Harvard Medical School.
Host: Paul Doghramji, MD
Guest: David H. Peyton, Ph.D.
The vaping epidemic is becoming more and more concerning, but could new research prompt people to quit? To find out, Dr. Paul Doghramji speaks with Dr. David Peyton about his recent study that challenges the claim that vaping devices take less of a toll on our health than tobacco smoking.
Host: Anne O'Donnell, MD
Guest: Patrick Flume, MD
Please note: This activity is no longer available for continuing education credit.
Nontuberculous mycobacteria lung disease (NTM-LD) is a relatively uncommon condition, although its prevalence is rising. In this interactive CME activity, Drs. Anne O’Donnell and Patrick Flume review two patient cases to demonstrate how clinicians can maintain a greater index of suspicion for the diagnosis of NTM-LD to enable timely and effective therapy. The management of NTM-LD remains challenging, owing to the need for long-term treatment, the potential for drug-related toxicities and patient nonadherence. These factors underscore the importance of specialty referral for the successful management of NTM-LD.
Host: Anne O'Donnell, MD
Guest: Robert "Brinkley" Sewell
Please note: This activity is no longer available for continuing education credit.
The successful management of nontuberculous mycobacteria lung disease (NTM-LD) remains challenging owing to the need for long-term treatment, the ongoing risks of adverse drug reactions, and the potential for nonadherence. These factors underscore the importance of specialty referral and shared decision making in the successful management of NTM-LD, as Dr. Anne O’Donnell and her patient Brinkley exemplify.
Host: Joseph K. Han, MD
Please note: This activity is no longer available for continuing education credit.
Chronic rhinosinusitis with nasal polyps (CRSwNP) is associated with significant morbidity and negatively impacts quality of life. The good news is that biologic therapies targeting type 2 inflammatory pathways provide additional treatment options for CRSwNP. However, clinicians not only need to accurately diagnose nasal polyps in patients but also recognize the role of the underlying pathology to incorporate biologic agents into treatment regimens when appropriate, as Dr. Joseph K. Han explains.
Host: Nicola A. Hanania, MD, MS, FCCP
Guest: Neil J. Freedman, MD
Coming from the 2019 annual CHEST conference in New Orleans, Dr. Nicola Hanania joins Dr. Neil Freedman to discuss the advances in the diagnosis and treatment of COPD as well as the updated GOLD guidelines that were covered at the conference.
Host: Kristina Montemayor, MD
Guest: Natalie E. West, MD
Guest: Allison Lambert, MD
Drs. Natalie West and Allison Lambert join Dr. Kristina Montemayor on the floor of the 2019 CHEST annual conference to talk about the sweat chloride test, CFTR modulator therapies, and other emerging strategies for diagnosing and treating patients with cystic fibrosis.
In this episode, Drs. West, Lambert, and Montemayor will share what clinicians should do to improve our patients with cystic fibrosis.
This episode is supported in part by an unrestricted/independent medical educational grants from the following: Chiesi USA, Inc., Mylan Specialty, and Vertex Pharmaceuticals Incorporated.
Host: Anoop Nambiar, MD
Guest: Joshua Mooney, MD, MS
At the 2019 CHEST annual conference, Dr. Anoop Nambiar got a chance to catch up with Dr. Joshua Mooney, who highlighted the conference’s key takeaways on interstitial lung disease, like recently developed screening tools, lung transplant technologies, self-care strategies for patients, and more.
Along with strategies and the latest treatment approaches, Drs. Nambiar and Mooney will discuss clinically relevant suggestions that healthcare providers can start to use today in patients with ILD.
This episode is supported in part by an unrestricted/independent medical educational grants from the following: Boehringer Ingelheim Pharmaceuticals, Inc., and Genentech.
Host: Sandhya Khurana, MD, FCCP
Guest: Monica Kraft, MD, FCCP
Recorded live at the 2019 annual CHEST conference in New Orleans, Dr. Monica Kraft joins Dr. Sandhya Khurana to talk about how the new available biologics are going to fit into the severe asthma treatment landscape along with other highlights from the conference.
Find out what Dr. Khurana and Dr. Kraft think you should do right now to improve treatment of severe asthma! This episode is supported in part by an unrestricted/independent medical educational grants from the following: Genentech, GlaxoSmithKline, and Novartis Pharmaceuticals Corporation.
Host: Reynold A. Panettieri, Jr., MD
Guest: Michael Wechsler, MD
Guest: Jonathan Corren, MD
Please note: This activity is no longer available for continuing education credit.
The management of severe asthma has changed drastically after the introduction of biologics. However, their introduction comes with many questions, such as, When should they be used and in whom? This Care Team ForumSM brings pulmonologists and an allergist/immunologist in dialogue with a patient about the immunologic underpinning of asthma pathology and how it relates to identifying patients appropriate for step-up care with biologics.
Host: Shira Johnson, MD
Guest: Amy L. Olson, MD, MSPH
Guest: Jeffrey Swigris, DO, MS
Guest: Katherine Rosen, RN, MSN, ANP-C
Please note: This activity is no longer available for continuing education credit.
This discussion highlights the diagnosis of and treatment approach for interstitial pneumonia with autoimmune features (IPAF).
Host: Shira Johnson, MD
Guest: Amy L. Olson, MD, MSPH
Guest: Jeffrey Swigris, DO, MS
Guest: Katherine Rosen, RN, MSN, ANP-C
Please note: This activity is no longer available for continuing education credit.
This discussion highlights the challenges associated with progressive-fibrosing ILD diagnosis, explains management differences for connective tissue disease-associated ILD, and reviews therapeutic options for the management of PF-ILD.
Host: Mario R. Nacinovich, Jr., MSc
Guest: Kalin Clifford, PharmD
Focusing on hospital-acquired and ventilator-associated pneumonia in older adults, Mario Nacinovich is joined by Dr. Kalin Clifford at the American Society of Consultant Pharmacists Annual Meeting. Together they dive deep into these two types of pneumonia to reveal new guidelines and the latest treatment options.
Host: Brian P. McDonough, MD, FAAFP
Tobacco use accounts for nearly half a million deaths in the U.S. each year and is the leading cause of lung cancer, according to the American Lung Association.
However, the economic and societal costs of smoking are also staggering. Every year, Americans spend more than $300 billion, which includes both medical care and lost productivity. Unfortunately, some people will have to pay more depending on the state in which they live.
Host Dr. Brian McDonough chats with analyst Jill Gonzales from Wallethub, a financial website that calculated the true per-person cost of smoking in each of the 50 states and the District of Columbia.
The FDA announced that a review of four large clinical safety trials shows that treating asthma with long-acting beta agonists (LABAs) in combination with inhaled corticosteroids (ICS) does not result in significantly more serious asthma-related side effects than treatment with ICS alone.
A link to the full communication detailing information for health care professionals and the Data Summary can be found at www.fda.gov/DrugSafetyCommunications.
Released 12/20/2017
Host: Brian P. McDonough, MD, FAAFP
Cigarette smoking is one of the leading cause of preventable death in North America, an unfortunate statistic that is rapidly replicating across the rest of the world. The World Health Organization (WHO) predicts based on current trends that cigarette smoking will kill a billion people this century.
But what can be done to reverse this trend?
Host Brian McDonough talks with David Sweanor, Adjunct Professor of Law, and Chair of the advisory committee for the Centre for Health Law, Policy and Ethics, at the University of Ottawa. Mr. Sweanor has been spearheading efforts to reduce cigarette smoking nationally and globally.
FDA medical oncologists discuss the approval of osimertinib for EGFR mutation-positive non-small cell lung cancer.
Released July 28, 2017
FDA medical oncologists discuss the FDA approvals of brigatinib and ceritinib for ALK-positive non-small cell lung cancer.
Released July 25, 2017
Host: Matt Birnholz, MD
Guest: Taine Pechet, MD
Dr. Taine Pechet, chief of surgery at Penn Presbyterian Medical Center and associate professor of clinical surgery at Penn Medicine joins host Dr. Matt Birnholz to discuss his thoughts on who should be regularly screen for lung cancer and the various diagnostic techniques from his perspective as a thoracic surgeon. Dr. Pechet also discusses the surgical outcomes for these patient and his thoughts on what is on the horizon for the lung cancer field.
A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients. Flume PA, VanDevanter DR, Morgan EE, Dudley MN, Loutit JS, Bell SC, Kerem E, Fischer R, Smyth AR, Aaron SD, Conrad D, Geller DE,Elborn JS. J Cyst Fibros. 2016 Jul;15(4):495-502. doi: 10.1016/j.jcf.2015.12.004. Epub 2016 Feb 4.
Abstract RATIONALE:
For patients with cystic fibrosis (CF), the use of inhaled antibiotics has become standard of care to suppress chronic Pseudomonas airways infection. There are limited antibiotic options formulated and approved for inhaled use and antibiotic efficacies attenuate over time, making additional inhaled antibiotic classes desirable. APT-1026 (levofloxacin inhalation solution, LIS) is a fluoroquinolone in development for management of chronic P. aeruginosa airways infection in patients with CF.
OBJECTIVES:
To compare the safety and efficacy of a 28-day course of treatment with LIS 240mg or placebo BID in persons ≥12years old with CF and chronic P. aeruginosa infection.
METHODS:
A multinational, randomized (2:1), double-blinded study of LIS and placebo over 28days in CF patients ≥12years with chronic P. aeruginosa infection. Time to exacerbation was the primary endpoint. FEV1 (% predicted) and patient-reported …
Microbial colonization and lung function in adolescents with cystic fibrosis. Hector A, Kirn T, Ralhan A, Graepler-Mainka U, Berenbrinker S, Riethmueller J, Hogardt M, Wagner M, Pfleger A, Autenrieth I, Kappler M, Griese M, Eber E, Martus P, Hartl D. J Cyst Fibros. 2016 May;15(3):340-9. doi: 10.1016/j.jcf.2016.01.004. Epub 2016 Feb 5.
Abstract With intensified antibiotic therapy and longer survival, patients with cystic fibrosis (CF) are colonized with a more complex pattern ofbacteria and fungi. However, the clinical relevance of these emerging pathogens for lung function remains poorly defined. The aim ofthis study was to assess the association of bacterial and fungal colonization patterns with lung function in adolescent patients with CF. Microbial colonization patterns and lung function parameters were assessed in 770 adolescent European (German/Austrian) CF patients in a retrospective study (median follow-up time: 10years). Colonization with Pseudomonas aeruginosa and MRSA were most strongly associated with loss of lung function, while mainly colonization with Haemophilus influenzae was associated with preservedlung function. Aspergillus fumigatus was the only species that was associated with an increased risk for infection with P. aeruginosa.Microbial interaction analysis revealed three distinct microbial clusters within the longitudinal course of CF lung disease. …
A novel treatment of cystic fibrosis acting on-target: cysteamine plus epigallocatechin gallate for the autophagy-dependent rescue of class II-mutated CFTR.
Tosco A, De Gregorio F, Esposito S, De Stefano D, Sana I, Ferrari E, Sepe A, Salvadori L, Buonpensiero P, Di Pasqua A, Grassia R, Leone CA,Guido S, De Rosa G, Lusa S, Bona G, Stoll G, Maiuri MC, Mehta A, Kroemer G, Maiuri L, Raia V.
Cell Death Differ. 2016 Aug;23(8):1380-93. doi: 10.1038/cdd.2016.22. Epub 2016 Apr 1.
Abstract
We previously reported that the combination of two safe proteostasis regulators, cysteamine andepigallocatechin gallate (EGCG), can be used to improve deficient expression of the cystic fibrosistransmembrane conductance regulator (CFTR) in patients homozygous for the CFTR Phe508del mutation. Here we provide the proof-of-concept that this combination treatment restored CFTR function and reduced lung inflammation (P<0.001) in Phe508del/Phe508del or Phe508del/null-Cftr (but not in Cftr-null mice), provided that such mice were autophagy-competent. Primary nasal cells from patients bearing different class II CFTR mutations, either in homozygous or compound heterozygous form, responded to the treatment in vitro. We assessed individual responses to cysteamine plus EGCG in a single-centre, open-label phase-2 trial. The combination treatment decreased sweat chloride from baseline, increased both …
Host: Jennifer Caudle, DO
Guest: K. Akaya Smith, MD
Pulmonary Arterial Hypertension (PAH): Who is at greatest risk for developing it? What do practitioners need to know about diagnosing, treatment and the overall prognosis? Host Dr. Jennifer Caudle welcomes Dr. Akaya Smith, Medical Director for Pulmonary Hypertension Program and Assistant Professor of Medicine at the Hospital of the University Pennsylvania. Dr. Smith answers these questions, as well as, the Penn Center of Excellence for Pulmonary Hypertension.
[Read the Article]
Air pollution is associated with chronic respiratory health problems in children. A new study examined whether decreases in air pollution levels are associated with significant reductions in respiratory symptoms in children.
Researchers from the University of Southern California followed over 4,600 children in eight Southern California communities across three different time periods from 1993-2012. In addition to monitoring air quality, they also looked at children with and without asthma, and whether they reported respiratory symptoms like bronchitis, congestion, phlegm production, or a daily cough for three months in a row, during the previous year.
Along with significant improvements in air pollution levels, the authors found a decrease in reported respiratory symptoms in children both with and without asthma. Respiratory symptoms decreased by 32 percent in children with asthma and 21 percent in children without.
[Watch more videos of The JAMA Report]
Host: Brian P. McDonough, MD, FAAFP
Respiratory complications of GERD are surprisingly common, particularly in patients experiencing silent, asymptomatic reflux for long periods of time. Yet the frequently subclinical nature of this disease progression is especially difficult to detect. How can clinicians better identify this rising issue, and are current treatment paradigms in primary care enough?
Joining Dr. Brian McDonough is Dr. Jamie Koufman, Professor of Otolaryngology at the Icahn School of Medicine at Mount Sinai and Director of the Voice Institute of New York. Dr. Koufman discusses the top considerations for helping prevent and treat reflux disease to help curb respiratory and other complications.
[Read the Article]
Emphysema is a serious lung disease that results in severe shortness of breath and impaired quality of life. Management of emphysema is challenging since there is no cure and current therapies, including lung reduction surgery, can be risky. A new study examined a minimally invasive procedure to see if it could improve shortness of breath and also be a safe and cost effective way to treat emphysema.
Researchers from Hôpital Universitaire de Reims, France studied a new procedure that permanently places several coils into the lung. The study included one hundred patients from ten centers across France. Fifty patients had coils placed in their lungs and the other fifty received standard medical treatment. Both groups were followed closely and assessed at six and twelve months. They participated in a six minute walk test to see if their breathing had improved, allowing them to walk farther.
Results showed that thirty-six percent of patients who received the coil treatment had improvement in the six minute walk test, compared to only eighteen percent in the control group. There was also a significant improvement in quality of life at six and twelve months for patients who received …
Host: Jennifer Caudle, DO
Guest: Christian A. Bermudez, MD
Christian A. Bermudez, MD is the Surgical Director of Lung Transplantation and ECMO, Director of Thoracic Transplantation, and Associate Professor of Surgery at the Hospital of the University of Pennsylvania. Dr. Bermudez discusses current technologies used in lung transplantation, including mechanical support as a bridge to oxygenation during the procedures themselves. He also reviews the role of Extracorporeal Membrane Oxygenation (ECMO) in lung transplantation.
Host: Brian P. McDonough, MD, FAAFP
On the subject of smoking, health risks differ from one form of smoking product to another. Yet these differences aren't always well understood by health professionals. Is there such a thing as a "safe" tobacco alternative, or is smoking cessation the only viable choice for risk reduction?Joining Dr. Brian McDonough to discuss the literature on tobacco harm reduction, as well as review the broadening spectrum of smoking formulations, from cigarettes to smokeless tobacco products to e-cigarette devices, is Dr. Brad Rodu, Endowed Chair in Tobacco Harm Reduction Research from the University of Louisville School of Medicine.
Host: Jennifer Caudle, DO
Lung cancer is the leading cause of cancer death and the second most common cancer among both men and women in the United States. But how can clinicians increase awareness and screening for this disease within their practices? Dr. Jennifer Caudle welcomes Dr. Nina Maouelainin, Director of Interventional Pulmonology at The Lung Center of Grand View Health in Sellersville, PA, to discuss the facts about lung cancer, screening approaches, and her personal journey in increasing awareness among primary care providers.
Host: Matt Birnholz, MD
In today's clinical practice, there is no appropriate "one size fits all" treatment approach for COPD. But while this progressive trend toward personalized medicine standards helps optimize COPD care for each patient, the cost-to-benefit ratio for drug development changes as COPD evolves from one disease state into a larger disease spectrum. What is the current to future pipeline for drug R&D in the COPD arena, and is the horizon optimistic for delivering better treatment methods to patients? Joining Dr. Matt Birnholz to discuss the "Pulmonary Pipeline" is Dr. Nicholas Gross, pulmonologist and industry news reporter. Dr. Gross is emeritus professor of medicine and molecular biology at Loyola University in Chicago.
Host: Brian P. McDonough, MD, FAAFP
Nearly 55% of infants in the United States sleep on unsafe bedding, despite warnings from the Centers for Disease Control and the American Academy of Sleep Medicine to use firm flat surfaces covered with fitted sheets. Parents are being presented with several more comfortable, "baby friendly" appearing alternatives, as well as having their infants children sleep with them in their own beds, both of which create risks of SIDS and roll-over suffocations, respectively. Joining Dr. Brian McDonough to discuss safety standards and health priorities for infant sleep habits is Dr. Shalini Paruthi, Assistant Professor in the Divisions of Pulmonary Medicine and Sleep Medicine, and Director of the Pediatric Sleep Research Center at St. Louis University School of Medicine.
Host: Matt Birnholz, MD
Antibiotic stewardship, or the responsible prescribing habits of antibiotics, is on the decline in the U.S, and the spread of multidrug resistant bacterial infections through communities has already begun to be observed. Dr. Steven Brown, staff physician at Mercy Hospital in St. Louis, MO and Medical Director of the Lung Injury Center, likens antibiotic prescription expectations by patients to that of gameshow participants, where everyone presumes to take home a "prize" of some kind by the end of the encounter. How can clinicians counteract this trend in antibiotic prescription habits, and what are the risks of ignoring this mandate for better stewardship?
Host: Brian P. McDonough, MD, FAAFP
Dr. Brian McDonough welcomes Tanya Winders, President and Chief Executive Officer for the Allergy and Asthma Network, the leading patient advocacy organization dedicated to ending needless suffering and death due to asthma, allergies, and related conditions. They discuss ways of addressing healthcare access challenges for asthma and allergy patients, from socioeconomic support structures to education models to special risk situations like enterovirus outbreaks.
Guest: Shelly Batra, MD
Host: Maurice Pickard, MD
Multidrug Resistant (MDR) Tuberculosis is a growing public health epidemic in India. The non-profit organization Operation ASHA has expanded its role considerably over the past few years to stem this tide of TB transmission within both the poorest and the most prosperous communities, bringing innovative treatment protocols right to the patients' doorsteps. Dr. Shelly Batra, president of Operation ASHA, discusses the progress being made in this increasingly global public health campaign. Hosted by Dr. Maurice Pickard.
Host: Matt Birnholz, MD
Current Guidelines conclude that enlisting greater numbers of primary care clinicians to improve access to quality care will help people gain control of their asthma and allergy, thusly improving patients' quality of life. This activity was developed based on the current recommendations and guidelines issued by national organizations, and is designated to close gaps in knowledge, awareness, attitudes, and decision-making patterns related to the treatment and referral of patients with asthma and allergy.
Presenting this Prova Education Live Event is Dr. Michael Wechsler, Assistant Professor of Medicine at Harvard Medical School and Associate Director of the Brigham and Women's Hospital Asthma Research Center.
This is Part 2 of a lecture in two parts.
Part 1 >>
To view the complete video recording of this and other Prova Education Live Events, visit http://www.provaeducation.com
And to download a copy of the American Lung Association's "Asthma Action Plan" referenced in this program, visit http://www.lungusa.org/lung-disease/asthma/living-with-asthma/take-control-of-your-asthma/asthma-action-plan.html
Host: Matt Birnholz, MD
Current Guidelines conclude that enlisting greater numbers of primary care clinicians to improve access to quality care will help people gain control of their asthma and allergy, thusly improving patients' quality of life. This activity was developed based on the current recommendations and guidelines issued by national organizations, and is designated to close gaps in knowledge, awareness, attitudes, and decision-making patterns related to the treatment and referral of patients with asthma and allergy.
Presenting this Prova Education Live Event is Dr. Michael Wechsler, Assistant Professor of Medicine at Harvard Medical School and Associate Director of the Brigham and Women's Hospital Asthma Research Center.
This is Part 1 of a lecture in two parts.
Part 2 >>
To view the complete video recording of this and other Prova Education Live Events, visit http://www.provaeducation.com
And to download a copy of the American Lung Association's "Asthma Action Plan" referenced in this program, visit http://www.lungusa.org/lung-disease/asthma/living-with-asthma/take-control-of-your-asthma/asthma-action-plan.html
Host: Aaron Carroll, MD
Guest: John M Reynolds, MD
Which patients are good candidates for lung transplantation? How sick does a patient need to be to qualify? How does the transplant allocation system work? Host Dr. Aaron Caroll welcomes Dr. John M. Reynolds, medical director of Indiana University Health Lung Transplant Program, to discuss these questions and other considerations regarding potential lung transplant candidates, including the lung allocation score system, and how to assess the optimal time frame to transplant patients for the best chances to improve overall quality of life.
Host: Matt Birnholz, MD
This year's meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI), held in San Francisco over March 18th through the 22nd, attracted over 7,000 participants from around the world, including clinicians, academics, allied health professionals, and others interested in allergic and immunologic disease. The conference highlighted recent advances in allergy and immunology research, with presentations also focusing on other developments in allergy, asthma, and immunologic diseases.
Host: Matt Birnholz, MD
Recognizing the respiratory manifestations of neuromuscular disease in children is a critical first step toward protecting their survival and improving their quality of life. In this session of Grand Rounds from the University of Arizona College of Medicine, participants learn about the art of assessing respiratory problems in these children, and the treatment options available for optimizing long-term management.
Presenting this session of Grand Rounds is Dr. Cori Daines, pediatric pulmonologist and associate professor of pediatrics at the University of Arizona College of Medicine. Dr. Daines is director of the pediatric bronchoscopy program, and co-director of the Tuscon Cystic Fibrosis Center.
This is Part 3 of a lecture in three parts.
Part 1 >>
Part 2 >>
To view the complete video recording of this and other Grand Rounds sessions from the University of Arizona College of Medicine, visit their website.
Host: Matt Birnholz, MD
Recognizing the respiratory manifestations of neuromuscular disease in children is a critical first step toward protecting their survival and improving their quality of life. In this session of Grand Rounds from the University of Arizona College of Medicine, participants learn about the art of assessing respiratory problems in these children, and the treatment options available for optimizing long-term management.
Presenting this session of Grand Rounds is Dr. Cori Daines, pediatric pulmonologist and associate professor of pediatrics at the University of Arizona College of Medicine. Dr. Daines is director of the pediatric bronchoscopy program, and co-director of the Tuscon Cystic Fibrosis Center.
This is Part 2 of a lecture in three parts.
Part 1 >>
Part 3 >>
To view the complete video recording of this and other Grand Rounds sessions from the University of Arizona College of Medicine, visit their website.
Host: Matt Birnholz, MD
Recognizing the respiratory manifestations of neuromuscular disease in children is a critical first step toward protecting their survival and improving their quality of life. In this session of Grand Rounds from the University of Arizona College of Medicine, participants learn about the art of assessing respiratory problems in these children, and the treatment options available for optimizing long-term management.
Presenting this session of Grand Rounds is Dr. Cori Daines, pediatric pulmonologist and associate professor of pediatrics at the University of Arizona College of Medicine. Dr. Daines is director of the pediatric bronchoscopy program, and co-director of the Tuscon Cystic Fibrosis Center.
This is Part 1 of a lecture in three parts.
Part 2 >>
Part 3 >>
To view the complete video recording of this and other Grand Rounds sessions from the University of Arizona College of Medicine, visit their website.
Guest: Christopher Slatore, MD
Host: Mary Leuchars, MD
Systemic corticosteroids increase the risk of diabetes, but what about in patients who take high-dose inhaled corticosteroids? How do we best manage the risk-benefit equation in patients with chronic obstructive pulmonary disease (or COPD)? Dr. Christopher Slatore, assistant professor in the division of pulmonary and critical care medicine, Portland VA Medical Center / Oregon Health and Sciences University, in Portland, Oregon, discusses the association between inhaled corticosteroid use and serum glucose concentration. Dr. Mary Leuchars hosts.
Guest: Donald Sefcik, MD
Host: Lisa Dandrea Lenell, PA-C, MPAS, MBA
After many years of discussion, the National Commission on Certification of Physician Assistants (NCCPA) will offer PAs Certificates of Added Qualification in 5 specialties, beginning in 2011. Dr. Don Sefcik, chairman of the NCCPA, joins host Lisa Dandrea Lenell to explain what it takes to obtain certification, what the benefits are to PAs, and why the NCCPA decided to institute the certification now, with the nation's healthcare system in flux.
Host: Janet Wright, MD
Guest: Karol Watson, MD, PhD
When patients present with shortness of breath, physicians often face a quandary: Is it the heart or is it the lungs? What is the relationship between chronic obstructive pulmonary disease, or COPD, and cardiac function? Are patients with even subclinical emphysema at risk for showing reductions in cardiac output and left ventricular volume? Dr. Karol Watson, director of the Women's Cardiovascular Center, co-director of the program in preventative cardiology, and director for the Center for Cholesterol and Hypertension Management at the University of California Los Angeles, discusses recent findings about mild- to moderate-COPD and cardiac function, and how this new evidence should impact the way physicians diagnose and manage patients with shortness of breath. Dr. Janet Wright hosts.
Produced in Cooperation with
Host: Mark Chyna, MD
Tune in for highlights and latest research presented at the American Association for Respiratory Care's 55th International Respiratory Congress. This meeting took place in San Antonio, Texas, December 5th through 8th. Findings included the effect of specialized rapid response teams on serious complications like cardiac arrest and respiratory failure, the ability of neonates to ventilate on Neurally Adjusted Ventilatory Assist, or NAVA, and research on the improved prevention of ventilator-associated pneumonia.
Guest: Norman Edelman, MD
Host: Matt Birnholz, MD
Host: Michael Greenberg, MD
We are moving closer to the height of what many feel will be an extraordinarily busy flu season, with H1N1 and the seasonal flu both central parts of the discussion. We don't know exactly how serious H1N1 will be, but we do know that it's here, that many more people could get sick, and that we have to be prepared to deal with it. Hosts Dr. Michael Greenberg and Dr. Matt Birnholz speak with Dr. Norman Edelman, chief medical officer for the American Lung Association and a professor of preventive medicine and internal medicine at the State University of New York at Stony Brook.
Dr. Birnholz and Dr. Greenberg will also give you their take on an amusing recitation of the health reform bill in the House known as HR 3200. They will also play back the winning entry in an entertaining yet informative contest to create a public service announcement on H1N1, co-sponsored by the U.S. Department of Health and Human Services. You won't want to miss it!
Guest: John Heffner, MD
Host: Maurice Pickard, MD
Do allergies to various types of fungi trigger worsening of asthma? Are patients with severe asthma sensitive to certain species of fungus more than others? Dr. John Heffner, professor of medicine at the Oregon Health and Science University, discusses how patients with asthma might benefit from antifungal agents. Does off-label use of itraconazole for patients with severe asthma require long-term adherence for optimal asthma control? Dr. Maurice Pickard hosts.
Guest: Norman Edelman, MD
Host: Shira Johnson, MD
More than 40 thousand people, including fire and rescue workers, were exposed to toxic dust in the wake of the attacks on the World Trade Center in New York City in September, 2001. Fast-forward more than a decade, and nearly a quarter of those first responders still have breathing issues. Dr. Norman Edelman, chief medical officer of the American Lung Association, joins host Dr. Shira Johnson to disuss what needs to be done for those who continue to suffer, as well as how children living in nearby neighborhoods have also been affected. The two also look at air quality and allergy and its affect on Americans.
Guest: Daniel Remick, MD
Host: Maurice Pickard, MD
While many patients with asthma are allergic to pollen or pet dander, new evidence suggests inner city asthma patients may be most allergic to cockroach remains found in household dust. Dr. Daniel Remick, chair and professor of pathology at Boston University School of Medicine, discusses his new research demonstrating the relationship between household dust from city buildings and asthma. What implications for treatment does this research provide? Will there be an attempt to desensitize children to this cockroach allergen in the future? Dr. Maurice Pickard hosts.
Guest: Shelly Batra, MD
Host: Maurice Pickard, MD
Tuberculosis is a public health epidemic in India. What strategies is the non-profit organization Operation ASHA using to treat and prevent T.B. in India? Tune in to hear Dr. Shelley Batra, gynecologist and president of Operation ASHA, discuss the progress being made in treating T.B. patients in India, and why she has dedicated her time to addressing this epidemic. Dr. Maurice Pickard hosts.
Guest: Rob Neville
Host: Bruce Japsen
Despite medical advancements in drugs and delivery devices for asthma and allergy sufferers, some patients are not getting appropriate dosages. But new advances are being worked on that could improve care for many through nanotechnology. Rob Neville, executive chairman of Savara Pharmaceuticals, tells host Bruce Japsen about the use of nanotechnology as an emerging way to administer drugs more effectively for improved respiratory care.
Guest: Robert Wise
Host: Lee Freedman, MD
What evidence links gastroesophogeal reflux to worsened asthma, and does prescribing a proton pump inhibitor to patients with asthma help alleviate their asthma symptoms? Dr. Robert Wise, professor of medicine at Johns Hopkins University School of Medicine, discusses the role of proton pump inhibitors for patients with asthma. In patients with poorly controlled asthma and asymptomatic reflux, is a proton pump inhibitor beneficial?
Guest: Harold S. Nelson, MD
Host: Jennifer Shu, MD, FAAP
The incidence of asthma has doubled in the past two decades, though the cause of this rise is difficult to pinpoint. While the hygiene hypothesis has, for years, served as one possible explanation, newer studies show a possible link between asthma and vitamin levels or exposure to certain chemicals or medications. How might this knowledge help us prevent the development of asthma, and what research still needs to be performed to determine the key factors here, and put an end to the increasing incidence of asthma? Dr. Harold Nelson, professor of medicine at the University of Colorado School of Medicine and National Jewish Health hospital in Denver, lays out the evidence for these potential risk factors, from the child's date of birth, to acetaminophen use, to vitamin D levels, to exposure to cleaning sprays and other household chemicals. Dr. Jennifer Shu hosts.
Guest: Jesse Joad, MD, MS
Host: Jennifer Shu, MD, FAAP
Long-acting, single-agent beta agonists should be used in tandem with a corticosteroid for the treatment of asthma. Despite a black box warning from the Food and Drug Administration (FDA) to this effect, evidence suggests nearly half of our patients do not take these medications together, which appears to result in more severe asthma attacks and an increased mortality risk. In theory, longer-acting beta agonists (LABAs) should help with compliance, but if these single-agent drugs aren't taken as recommended, is there a role for them in the treatment of asthma? Dr. Jesse Joad, professor of pediatrics at the University of California, Davis School of Medicine and a former member of the FDA's Pulmonary and Allergy Drug Advisory Committee, talks with host Dr. Jennifer Shu about the pharmacologic and logistical differences between LABAs taken as monotherapy and LABAs taken in combination with a steroid. Dr. Joad …
Guest: Bob Baltera
Host: Bruce Japsen
Asthma remains a difficult disease to treat and control, with a large portion of the patient population not receiving adequate treatment options. But next-generation therapies are targeting this inflammation by being more targeted, getting at the root of the pathways that play a larger role in the disease. Bob Baltera, chief executive officer of Amira Pharmaceuticals, tells host Bruce Japsen about developments in more targeted therapies.
Guest: William Thomas, MD
Host: Lee Freedman, MD
Why are conventional emergency departments less than ideal environments for older patients, and how can EDs be acclimated for seniors? Dr. William Thomas, geriatrician and professor of aging studies at the Erickson School at the University of Maryland, describes to host Dr. Lee Freedman the philosophy behind the nation's first ED designed specifically for older patients, at Holy Cross Hospital in Silver Springs, Maryland. How do staffing and design changes, as well as new screening methods, help physicians better care for older patients? Is this model cost-effective and efficient enough for other hospitals to emulate?
Guest: David P. Skoner, MD
Host: Ketan Sheth, MD, MBA
Is there evidence that suggests corticosteroids used to treat asthma might affect growth? Are growth effects from using inhaled or intranasal steroids to control asthma or allergic rhinitis a significant concern? Dr. David Skoner, professor of pediatrics at the Drexel University College of Medicine, discusses the challenges of evaluating the systemic effects of these medications, and suggests what physicians can do to minimize the risk of growth effects when using corticosteroids. Dr. Ketan Sheth hosts.
Guest: Michael Foggs, MD
Host: Ketan Sheth, MD, MBA
In what populations is asthma becoming more prevalent, and is asthma becoming a significant public health issue? How can physicians better care for under-served communities with a prevalence of asthma? Dr. Michael Foggs, chief of allergy, asthma, and immunology at Advocate Health Centers, discusses the impact of asthma on under-served communities, and how physicians can be mindful of related socioeconomic issues. Hosted by Dr. Ketan Sheth.
Guest: Caroline Hall, MD
Host: Jennifer Shu, MD, FAAP
Respiratory syncytial virus (RSV) is a well-known cause of hospitalization in infants, but new research suggests the burden of illness may be more substantial than previously recognized in healthy, older children as well. Investigators estimate over two million children under the age of five require medical treatment for RSV each year. Because it can be difficult to prevent and treat RSV infections, is there a role for a vaccine against the illness? Host Dr. Jennifer Shu welcomes Dr. Caroline Hall, professor of pediatrics and medicine at the University of Rochester School of Medicine and Dentistry, to explore these questions. Dr. Hall also explains how the characteristics of the virus and its mechanisms of transmission contribute to its proliferation.
Guest: Jian Han, MD
Host: Bruce Japsen
Diagnostic tests can sometimes get to patients too late but technology is changing to treat patients early, particularly for respiratory problems and infectious diseases. Dr. Gian Han, director of Diatherex Laboratories, tells host Bruce Japsen about the diagnostic industry's progress in testing for respiratory diseases and superbugs via the latest in research and technology in molecular generics.
Host: Ketan Sheth, MD, MBA
Guest: Carlos Camargo, MD, DrPH, MPH
What's the best strategy for managing patients with chronic asthma, and how can physicians create an action plan with their patients to treat an asthma exacerbation? Host Dr. Ketan Sheth reviews recent guideline recommendations for preventing asthma exacerbations with Dr. Carlos Camargo, associate professor of medicine and epidemiology at Harvard Medical School. How are acute and chronic management of asthma different?
Guest: James Sublett, MD
Host: Todd Mahr, MD
Indoor allergens can exacerbate or trigger allergic or asthmatic responses. What effect do carpeting, cleaning solutions, pets, and humidifiers have on indoor environments? Dr. James Sublett, clinical professor and section chief of pediatric allergy at the University of Louisville School of Medicine, offers tips on creating safer homes for patients with allergies. Dr. Todd Mahr hosts.
Host: Todd Mahr, MD
Guest: Sidney Braman, MD, FACP, FCCP
Chronic obstructive pulmonary disease, or COPD, is often diagnosed in late stages, as it is a slowly progressing condition. How can physicians diagnose patients with this deadly disease in its earlier stages, to increase the success of reversing some of its symptoms? Dr. Sidney Braman, professor of medicine at the Warren Alpert Medical School of Brown University, describes who is affected by COPD, and how physicians can best treat these patients. Dr. Todd Mahr hosts.
Host: Ketan Sheth, MD, MBA
Guest: William Silvers, MD
Are the symptoms of exercise-induced asthma always apparent, and if not, how can physicians diagnose the condition? Can exercise-induced asthma exist independently, or does it always signify an underlying asthmatic condition? Host Dr. Ketan Sheth discusses the pathogenesis of and treatments for exercise-induced asthma with Dr. William Silvers, clinical professor of medicine at the University of Colorado School of Medicine. Dr. Silvers will explain the phenomenon that the seemily innocuous food celery can specifically cause exercise-induced allergic reactions.
Host: Mary Leuchars, MD
Guest: Jeffrey D. Cirillo, PhD
Mycobacterium tuberculosis, the bacteria that causes tuberculosis (TB) has been present in the human population since antiquity. Today over 2 billion people have been exposed. What can we learn form this remarkably resilient bacteria, and how do we address the formidable challenge of treating drug resistant strains? Dr. Jeffrey Cirillo, associate professor of microbial and molecular pathogenesis at the Texas A&M Health Science Center College of Medicine, examines tuberculosis from molecular to organ-specific levels and outlines the emergence of multidrug resistance across the world. Hosted by Dr. Mary Leuchars.
Guest: Jeffrey D. Cirillo, PhD
Host: Mary Leuchars, MD
Tuberculosis affects the lives of one third of the world's population. How are newly advancing optical imaging technologies poised to help clinicians achieve more accurate diagnosis and treatment for patients with this serious disease? Tune in to hear host Dr. Mary Leuchars explore with Dr. Jeffrey Cirillo, associate professor of microbial and molecular pathogenesis at the Texas A&M Health Science Center College of Medicine, the optical imaging techniques under development to directly detect TB at low levels. Dr. Cirillo explains how the light waves can be used to detect and definitely confirm tubercolosis without invasive techniques, which currently is not possible using CT scans.
Guest: Paolo Macchiarini, MD, PhD
Host: Lee Freedman, MD
Recently, scientists were able to engineer for the first time a trachea developed from a patient's own stem cells, wherein a donor's trachea was lined with the patient's stem cells to prevent transplant rejection. Immunosuppressive therapy was not necessary, and the patient remains in good condition months after the surgery. Dr. Paolo Macchiarini, head of thoracic surgery at Hospital Clinic in Barcelona, Spain, delves into the details of this breakthrough surgery with host Dr. Lee Freedman.
Host: Todd Mahr, MD
Guest: Bradley E. Chipps, MD, FAAP, FACAAI, FAAAAI, FCCP
What criteria are included in the modified asthma predictive index, and how does this index help physicians diagnose young patients with wheezing and coughing? When is bronchoscopy recommended as an important diagnostic tool for evaluating pediatric lower respiratory symptoms? Dr. Bradley Chipps, medical director of respiratory therapy at Sutter Medical Center, reviews how physicians might work up a young patient with these respiratory symptoms, and suggests the most effective treatments. Dr. Todd Mahr hosts.
Host: Todd Mahr, MD
Guest: Jason Knuffman, MD
A cough that continues for more than a couple of months is considered chronic. What are the most likely causes of chronic cough in non-smoking adults, other than asthma? Dr. Jason Knuffman, allergist in the department of allergy at Gunderson Lutheran Health System in LaCrosse, Wisconsin, discusses how to avoid some common pitfalls that are often encountered when evaluating and treating adults with chronic cough. Dr. Todd Mahr hosts.
Guest: Mark Denison, MD
Host: Mark Nolan Hill, MD
Severe acute respiratory syndrome (SARS) made significant headlines in 2003, testing the mettle of our global public health infrastructure. Since then, we have seen robust evidence to suggest that bats were the original animal host for the virus, with the latest data coming from a synthetic SARS-like bat coronavirus. These most recent efforts were led by the research team of Dr. Mark Denison, professor of pediatrics and associate professor of microbiology and immunology at Vanderbilt University School of Medicine. Dr. Denison details this work with host Dr. Mark Nolan Hill. From a global perspective, how does our ability to synthesize complex viruses like this one enhance our capacity to deal with threatening pathogens?
Host: Ketan Sheth, MD, MBA
Guest: Renata Engler, MD
How do insect allergies present challenges in emergency situations to first responders? What are the best ways to diagnose and treat anaphylaxis in patients away from a clinical setting? Host Dr. Ketan Sheth talks with Dr. Renata Engler, associate professor in the department of medicine at the Uniformed Services University of the Health Sciences, about treating insect allergy in the field. How is proper transport and storage of epinephrine particularly difficult for those in the military or others traveling to remote locations, and what can physicians do to ensure safety for patients in these situations?
Guest: Andrew Haas, MD, PhD
Host: Lee Freedman, MD
Until recently, bronchoscopy has involved using cameras with CT guidance to determine abnormalities along the airway and lymph nodes. How is ultrasound now being used for bronchoscopic needle biopsies? What are other novel therapeutic applications for endobronchial ultrasound-guided transbronchial needle aspiration? Dr. Andrew Haas, assistant professor of medicine in the pulmonary, allergy and critical care division at the University of Pennsylvania Medical Center, discusses the diagnostic and therapeutic uses of ultrasound-guided bronchoscopy. Dr. Lee Freedman hosts.
Guest: Mohammed Khan, MD
Host: Doug Weaver, MD
Investigators are pursuing more aggressive strategies to maintain sinus rhythm. One area of current inquiry for certain arrhythmias centers on pulmonary vein isolation as an alternative to atrioventricular node ablation with biventricular pacing. How effective is pulmonary vein isolation for preventing an arrhythmia relapse? Dr. Mohammed Khan, an electrophysiologist at Cardiovascular Associates in Elk Grove Village, Illinois, joins host Dr. Doug Weaver to explain which of your patients may be optimal candidates for pulmonary vein isolation.
Host: Ketan Sheth, MD, MBA
Guest: I. Leonard Bernstein, MD
The Joint Task Force on Practice Parameters for the Diagnosis and Treatment of Asthma has revised its allergy diagnostic testing parameters. What are the parameters trying to establish? What are the advantages of intracutaneous, skin prick, and in vitro testing for diagnosing allergies? Dr. I. Leonard Bernstein, co-director of the allergy research laboratory in the department of medicine at the University of Cincinnati Medical Center, and co-author of the parameters, explores allergy diagnostic testing options with host Dr. Ketan Sheth.